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Many RHD allele molecular bases studies on serological D negative phenotype have 
been conducted in Caucasian and African populations. Study of RHD alleles was lacking in 
Arabs from Gulf (Omanis) which could be very helpful to come up with a molecular 
screening protocol for managing donors and patients carrying an RHD molecular variant. In 
the present study, we analyse the molecular background of serological D negative Omani 
population. 
A total of 203 dry blood samples on Whatman’s FTA card were collected from Omani 
cohort from different regions of the country. The samples were first analysed serologically 
followed by RHD genotyping using allele specific real-time PCR with melting curve analysis, 
a commercial allele specific PCR (BAGene kits), digital PCR and Sanger sequencing. Among 
the 203 serological D negative samples, 189 (93.1%) were phenotyped as true D negative.  
The true serological D negative samples indicated two patterns that were presence of 37 bp 
insertion in exon 4 that is unique for RHDѰ (n = 8) and presence of RHDѰ in cis to partial D 
without RHCE hybrid (n = 2). Total of 9 samples (4.43%) were reclassified as D positive 
(serological false D negative) indicated patterns that are; RHD-CE-Ds/RHD-CE(4)-D (n = 1), 
RHD-CE(5)-D in cis to weak D DAR2.00 (n = 1), partial D without RHCE hybrid (DIIIb) in 
cis to weak D type 45 (n = 1), RHD-CE(4)-D in cis to weak D DAR2.00 (n = 1), weak D type 
4.2 in cis to weak D type 41 (n = 1), RHD-CE(4)-D in cis to RHD-CE(8-9)-D (n = 1), RHD-
CE(4)-D in cis to weak D type 4.2 (n = 2,) and DVI.2 (RHD-CE(4-6)-D in cis or trans to 
DEL(IVS8-31T>C) (n = 1). Total of 5 samples were unclassified. Altogether, these studies 
showed serological limitation existence in 4.4% of the samples that reinforce RHD molecular 
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1 CHAPTER ONE 
1.1 Introduction 
Effective and safe blood transfusion requires donor and recipient to have exact blood 
types in most of the cases. Therefore, compatibility testing is essential for both donor and 
recipient before any transfusion can take place. Serological and molecular techniques can 
help to identify different blood types. Performing ABO and RhD (Rh blood group, D antigen) 
compatibility test is necessary in blood transfusion as incompatibility may cause severe 
haemolysis that possibly lead to death (ABO blood group incompatibility). Based on RhD 
typing, blood donors and blood transfusion recipients have been categorized as either D 
positive or D negative (Sandler, Chen and Flegel, 2017). This categorization is very 
important during blood transfusions as the D antigen is clinically significant and the correct D 
typing helps to reduce the risk of alloimmunisation in the transfusion recipient and avoid 
haemolytic transfusion reaction (HTR). Correct RhD typing is also important for childbearing 
D negative women for Rh immunoprophylaxis with Rh immune globulin in case if the foetus 
is D positive and thus avoiding haemolytic disease of foetus and newborn (HDFN).  
Serological methods which is a common method worldwide for RhD typing may 
result in false D negative that are in fact RHD variants (Sassi et al., 2014).  These variants can 
be quantitative and reduce D antigen number on red blood cells (RBCs) such as weak D and 
DEL phenotypes or qualitative with or without weakening of D antigen such as partial D and 
RHD hybrid (Avent and Reid, 2000). In serologic D phenotyping it is necessary to detect 
these variants, which result from the amino acid substitutions (Sandler, Chen and Flegel, 
2017). Serological methods are less effective in identifying various types of antigens, while 





1.2 Rh blood group history  
In 1939, blood transfusions were based on ABO compatibility alone. It first came in 
to the spotlight in 1939 (Levine and Stetson, 1939) in New York when a woman had a severe 
acute haemolytic transfusion reaction (AHTR) after having had a matching ABO blood 
transfusion from her husband following the delivery of her stillborn infant. Her serum 
showed antibody that reacted at 25oC and 37oC with husband’s RBCs. It was then postulated 
that father and infant had a factor mother lacked and this factor was introduced by the infant 
during pregnancy which produced antibody that reacted with father´s transfused RBCs in-
vivo and 80% of other ABO compatible blood in-vitro. This antibody was named human anti-
Rh in 1940. Landsteiner and Wiener injected Rhesus monkey RBCs into rabbit and isolated 
antibodies that agglutinated Rhesus monkey RBCs and 85% of human RBCs, hence the name 
Rh (Rhesus) was given (Landsteiner and Wiener, 1940).  By 1962, it was determined that 
anti-Rh antibody differed to human derived anti-D and was renamed anti-LW in honour of 
Landsteiner and Wiener, while a human antibody as anti-D of the Rh (not rhesus) was 
retained.  
Continuous research and investigations showed Rh as a common cause of AHTR and 
HDFN.  From 1943 onwards, the Rh started to be more complex and appreciated to compose 
of numerous alleles as many other Rh factors were defined associated with original agglutinin 
(Race et al., 1944; Mourant, 1945; Stratton, 1946). Fisher and Race had 4 different Rh-
specificities anti-sera, anti-C, anti-E, anti-c and anti-e that determined seven alleles and they 
postulated three loci producing D/d, E/e and C/c (Race et al., 1944), whereas Wiener defined 
8 alleles and suggested only one Rh locus (Wiener, 1943). In 1986, Tippett postulated an 
alternative theory of two loci; one encoding D or no d and the other encoding C or c and E or 





After the determination of the Rh factor in 1939, blood recipients and donors Rh 
RBCs had been categorized as D positive or D negative. However, the first D variant was 
defined in 1946, when red cells from a donor at Manchester Royal infirmary was tested with 
a panel 32 different human anti-D sera. Agglutination was only seen with 12 of these anti-
sera (Stratton, 1946). Such D variants were named Du.  Another class of D variant was 
initially defined as blood factors as Rh positive individual’s has anti-Rh which failed to react 
with own cells and cells of some other rare Rh positive (Unger, Wiener and Katz, 1959). It 
was then defined mosaics (Wiener and Unger, 1962) and eventually renamed as partial D by 
Salmon et al, in 1984 (Issitt and Telen, 1996).  DEL phenotype a third class of D variant 
detected by adsorption and elution of anti-D was first reported in 1984 (Okubo et al., 1984). 
Many cases later were reported some Du / D-positive who have had D positive blood 
transfusion or exposed to D positive foetus RBCs during pregnancy developed anti-D 
(Argall, Ball and Trentelman, 1953; Simmons and Krieger, 1960; Ostgard, Fevang and 
Kornstad, 1986).      
1.3 Rh terminology  
Number of Rh alleles increases as methods for molecular blood group determination 
are widely used. Many developed countries adopted strategies for transfusion support from 
genotyping data. As reporting of genotypes is becoming a routine, and the results obtained 
could develop to a major task for transfusion scientists. Therefore, knowledge of 
nomenclatures on alleles is essential (Wagner, 2019). 
Four systems have been developed to explain the relationships and inheritance of the 
5 original Rh antigens. Two systems proposed by Fisher & Race and Weiner were based on 
serological tests and inheritance studies. Additional two theories were developed by 
Rosenfield & International Society of Blood Transfusion (ISBT) to symbolise the 




postulated that the Rh antigens were inherited as haplotype from each parent and follow 
Mendelian inheritance (Race, 1948). Each haplotype comes from three separate loci and 3 
alleles (locus one = D or d allele, locus two = C or c allele and locus three = E or e allele).  
However, it was later considered d as amorphic allele and now it is very well known that 
there is no d antigen. Loss of D antigen expression can be due to entire RHD gene deletion 
(Caucasian) or inactive or silent gene due to RHDѰ or RHD-CE-Ds hybrid gene (African) 
(Moussa et al., 2012). For example, individual with the genotype DCe/DcE would have D, c, 
e, C and E antigens whereas dCe/dcE would have all the antigens except D.   
Weiner proposed shorthand designation for Rh common antigens haplotype and 
phenotype based on symbols. He believed that Rh gene responsible for the production of 
phenotype called agglutinogen (allele) that has at least 3 three factors (Wiener, 1943). These 
agglutinogens and blood factors are shown in Table 1.1. This theory has been proven to be 
inaccurate; however, the terminology has been in use and developed further.  
As more Rh antigens discovered, the system became more complex and difficult to 
give names to the new antigens. In 1962, Rosenfield with colleagues numbered each Rh 
antigen based on its discovery order (Rosenfield et al., 1962).  The proposed system, 
determines only the presence or absence of Rh antigen. The absence of Rh antigen is 
preceded by negative sign. For the Rh major antigens D, C, E , c and e numbers 1, 2, 3 , 4 and 
5 respectively were assigned.  For example, RBCs that type positive for D, c & e antigens and 
negative for C and E would be designated as Rh: 1, -2. -3, 4 , 5. If the same sample was not 
tested for E antigen the designation would be Rh: 1, -2, 4 , 5 ( 3 which represents E antigen is 
not stated).  
Further development of the blood groups system was necessary as the blood 
transfusion world became to share data. In 1980, the ISBT working party formed a committee 




read by eye and machine keeping with the blood groups genetic bases. The monograph was 
published in 1990 describing 242 RBCs antigen (The ISBT Working Party on Terminology 
for Red Cell Surface Antigens, 1990), 254 antigens with 23 blood group systems in 1995 
(Daniels et al., 1995), 284 antigens with 29 blood group systems (Daniels et al., 2004) and 













Rh0 Rh0 Rh0hr'hr˝ R0 Dce 
Rh1 Rh1 Rh0rh'hr˝ R1 DCe 
Rh2 Rh2 Rh0hr'rh˝ R2 DcE 
Rhz Rhz Rh0rh'rh˝ Rz DCE 
rh rh hr'hr˝ r ce 
rh' rh' rh'hr˝ r' Ce 
Rh˝ Rh˝ hr'rh˝ r˝ cE 
rhy rhy rh'rh˝ ry CE 
Agglutinogen represents a single haplotype capable of expressing 3 different antigens. The 
uppercase R indicates D antigen presence whereas the lowercase r denotes D antigen absence. 
The Uppercase C is denoted by a single prime ( ' ) or a 1. Lowercase c is implicit when there 
is no ' or 1 denoted and the third antigen (e) presence is assumed. For example, R1 denotes 
for the presence of D, C and e antigens whereas R0 indicates D, c & e antigens presence. 
Number 2 or double prime ( ˝ ) indicates the presence of uppercase E antigen whereas 
lowercase e is implied when there is no double prime ( ˝ ) or 2. To illustrate, R2 indicates the 
presence of D, c & E antigens, r˝ for c & E antigens and r for c and e antigens (where the 
presence of c antigen is assumed). When both uppercase C & E are present, Letter Z or y is 
denoted with presence or absence of D antigen respectively - That is Rz indicates D,C & E 
antigens whereas ry indicates C & E antigens. The presence of Rh factors (antigens) D, C, c, 
E and e in agglutination were denoted Rh0, rh', hr', rh˝ and hr˝ respectively as rh was given to 













1.3.1 International Society of Blood Transfusion (ISBT) RH nomenclature  
Each antigen belonging to a blood group system was given a six-digit number for 
each by ISBT. The first three numbers represent the system and the remaining three the 
antigenic specificity (Harmening, 2012). Number 004 was assigned to the Rh blood group 
system, and then each antigen assigned to the Rh system was given a unique number to 
complete the six-digit computer number. Table A1.1 in Appendix 1 provides a listing of these 
numbers. When referring to individual antigens, an alphanumeric designation similar to the 
Rosenfield nomenclature may be used. The alphabetic names formerly used were left 
unchanged but were converted to all uppercase letters (e.g., Rh, Kell became RH, KELL). 
Therefore, D is RH1, C is RH2, E is RH3, c is RH4 and e is RH5 and so on (Table A1.1 in 
Appendix 1).  
For RH alleles a special ISBT nomenclature rules were adopted (Storry et al., 2011). 
The ISBT RH allele names consist of the gene symbol (RHCE or RHD), followed by a 
number or name indicating the main antigenic group, and as many groups of numbers 
following to indicate the allele (Figure 1.1). Non-expressed alleles are characterized by 
addition of an ‘N’ to the initial number, weak D alleles by an additional ‘W’, DEL alleles by 





Figure 1.1 Overview of the ISBT RH allele nomenclature  
For RHCE, the ‘standard’’ ce allele is RHCE*01, Ce RHCE*02, cE RHCE*03 and CE 
RHCE*04. Variant alleles are derived from the respective ‘standard allele’ indicated by 
numbers following a dot, possibly with subgrouping for related alleles. RHD alleles with 
relevant partial D (or without weakening) are grouped according to their phenotype up to 
RHD*62. Non-expressed alleles are characterized by addition of an ‘N’ to the initial number, 
weak D alleles by an additional ‘W’, DEL alleles by an additional ‘EL’. The blue and purple 













1.4 Rh proteins 
The Rh blood group system is highly polymorphic and complex system composed of 
RBCs specific protein antigens such as D and others over 58 different proteins as per the last 
report in 2015 (Harmening, 2012; EL Wafi et al., 2016). Scientists spent several years trying 
to uncover the complexity of the Rh blood group system from serology, biochemical structure 
of the Rh proteins, mode of inherence and the genetic control. These efforts revealed the 
importance of some Rh blood group proteins such as (D) in clinical practice, as they can be 
associated with HDFN and HTR. 
The Rh proteins can be divided into Rh blood group erythrocyte proteins such as D, 
C, c, E and e, Rh associated glycoproteins on erythrocytes such as RhAG and non-erythroid 
proteins such as RhBG and RhCG found in other tissues (Westhoff, 2007).   The complex of 
the Rh protein family is estimated by density ultracentrifugation to be 170 000 daltons 
(Hartel-Schenk and Agre, 1992). The complex structure as tetramer was originally proposed 
in 2000 but since 2005, a trimeric structure has been favoured by several authors. RhCE and 
RhD associate as Rh core complex that comprises one RhD/CcEe protein and most likely two 
Rh-associated glycoproteins (RhAG) as a trimer (Avent et al., 2006). Conroy and colleagues 
used E.coli ammonium channel (AmtB) as a template for the generation of Rh proteins 
models (Conroy et al., 2005). The tetramer structure that was widely quoted contrasted with 
trimeric structure of E.coli AmtB. By sequence alignment between E.coli AmtB, RhD and 
RhAG and comparing homology model of these, they suggested trimeric structure of Rh 
complex on erythrocytes. Merrick and colleagues study used the structure of E. coli AmtB as 
a template, together with secondary structure predictions for Rh polypeptides and the 
extensive available biochemical data on Rh proteins, constructed homology models for 
human RhAG and RhD and concluded the possibility for the Rh proteins to adopt a trimeric 




1.4.1 Biochemical composition of RhD and RhCE proteins  
Blood group antigen can be carbohydrates, proteins, glycolipids or glycoproteins  
attached to a component on the surface of the RBCs membrane (Dean, 2005; Alimba, 
Adekoya and Oboh, 2010). Unlike ABO blood group sugar antigens, the biochemical 
appearance of Rh antigens is hydrophobic non-glycosylated protein which is physically 
supported by lipid in the RBCs membrane and exist as integral cell membrane (Hillyer, 2007; 
Whitlock, 2010). Among the current 62 Rh antigens recognized by the ISBT, proteins  D, C, 
c, E and e are the most immunogenic and are the most common antigens in Rh blood group 
system (Flegel, 2007; Flores-Bello et al., 2018). The immunogenicity of Rh antigens differs, 
with D being the most immunogenic followed by c, E, C and e antigens (Harmening, 2012).  
The RhD protein expresses the D antigen, while the RhCcEe protein carries either C 
or c antigens (involving the second extracellular loop) together with E or e antigens 
(involving the fourth extracellular loop) on the same protein (Mouro et al., 1993; Blunt, 
Daniels and Carritt, 1994; Avent et al., 1996b; Smythe et al., 1996). Rh antigens appear early 
during erythropoietic differentiation. RhCcEe protein is detectable on CD34 progenitors 
isolated from cord blood after 5 to 7 days, while RhD appears after 9 to 11 days of culture 
(Southcott, Tanner and Anstee, 1999).  
The RhD and RhCE proteins are composed of 417 amino acids that transverse the 
RBC membrane 12 times and display short loops of amino acids on the exterior (Cartron, 
1994) with N and C termini located in the cytoplasm of the RBC (Scott, 2004)- (Figure 1.2). 
The N terminal methionine, which represents the mRNA translation-initiation signal, is 




Figure 1.2 RhD , RhCE and RhAG model protein.  
The Rh proteins RhD, RhCE and RhAG transverse the membrane 12 times and display short 
loops of amino acids on the exterior with N and C termini located in the cytoplasm of the 
RBC.  The amino acids sequence from amino acid 2 (first amino acid methionine is cleaved) 
to 417 with their names for RhD and RhCE protein (417 amino acids) are shown. The 
difference in amino acid sequence between RhD and RhCE indicated as black and violet 
circles respectively. Positions 103 for (C/c) [Ser103Pro] and 226 for (E/e) [Pro226Ala] in 
RhCE are indicated as blue and orange circles respectively.  The RhAG protein consist of 409 
amino acids with N-Glycan at the first extracellular loop as branched structure. RhD and 
RhCE structure was adapted from (Flegel, 2007) and modified by the author. RhAG structure 






 Although the RHD and RHCE cDNA open reading frames encode 417 amino acid 
polypeptides, the N terminal methionine, which represents the mRNA translation-initiation 
signal, is cleaved from the mature proteins (Merrick et al., 2006). Both RhD and RhCE 
proteins have 6 extracellular loops (Flegel and Wagner, 2002) with unknown function, but 
RBCs lacking all Rh antigens have structural abnormalities such as stomatocytes (Vege and 
Westhoff, 2019). The difference in amino acids sequence in the antigen is the residue number 
103 for Cc (C: Serine & c: Proline) and 226 for Ee (E: Proline & e: Alanine) [Figure 1.2]. In 
RhCE, the protein of C differs from c by four amino acids and E protein differs from e by one 
amino acid (Daniels, 2013b). On the other hand, there is a difference of 32 to 35 amino acids 
for the RhCE and RhD proteins (Hillyer, 2007). The small loops at exterior part on the 
surface of the RBCs provide the different serological antigenic shape called epitopes for 
different Rh blood types. Nonetheless, the relation between the RhD epitopes and the 
polymorphisms of proteins of the Rh system, are not completely understood (Howe and 
Stack, 2017).  
RhD and RhCE proteins are also called Rh30 (Table 1.2)  proteins as they migrate in 
sodium dodecyl sulphate polyacrylamide gel electrophoresis gels (SDS-PAGE) with about 
molecular weight ratio of 30,000 (Hillyer, 2007). The Rh complex at its core is a hetero-
oligomeric trimer consisting of Rh polypeptides (RhD and RhCE) and Rh-associated 
glycoproteins (RhAG) (Burton and Daniels, 2011). The expression of RhD and RhCE 
proteins on erythrocytes is mediated by co-expression of RhAG protein (Raud, Ferec and 












RhD Rh30, Rh30B, Rh30D, D30, Rh30 polypeptide [30 kd], RhXIII, Rh13 
RhCE Rh30, Rh30A, Rh30C [RhCE], Rh30 polypeptide [32 kd], RhIXb cDNA, 
[RhcE], Rh21 cDNA [RhcE], R6A32, Rhce, RhCe, RhcE, RhCE, CcEe 
RhAG Rh50, Rh glycoprotein Rh50A, D50, MB-2D10 protein, R6A45, GP50, 
GP50A 
 
1.4.2 RhAG protein  
As stated, the Rh proteins carry Rh antigens but are only expressed on the erythrocyte 
surface if glycoprotein RhAG is also present. RhAG protein is detectable on CD34 
progenitors isolated from cord blood, after culture for 3 to 5 days (Southcott, Tanner and 
Anstee, 1999). The amino acid sequence homology (approximately 40%) of the Rh and 
RhAG proteins indicates an ancestral relationship, and collectively they are referred to as the 
``Rh protein family.'' Hydrophobicity profiles, immunochemical analyses, and data obtained 
through site-directed mutagenesis imply that RhAG proteins are similar to Rh proteins and 
have 12 transmembrane spans with both the N-terminus and C-terminus oriented to the 
cytoplasm like Rh proteins (Figure 1.2) (Westhoff, 2004). One of the 2 potential N-glycan 
sites is glycosylated. A third site is predicted to be cytoplasmic and, therefore, not accessible 
for glycosylation (Ridgwell et al., 1992; Ridgwell et al., 1994). Based on the amino acid 
sequence, RhAG shares 39.2% and 38.5% amino acid sequence identity with, respectively, 
the Rhce and RhD proteins (Avent et al., 1990; Cherif-Zahar et al., 1990; Le van Kim et al., 




The RhAG protein is controlled by approximately 32 kb RHAG gene located on 
chromosome 6p12.3 with 10 exons. RHAG gene exons 2–9 are 47% homologous to RHCE 
and RHD (Daniels, 2013a). RhAG is 409 amino acids with a molecular weight between 
40,000 and 100,000 protein is associated with the expression of the Rh system and is part of a 
membrane channel, which is responsible for transporting ammonium and possibly carbon 
dioxide through the membrane of RBCs (Huang, 1998). RhAg antigen does not carry Rh 
antigens but is required for the correct assembly of the Rh proteins (RhD & RhCE) in the red 
cell membrane for expression.  Mutations in the RHAG gene can lead to regulator type of 
Rhnull phenotype  (Hou, Yan and Tian, 2017). In 2010, RHAG blood group system was 
established based on the recognition of three RBCs antigens on RhAG protein encoded by 
RHAG gene (Tilley et al., 2010). The RHAG blood group system consists of two high 
frequency antigens and two low frequency antigens (Table 1.3).  
 
  Table 1.3 Antigens of the RHAG blood group system  
Antigen   
No Name  Frequency     Amino acids* 
RHAG1 Duclos High Gln106Glu 
RHAG2 O1a Low Ser227Leu 
RHAG3 DSLK High Lys164Gln 
RHAG4  Low Val270Ile, 
Ala280Ala 
*Amino acid substitution for negative phenotype. Adapted from 











1.5 RHD and RHCE genes  
The human RH locus is responsible for the expression of the Rh blood group antigens. 
The Rh blood group system has two main genes (RHD and RHCE) that encode for the Rh 
protein. Both genes (loci) are located on chromosome 1p36.11 and are in very close 
proximity to each other (Westhoff, 2004) but are in opposite orientation 5’-RHD-3’-3’-
RHCE-5’ with 10 exons each (Wagner and Flegel, 2000). RHD is flanked by two 9000 base 
regions of 98.6% homology, named the Rhesus boxes (Daniels. G., 2008; Khosroshahi et al., 
2019). RHCE & RHD composed of 57831 and 57295 bp respectively (Okuda et al., 2000) 
separated by small membrane protein 1 SMP1 gene (Wagner and Flegel, 2000) which has 
been renamed TMEM50A (Figure 1.3).  
Bioinformatics using online Ensembl browser showed, messenger RNA (mRNA) 
transcript known as complementary DNA (cDNA) of both RHD and RHCE genes composed 
of 2814 bp and 1660 bp respectively ( Figure A1.1, Appendix 1). However, the coding 
sequence that is translated into 417 amino acids polypeptide is composed of 1254 bp for both 
RHD and RHCE genes.   
RHD and RHCE genes carry different antigens, one carries the D antigen and the 
other carries CE antigens which can be ce, Ce, cE or CE (Arce et al., 1993).  The RhD protein 
is encoded by RHD (synonyms: RH30, RH30B, RH30D, RHXIII, RH13); the RhCcEe protein 
is encoded by RHCE (synonyms: RH30, RH30A, RH30C (RHCE), RHIXB, RH21) (Figure 
1.3); and the RhAG glycoprotein is encoded by RHAG (synonyms: RH50, RH50A).  
Previous studies have found the RHD and RHCE genes to be 93.8% identical to each 
other (Westhoff, 2004; Granier et al., 2013).  The homology even higher between RHD and 
RHCE exons. For example, both RHD and RHCE exon 8 are 100% identical. There are no 
differences or single or very few polymorphism(s) that can differentiate RHD and RHCE (ce, 




recent duplication event.  Previously a study of nonhuman primate RH-like genes 
demonstrated that ancestral RH gene duplication occurred in the common ancestor of man, 
gorillas and chimpanzees. The two genes differences is responsible for the amino acids 
differences along the entire protein dependant on the RHCE allele (Avent and Reid, 2000; 
Flegel, 2006; Daniels, 2013b), exons 1–7 encoding 50–60 amino acids each and exons 8–10 
encoding the last 58 residues (Table 1.4 and Figure 1.5) (Cherif-Zahar et al., 1994; Cherif-
Zahar, Raynal and Cartron, 1997). The most frequently occurring forms of RHCE and RHD 
encode 8 haplotypes: Dce, dce, DCe, dCe, DcE, dcE, DCE, and dCE, known in short, 
respectively, as R0, r, R1, r´´,Rz and ry. 
The intronic region of the gene has a notable difference in intron 4, as RHD gene has 
a 600 bp deletion compared to RHCE gene (Arce et al., 1993; Avent et al., 1997c; Okuda et 
al., 1997; Okuda et al., 2000). Other intronic region over 100 bp deletions or insertions were 













Figure 1.3 RHD and RHCE loci and their product protein.  
Both genes are in apposite orientation with 10 exons each and separated by TMEM50A gene, 
RHD exons represented as black box and RHCE exons as white box (A). Structure of RhD & 
RhCE protein in the RBCs membrane as products of RHD & RHCE genes respectively, N & 
C termini located in the cytoplasm of the RBC (B).  The amino acids arrangment from amino 





Figure 1.4 Schematic representation of the coding sequence (transcript) of wild type 
RHD gene (D*) compared with alleles of RHCE gene (ce, Ce and cE).  
The 10 exons of the RHD & RHCE genes are symbolized by squares and numbered 1 to 10. 
Letters a and b denote the coding sequence transcript of exon 1 with 5´UTR and exon 10 with 
3´UTR respectively.  The blue boxes denote the coding sequence exons for wild type RHD 
gene.  The black boxes denote 100% homology between wild type RHD and RHCE allele 
exons. The white boxes with black borders denote presence of polymorphism(s) within the 
exon distinguishing RHD and RHCE allele. The white boxes with red borders denote 
polymorphisms distinguishing RHD and RHCE alleles at 3´UTR, with sequence share in 
exon 10 between RHD & RHCE. RHce and RHcE alleles share sequence with wild type RHD 
gene; whereas RHCe allele show polymorphism. Wild type RHD & all three RHCE alleles 
shown; share sequence in exon 8, but are different in exon 2 through 7 and exons 9 and 10 










Figure 1.5 Amino acids difference between RhD and RhCE protein. 
Sequence alignment of RhD and RhCE proteins as displayed in online software CLUSTAL O 
(1.2.4) multiple sequence alignment. The amino acid sequence data were deduced from 
cDNA nucleotide sequences from Ensembl genome browser. Black letters indicate amino 
acids translated from exon and blue letters indicate the same from another exon. Red letters 
indicate residue overlaps splice site. Yellow highlights the amino acid difference between 
RhD and RhCE polypeptides C, c, E and e. Four amino acid changes (Cys16Trp; Ile60Leu; 
Ser68Asn; Ser103Pro) are associated with the C to c polymorphism, whereas one amino acid 









1 1 – 49 
2 50 – 112 
3 113 – 162 
4 163 – 211 
5 212 – 267 
6 268 – 313 
7 314 – 358 
8 359 – 384 
9 385 – 409 
10 410 – 417 





1.6 Molecular basis of D  
Since the first descriptions of Rh cDNAs (Avent et al., 1990; Cherif-Zahar et al., 
1990; Le van Kim et al., 1992; Arce et al., 1993), much effort has been made in 
differentiating the molecular bases underlying the antigens of the Rh system. The different 
genetic mechanisms that change the Rh protein include gene deletion (D-negative 
phenotype); gene conversion (C/c polymorphism); antithetical missense mutations (E/e); 
gene hybrid (RHD-CE-D), single-nucleotide polymorphisms (DEL variant K409K) and other 
missense mutations such as RHD-CE-Ds and RHD*Ѱ. The RH genes appear to be a source of 
massive diversity, and combinations of these different genetic rearrangements abound among 
all racial groups.  
Most individuals are either D positive or D negative. However, there is a grey area in 
the form of D variants that affects qualitative and/or quantitative appearance of D antigen. 
The D negative phenotype has different genetic backgrounds with variable distribution in 
different populations (Figure 1.6). The D negative phenotype can arise either due to complete 
absence of the RHD gene which is common in Caucasians or few D variants that are common 
in African. These D variants may give inactive or silent RHD gene such as RHD pseudogene 
(RHD*Ѱ) or RHD-CE-Ds hybrid gene that does not express D but altered C (Moussa et al., 




   
Figure 1.6 Frequency of D negative among different world populations.  
The map was created using mapchart.net online software. The frequency of D negative 
decreases as we go far East from America continental and Europe towards Middle East and 
rest of Asian countries with exception of Australia. Some American continental countries 
such as Mexico and Brazil show different frequencies of 1-5% (green) and between 10-15% 
(dark brown) respectively. Other Americans, Europe and Australian population have the 
highest D negative frequency (>15% - Red). African have mixed frequency whereas all 
Middle East and Gulf countries have frequency between 5 and 10% (orange). The lowest 
frequency of D negative is found in East Asia countries such as China, Thailand and 





There are two types molecular bases of D variants: (1) one or more nucleotide 
substitution in RHD gene that changes the amino acid in RhD protein, (2) genetic 
recombination which causes replacement of one or more RHD exons by RHCE (Daniels, 
2013b).  These variants can be categorized as partial D, weak D and DEL phenotype.  
1.6.1 Complete RHD gene deletion   
The D negative phenotype usually results from a complete absence of the RhD protein 
that results from complete deletion of RHD gene, explaining the high immunogenicity of D. 
As the D negative phenotype is associated with the absence of the RhD protein, there is no 
antigen negative D is found. Typically, the symbol d indicates that there is no D. Among 
Caucasians the D negative phenotype is associated with homozygosity for the complete RHD 
deletion, with percentage between 15% and 17% (Westhoff, 2007). Homozygous deletion of 
RHD, appears to have occurred between a 1463-bp region of identity in each of the Rh boxes 
(Figure 1.7) (Wagner and Flegel, 2000). In a very recent study, it has been observed that 
Basques presents the highest frequency (47.2%) of the RHD deletion (Flores-Bello et al., 
2018).  
Few studies have been conducted on D negative phenotype on Asian and African 
populations. Khosroshahi and colleagues detected Hybrid Rhesus box was detected in all 
tested samples, and Polymerase chain reaction-Restriction fragment length polymorphism 
(PCR-RFLP) confirmed that 99% were homozygous for RHD gene deletion (Khosroshahi et 
al., 2019). Moussa and colleagues observed RHD gene deletion is the most prevalent cause of 
D-negative phenotype (98.6%) among Tunisian population (Moussa et al., 2012). Both 







Figure 1.7 Genomic organization of the Rh genes in typical D positive (D+) and D 
negative (D-) haplotypes. 
 The RH gene shows RHD gene with exons 1-10 (black boxes), the two homologous Rhesus 
boxes, and TMEM50A in 5´ to 3´ orientation, and RHCE gene with exons 1-10 (grey boxes) 
in 3´ to 5´ orientation. In the D negative haplotype, there is a deletion of part of each Rhesus 




1.6.2  RHD pseudogene (RHD*Ѱ)-RHD*8N.01 
RHD pseudogene is characterized by inactivation of D gene by insertion of 37 bp at 
the intron 3/exon 4 boundary of RHD gene that introduces a frame shift and translation 
termination (Figure 1.8). In addition, a nonsense (Tyr>stop) mutation in exon 6 that causes 
premature termination of translated protein (Singleton et al., 2000).  RHD*Ѱ associated 
nucleotides and amino acids changes related to wild type RHD gene can be viewed in Table 
1.5 and Figure 1.9.  
RHD gene deletion is a common cause of D negative in African, however around 67% 
are at least heterozygous to RHD*Ѱ (Daniels, 2013b). Molecular analysis of RHD alleles in 
native Congolese revealed that 20.5% of D negative samples have RHD*Ѱ (Touinssi et al., 
2009). Moussa and colleagues found that Tunisian population has very low frequency of 
RHD*Ѱ (0.5%) compared with that described in the African population (Moussa et al., 
2012).  
 
Table 1.5  RHD*Ѱ associated nucleotides and amino acids changes related to wild type 
RHD gene 
RHD intron/exon* Nucleotide changes 
relative to "standard 
RHD gene 
Amino acid changes relative 
to standard protein 
Remarks 
Intron 3/Exon 4 IVS3-19 dupl 37 (D209N) reading frame or 




Exon 4 609G>A - No change 
 
Exon 5 654G>C (M218I)  




Exon 6 807T>G (Y269X) Stop codon at 
269 







Figure 1.8 The presence of RHD*Ѱ in Africans with the Rh D-negative blood group 
phenotype.  
RHD intron 3 sequence shown in small letters whereas exon 4 sequence shown in capital 
letters.  The region of the 37 bp duplication is underlined (single and double). The putative 
exon sequence derived from intron 3 is double-underlined. This insert introduce a reading 
frameshift and a potential translation-termination codon at codon 210 (indicated as *). The 37 
bp insertion and subsequent frameshift gives also rise to an aspartic acid to asparagine 
substitution at codon 203 (original reading frame) or codon 216 (new reading frame) due to 










Figure 1.9 Schematic diagram on molecular background of RHDѰ gene that gives D 
negative phenotype.  
The numbers indicate exon number on the RHD and RHCE genes. Pink box represent RHD 
exons and grey box represents RHCE exons. The orange box within pink box of RHD exon 4 
represents 37 bp insert which is a duplication of a sequence spanning the intron 3 (at -19 
nucleotide sequence)–exon 4 boundary (IVS-19 dup 37). Green lines represents point 
mutations associated with RHDѰ gene at RHD exon 4 (609G>A), RHD exon 5 (654G>C, 
667T>G and 674C>T) and RHD exon 6 (807T>G). * indicates a point mutation that does not 






1.6.3 Partial D  
The D antigen is a collection of conformation-dependent epitopes along the entire 
RhD protein. These epitopes are the binding sites of antibody. Changes in the amino acids 
and one part of the protein may affect the expression of the epitope sequence or result in new 
epitopes. As such, the antigens of the Rh D blood group may exhibit variations of their 
expression in the erythrocyte membrane of the RBCs. In partial D, RhD protein is altered 
from wild type protein and results in absence of one or more epitopes. The altered protein 
have amino acids changes in the extracellular loop (Daniels, 2013b). People whose RBCs 
have an altered form of RhD protein (partial D) may make allo-anti-D against altered or 
missing epitope. Such RBCs, depending on which D epitopes are altered, are agglutinated by 
a proportion of monoclonal anti-D reagents. Three types of molecular bases of partial D have 
been found: RHD-CE hybrid alleles, missense mutations in the extracellular protein 
segments, and dispersed missense mutations (Flegel and Wagner, 2002). According to 
RhesusBase website, more than 50 partial D alleles have been reported, the latest was in 2018 
a weak partial D due to single missense mutation RHD(L214F)-CE(7)-D and a hybrid allele 
RHCE(5:697-5:744)-RHD (Fichou et al., 2018).  
RHD/CE hybrid alleles results from rearrangements and genetic recombination 
between RHD and RHCE due to gene conversion events. This may result in part of an exon, a 
whole exon, or several exons of RHCE to combine with RHD gene (Figure 1.10) (Daniels, 
2013b). As a result, RHD encode hybrid proteins that have RhCE-specific amino acids. This 
change affects a long string of amino acids, which is always located on the erythrocyte 
surface and the new hybrid can generate antigens; for example, DIV & DVI RBCs carry the 
Rh antigens called Evans (RH37) & BARC (RH52) respectively (Flegel and Wagner, 2002; 




DIV has been divided serologically into DIVa  which is Goa positive and DIVb which 
is Goa negative using polyclonal anti-Goa, an antibody defining the low-prevalence D antigen 
RH30 (Goa) (Tippett and Sanger, 1977). Several molecular subtypes have been reported for 
DIVb while DIVa is less diverse at the molecular level. A low frequency antigen called Evans 
carried by DIVb is due to hybrid RHCE (7-9) seen in CDIVbe and cDIVbE haplotypes (Daniels, 
2002).  
DVI occurs in CDe, cDE, and cDe haplotypes (Jones, Scott and Voak, 1995).  The 
CDVIe haplotype is due to hybrid RHCE (4-6) (Mouro et al., 1994) and cDVIE haplotype is 
due to hybrid RHCE(4-5) (Avent et al., 1997b).  Most CDVIe haplotypes carry the low 
frequency antigen BARC (Flegel and Wagner, 1996). According to Rhesus base website, 
DVI type 2 and DVI type 3 carry BARC antigen with hybrid RHCE (4-6) and hybrid RHCE 
(3-6) respectively.  
There are many other low frequency antigens that are carried by partial D caused by 
hybrid RHCE. For instance, DW (RH23) is an antigenic marker for category DVa partial D 
that is raised from hybrid RHCE (5) and can be seen in CDVae and cDVae haplotypes. RH32 is 
another low frequency antigen associated with CDBT-2e haplotype that is due to hybrid RHCE 
(5-9) that is carried by DBT-2 partial D where it shows weak expression of both C & e 










Figure 1.10 Partial D hybrid alleles compared to normal RHD gene.  
The numbers indicate exon number. Black box represents RHD exon, whereas white box 
represents RHCE exon. The first row represents wild type RHD gene, whereas second row 
onwards represents different partial D types caused by RHCE hybrid. Many partial D arise 
from part of RHCE exon hybrids with RHD exon (e.g DV-1, DVa-4, DVa-6 and DCS-1 result 
from part of RHCE exon 5 hybrids with RHD exon 5). Other types of partial D result from 
full RHCE exon hybrid (e.g DIIIb type has exon 1 and 3 through 10  of RHD and exon 2 of 
RHCE, DIIIC with exons 1, 2 and 4 through 10 of RHD and exon 3 of RHCE. Two or more 
full exons of RHCE hybrid can also result in partial D (e.g DBT-2 results from RHCE hybrid 
of exon 5 through 9, DHAR with RHCE hybrid of exon 1 through 4 and 6 through 10, DVI-3 





According to the updated data from the RhesusBase website 
(http://www.rhesusbase.info/), 27 partial D are caused by single missense mutations (SMM), 
the latest reported mutation  is RHD*52 which is 668 T>C (F223S) predicted to cause 
damaging effect on RhD protein (Filosa et al., 2016). The phenotypes of SMM causing 
partial D are much more diverse than the phenotypes caused by gene conversion and 
determined by the localization and type of substitution (Figure 1.11). In addition, fewer 
epitopes are affected in partial D caused by SMM compared to partial D that results from 
gene conversions (Flegel and Wagner, 2002).  
Figure 1.11 Aberrant RHD alleles with single missense mutations. 
Amino acid positions affected in weak D types are shown in black; those affected in partial 
D, including D categories, are shown in grey. Amino acid substitutions in weak D are located 
in the intracellular or transmembraneous protein segments, those found in partial D 






Multiple missense mutation results in multiple amino acid substitutions which are 
dispersed in the RhD protein may also cause partial D variant. D category, DII, DIII type 4, 
DIII type 5 and DIV type 1.0 are few examples of dispersed amino acid substitutions. More 
than 30 multiple missense mutation causing partial D have been reported as per the data from 
RhesusBase website. ISBT RHD*DAR6 with multiple mutations RHD 
(150T>C,178A>C,201G>A,203G>A,602C>G,667T>G,957G>A,1025T>C) is the latest type 
that has been noted in African ancestry.  
Few aberrant RHD alleles can easily cause clinical problems in transfusion recipients 
and pregnant women. The carrier of these alleles may easily be anti-D immunised (Flegel and 
Wagner, 2002). For example, carriers of partial D type DVI can be anti-D immunised if 
transfused with D positive RBCs. Therefore, most transfusion services in the hospital use 
type of monoclonal anti-D that does not react with DVI RBCs and thus deliberately 
mistyping transfusion recipients and pregnant women as D negative. This is to avoid 
exposure of D positive RBCs for the missing epitope(s) and prevent allo-anti-D immunisation 
and select the pregnant candidates for anti-D immunoglobulin.  
Cases of anti-D immunisation in women with partial D causing mild to severe HDFN 
have been reported and involve mothers with DNB (Lukacevic Krstic et al., 2016; Quantock 
et al., 2017), DIIIa (Beckers et al., 1996), DIVb (Okubo et al., 1991), DVa (Lukacevic Krstic 
et al., 2016), DVI (Lacey et al., 1983) and DBT (Wallace et al., 1997).  Very few cases of 
HTR due to anti-D in D positive recipient  have been reported and involve HTR in sickle cell 
disease (SCD) patient with homozygous partial D for RHD*DAU4 (Ipe et al., 2015). 
Therefore, partial D patients with anti-D should be transfused D negative blood (Daniels, 
2013b). Child bearing women with partial D should be treated as D negative to get anti-D 





Donors RBCs that can be used to immunise D negative recipients for anti-D should be 
labelled D positive. For new donors it is essential to test the RBCs for partial D types DIV, 
DV and DVI and for known repeated donors a blended anti-D reagent of DIV, DV and DVI 
and weak D (Daniels, 2013b).  
1.6.4  Weak D 
Wagner and colleagues proposed that only amino acid substitutions located within the 
membrane spanning or cytosolic domains of the D protein are responsible for weak D (Figure 
1.11) (Wagner et al., 1999). Through RHD sequencing, they identified many different types 
of weak D, numbered weak D type 1, 2, 3. This has now been expanded to many weak D 
types, with several subtypes (e.g. weak D type 4·1) Most serological weak D phenotypes 
(>95% in Northern Europeans) are the expression of weak D types 1, 2, 3 or 4·0/4·1 (Flegel, 
2011).  
To date, 159 weak D types have been detected out of which 154 are listed on the 
Rhesus database (http://www.rhesusbase. info/). These weak D types cannot be distinguished 
serologically, though they are associated with different degrees of weakness and some can. 
Among white German and Austrian blood donors with weak D red cells, 70%, 18%, and 5% 
were weak D types 1, 2, and 3 respectively (Wagner et al, 1999), whereas among French 
patients the equivalent frequencies were 38%, 27%, and 8% (Noizat-Pirenne et al., 2007). 
Novel weak D (not yet given ISBT nomenclature) types 150, 151 and 152 have been reported 
recently (Fichou et al., 2018).  
The estimated number of D antigen on RBCs has been noticed to vary between 
different D phenotypes (Table 1.6). Fluorescence flow cytometry using mono and polyclonal 
anti-D shown the following decrease in number of D antigens on the phenotypes: D-- > R2R2 
> R1R2 > R1R1 > R2r > R0r > R1r (Nicholson et al., 1991; Harmening, 2012). The number of 




This is in contrast with 13,000–24,000 for ‘normal’ D+ red cells and 3000 on DVI type 2 and 
33,000 on DIII type 4 red cells (Wagner et al, 2000). 
 
 
Table 1.6 Estimated number of D antigens on different Rh phenotypes 
Rh Phenotype Number of D antigen sites* 
R1r 9,900 – 14,600 
R0r 12,000 – 20,000 
R2r 14,000 – 16,600 
R1R1 14,500 – 19,300 
R1R2 23,000 – 31,000 
R2R2 15,800 – 33,300 
D-- 110,000 – 202,000 
The highest number of D antigen can be found in D-- phenotype, whereas the lowest number 












Table 1.7 Few weak D types with number of D antigens on RBCs and their ability to 
enhance anti-D allo-immunisation 
Weak D 
type 
Anti-D Number of D antigen References 
DOL Yes 4,700 (Avent, Poole and Singleton, 1999) 
1  1285 (Wagner et al., 1999) 
2  489 (Wagner et al., 1999) 
3  1932 (Wagner et al., 1999) 
4  2288 (Wagner et al., 1999) 
4.1  3811 (Wagner et al., 1999) 
15 Yes 297 (Wagner et al., 1999) 
The lowest number of D antigen on RBCs can be seen in weak D types 2 and 15. Individuals 
with weak D type DOL and 15 are capable of producing anti-D.  
 
Serological weak D phenotype is negative or less than +2 reactivity of RBCs with an 
anti-D reagent in initial testing, followed by moderate to strong agglutination with anti-
human globulin (Sandler et al., 2015). In many countries, longstanding laboratory practice is 
not to test for weak D any patient or child bearing woman who shows D negative in initial 
serological anti-D test. Thus, typing them as D negative and protect them against anti-D 
immunisation. However, this practice results in unnecessary transfusion of D negative RBCs 
and unnecessary administration of anti-D immunoglobulin prophylaxis. The practice used to 
test the donor for weak D if direct agglutination test is negative.  
Current protocol requires a weak D test for the donor, thus protecting D negative recipients 
from immunogenic RBCs with a serological weak D phenotype (Ooley, 2015).  A study by 




type 1, 2 or 3 in the homozygous or hemizygous state are not at risk for forming alloanti-D 
when exposed to D positive RBCs. As a current protocol, transfusion recipient with weak D 
should be tested for weak D type 1, 2 and 3, if positive transfusion of D positive RBCs blood 
should be safe, if negative transfusion of D negative RBCs should be offered (Figure 1.12). 
Likewise, homozygous and hemizygous weak D types 1, 2 and 3 pregnant and women with 
childbearing age typed as D positive. They do not require anti-D immunoglobulin 
prophylaxis, as they are not at risk of anti-D immunisation if foetus is D positive (Figure 
1.12) (Sandler et al., 2015).   
 
Figure 1.12 Management of serological weak D phenotype.  
If the result of serological RhD typing is D negative, the individual should be managed as D 
negative and offered D negative unit for transfusion / candidate for RhIG; and if D positive, 
the individual should be managed as D positive and offered D poitive unit for transfusion / 
not a candidate for RhIG. If the result of RhD typing is a serological weak D phenotype, the 
laboratory should retest the blood sample and do RHD genotyping for Weak D type 1, 2 and 
3. If a weak D type 1, 2 or 3 is not detected, the individual should be managed as D negative. 
If a weak D type 1, 2 or 3 is detected, the individual can be managed safely as D poitive 





1.6.5 DEL phenotypes  
DEL is a very weak form of D that cannot be detected by conventional serological 
tests but by adsorption and elution tests (Kulkarni et al., 2018). The antigen site density per 
red cell was estimated to be less than 22 (Kormoczi et al., 2005). However, density below 
200 may also be involved in DEL phenotype. DEL phenotype is linked with RhCE*Ce or 
RhCE.cE as noted previously (Flegel and Wagner, 2002; Shao et al., 2002).    
DEL phenotype is usually caused by single nucleotide polymorphism (SNP) that 
causes change in the transmembrane or cytosolic domains of the RhD protein (Nuchnoi et al., 
2014). They can also be associated with certain partial or hybrid DEL alleles (Sandler, Chen 
and Flegel, 2017). According to RhesusBase website, more than 40 DEL alleles are currently 
listed. The commonest DEL alleles are found in Eastern Asia population (1227G>A, K409K) 
and Caucasian (M295I) and (IVS3+1 G>A).  
In Eastern Asia, DEL (also called Asian-type DEL) was found to be between 10% and 
33% of D negative RBCs tested by conventional serological (Daniels, 2013b). This DEL 
associate allele  has SNP (1227G>A, K409K) in a splice site on exon 9 that leads to reduced 
D antigenic density (Luettringhaus et al., 2006). A study conducted by (Shao, 2010) showed 
that Asian-type DEL is not usually associated with alloanti-D production. Another 
retrospective study by Wang and colleagues on 227 D negative transfusion recipients in 
China who received transfusion, some of which were D positive. None of the transfusion 
recipients with anti-D had a DEL phenotype associated with the (K409K) allele (Wang et al., 
2014). 
Caucasian DEL allele (IVS3+1G>A) has the splice site mutation RHD at first 
nucleotide of intron 3 (Wagner, Frohmajer and Flegel, 2001). This type of DEL allele has 
been associated with alloanti-D production. Four individuals with RHD (IVS3+1G>A) had 




women with a complete DEL phenotype (K409K) who deliver an D positive newborn are not 
at risk for forming anti-D, but pregnant women with certain partial or hybrid DEL alleles are 
at risk for forming anti-D (Sandler, Chen and Flegel, 2017). 
Donors must be tested for DEL phenotype as evidences have shown that alloanti-D 
immunisation occurred on individuals who were exposed to DEL RBCs. Despite low number 
of D antigens on RBCs of DEL phenotype, RHD (K409K) and RHD (IVS2-2A>G) have 
shown to cause primary & secondary immunisation when transfused to D negative patient 
(Wagner et al., 2005). 
1.7 Unusual Rh phenotypes  
There are many less frequently encountered Rh antigens that can be found in different 
ethnic groups.  Few antigens were already described in section 1.6.3.  
1.7.1 Cw (RH8) 
The first example of anti-Cw was found in the serum of a DCe/DCe patient who had 
been transfused with DCe/DCe Cw+ red cells (Callender and Race, 1946). The prevalence of 
this antigen in Northern Eurpean and white American is 2.6% (Daniels, 2002). Cw+ red cells 
are almost always C+, but the C antigen associated with Cw is weaker than normal C, though 
recognition of this weakness depends on the anti-C used. Although Cw is usually produced by 
a DCe haplotype, Cw associated with dCe (Callender and Race, 1946) and dCE (Dunsford 
and Aspinall, 1951) have also been found. Cw is usually produced by a Ce allele of RHCE 
encoding Arg41. Cw associated with c is produced by a ce allele encoding Arg41 and Cys16 
(Mouro et al., 1995). CCwe and cCwe alleles therefore have exons 1 of identical sequence and 
cCwe could have arisen by recombination between CCwe (exon 1) and ce (exons 2–10) alleles 




1.7.2 VS (RH20) and V (RH10) antigens 
VS and V define antigens that are common on the red cells of Africans with a 
frequency of up to 50%, but are very rare in other populations. VS is associated with unusual 
weak e expression called es. When VS is produced by RHCE that encodes for c and es but not 
C, another antigen called V is also expressed (Denatale et al., 1955).  VS is produced by the 
haplotypes Dces, dces, and d(C)ces, whereas V is produced by Dces and dces, but not d(C)ces.  
The haplotype d(C)ces produces partial c, es, ce (f), a weak partial C, G, and VS; it does not 
produce D, Ce, V, hrB (RH31) and Bastian antigen HrB (RH34) (Daniels, 2002; Pham et al., 
2009a; Pham et al., 2009b). Some individuals with d(C)ces phenotype have produced 
alloanti-C, confirming that the weak C is altered C antigen.  
At molecular and protein level, the presence of V and VS occur with a nucleotide 
polymorphism 733C>G in exon 5 of RHCE gene that leads to amino acid substitution 
(Leu245Val) predicted to be within a transmembrane domain (Daniels GL, et al, 1998). The 
V antigen (in the presence of VS) is not expressed when another transmembrane amino acid 
substitution at residue Gly336Cys is present due to a nucleotide polymorphism 1006G>T in 
exon 7 of RHCE  (Faas et al., 1997; Daniels et al., 1998). The membrane location of residues 
245 and 336 suggests Rh antigen expression is affected significantly by non-exofacial amino 
acids and the prediction of some Rh epitope expression cannot be based solely on 
externalized residues. 
The (C)ces haplotype is composed of hybrid RHD-CE-D allele linked to ces allele of 
the RHCE gene. There are two types of (C)ces haplotype . (C)ces type 1 haplotype when the 
hybrid RHD-CE-D allele consists of exons 1 and 2, part of exon 3, and exons 8 through 10 
from RHD and the remainder of exon 3 and exons 4 through 7 from RHCE. (C)ces type 2 
haplotype exists with hybrid RHD-CE-D allele consists of exons 1 and 2, complete exon 3, 




733C>G (Leu245Val) and 1006G>T (Gly336Cys) nucleotide polymorphisms (Fasano et al., 
2010).  
1.8 RHD  detection in molecular Immunohaematology laboratory  
 Serological tests usually precede molecular tests and inform the choice of 
molecular biology technique for subsequent testing (Olsson et al., 2005). Hemagglutination is 
the original method to test for blood group antigens using commercially available antibodies. 
However, it does not reliably predict a foetus at risk of HDFN, it is difficult to phenotype 
RBCs from a recently transfused patient or when RBCs are coated with IgG, and has poor 
ability to predict zygosity in Rh-positive individuals (Reid and Denomme, 2011).  
The blood of serologically negative donors with weak D antigen expression may be 
immunogenic and induce the formation of immunogenic alloantibodies in the recipient 
(Flegel and Wagner, 2002). In addition, D detecting serological methods can mistype few D 
positive individuals (e.g DEL phenotype) as D negative and increase risk of HTR. Therefore, 
a proper DNA testing for RH gene could help a lot to get rid of these problems.  
Since 1990s, molecular biology methods have gradually been introduced into the 
diagnostic process.  Methods are based on the polymerase chain reaction (PCR). The earliest 
developed PCR based assays rely on the amplification using sequence specific primers (PCR-
SSP) and pattern analysis of the PCR products in agarose gel or on the electrophoretic 
analysis of PCR-RFLP. The conventional PCR is based on in-house primers design and 
optimization of PCR or on standardized and optimized in-vitro diagnostics (IVD) commercial 
tests such as BAGene kit. Most of the common RHD alleles involved in serological D 
negative in Caucasians and African were determined using conventional end point PCR 
(Singleton et al., 2000; Wagner, Frohmajer and Flegel, 2001).   In a study to determine the 
polymorphisms associated with antigen expression for RHD and  RHCE in 39 multi-




detected discrepancies between genotyping and phenotyping results in many alleles (Bakanay 
et al., 2013). Additional tests such as Sanger sequencing might be required if serological 
testing yields equivocal results. Many studies used PCR-RFLP for the detection of RHD 
deletion and D zygosity (Wagner and Flegel, 2000; Kacem et al., 2015; Khosroshahi et al., 
2019). A more recent modification of this technique is PCR based on real-time PCR with 
allele specific TaqMan or HybProbe probes or with SYBR Green DNA intercalating dyes. 
Real-time PCR technique has also been useful to determine different RHD alleles in 
serological D negative phenotype (Moussa et al., 2012; Szulman et al., 2012; Khosroshahi et 
al., 2019).  
The blood transfusion service in some countries makes use of a technique based on 
Multiplex Ligation-dependent Probe Amplification (MLPA) (Haer-Wigman et al., 2013). 
Kim and colleagues investigated the molecular basis of serologically D negative phenotypes, 
including the DEL type using MLPA and found that 17.9% of the Korean cohort had DEL 
RHD (1227G>A) allele (Kim et al., 2018). A growing number of tests started to use 
technologies designed for larger-scale research, including technologies based on digital PCR 
(dPCR). Recent studies used dPCR and were successfully able to do fetal RHD genotyping 
from cell free fetal DNA (Sillence et al., 2015; Svobodova et al., 2015; Lucie et al., 2016).  
Following 1000 genome project, there was a need of sequencing with a high 
throughput, the development of tools for reading DNA sequences and for collecting and 
analyzing the data obtained, and as a result, the development of the high-throughput solution 
known as Next Generation Sequencing (NGS). The various levels of sequencing may be 
achieved by NGS, these are either the whole genome (WGS), exomes or only selected genes 
or regions of interest. It has been successfully implemented in transplantation medicine for 
testing donors genotypes of HLA antigens in high-throughput mode (Schöfl et al., 2017). 




(Tounsi, Madgett and Avent, 2018). Another study used NGS to genotype RHD and RHCE 
using gene specific primers that successfully identified 10 and 25 RHD and RHCE alleles 
respectively (Dezan et al., 2017).  
Efforts were also made in prenatal diagnosis of fetal D status for the management of 
D negative women with partners heterozygous for the RHD gene. Due to the invasive 
limitations associated with conventional methods, cell-free fetal DNA from from maternal 
plasma and serum was used for the determination of the fetal D status (Faas et al., 1998; Lo et 
al., 1998; Bischoff et al., 1999). This development represented an important step towards the 
routine application of noninvasive fetal blood group diagnosis and possibility of doing direct 
genetic analysis using free plasma DNA.  
1.9 Oman, a multi-ethnic country  
Oman is an Arab country bordered by Saudi Arabia to the west, the United Arab 
Emirates to the northwest and Yemen to the southwest, Oman shares marine borders with 
Iran and Pakistan. According to Central Intelligence Agency (CIA, 2014), Oman's population 
consists of African, Arab, South Asian (Pakistani, Sri Lankan, Indian, Bangladeshi), Baluchi 
ethnic groups. 
Many Omanis in the capital city Muscat and coastal areas are of non-Arab origin, 
namely Baloch, Zanzibari, Al-Lawati and Persian (Al Shaibany, 2010) Al-Lawati and 
Persian. Lawatis are of South Asian descent and are believed to share similar origins with the 
India and Pakistan. The Baloch are an Iranian and Pakistani people who mainly speak the 
Balochi language, a branch of North western Iranian languages. Balochis account for 25% of 
the Oman population.  
The Swahili-Arab people come from east coast of Africa, mainly Zanzibar, 
Bagamoyo, and Dar es Salaam They are a mixture of Omani and some Yemeni Arabs who 




These Arabs had children with their African wives and slaves. In the mid-1960s an African 
revolution against Arabs in East Africa resulted in the killing of tens of thousands of Omani 
and Yemeni people. It was after this that Sultan Qaboos bin Said (18 November 1940 – 10 
January 2020) invited many Omanis living in East Africa back to Oman.  
Based on the population distribution and their geographic isolation, it is conceivable 
that the blood types that are present in these countries may also be found in Oman as well. we 
anticipate that the RhD and RhCE antigens present a distinct pattern compared to Caucasian 
populations.  
1.10 Scope  
The D-negative phenotype accounts for less than 1% of Asian individuals. The very 
low frequency of the D-negative in Asian populations brings into question the necessity of 
routinely testing donors and patients for D in this region of the world. The data for the 
distribution of RHD variants and alleles are important for public health care system to 
implement good and effective population specific transfusion practice and obstetrical 
management (Thongbut et al., 2019). However, there are limited studies published on the 
RhD and RhCE antigens for Gulf Arabs broadly or the Omani population specifically, to the 
best of our knowledge and no published data on RHD and RHCE genotyping (Al-Riyami et 
al., 2019). This contrast with studies on African populations, where two  RHD alleles are 
mainly responsible for the D negative phenotype that are RHD*Ѱ (66%) (Singleton et al., 
2000) and RHD-CE-Ds (15%)  (Daniels et al., 1998; Faas et al., 1998), while in Iran, the main 
cause of the D negative phenotype is complete deletion of RHD gene (Khosroshahi et al., 
2019) .  There are no reports of DEL phenotypes among either African or Iranian D negative 
populations. Given the Omani connection to both African and Iranian populations, we 
hypothesized that Omanis may have a silent, inactive African RHD alleles and/or complete 




1.11 Aim and objectives  
To begin addressing this hypothesis, we conducted a retrospective study to find out 
the frequency of ABO/Rh blood group in the Omani population.  Evaluation of 3416 Omani 
donors using serological typing found that 8.4% were D negative, which is in close 
agreement to the 5–10% reported for Arab Gulf and Iranian populations (see Figure 1.6). Al-
Riyami and colleagues conducted a prospective study to find out frequencies of different 
blood groups in Omani population and found that 10.7% of the population is D negative (Al-
Riyami et al., 2019). Some literature shows that RHD genotyping should be recommended 
primarily for D negative C or E positive donors, taking into consideration the results of some 
authors who found weak D or DEL phenotypes in serologically typed D negative and C/E 
positive individuals only by RHD molecular typing (Gassner et al., 2005; Engelfriet and 
Reesink, 2006). 
The first aim of this study then was to determine the Rh serological backgrounds of 
the D negative phenotypes in the Omani population. Serological testing relies on Rh reagents 
that primarily anti-D typing reagents to detect D antigen or reagents to detect the presence or 
absence of the C, E, c and e antigens. These reagents can either be of high protein derived 
from human serum of immunized person or monoclonal IgM or monoclonal or polyclonal 
IgG of low protein derived from human/murine heterohybridoma sources (Rudmann, 2005).  
The current consensus laboratory standard guidelines for Rh phenotyping 
recommended by Central Blood Bank (CBB) Oman does not include confirmation of D status 
in serological D negative by molecular typing. In the Middle East, most published studies that 
investigated the frequencies of red blood cell types were based on serology typing with 
different commercial monoclonal/polyclonal antibodies. Genotyping studies have been 




haemoglobinopathies (Chou and Westhoff, 2011; Dhawan et al., 2014). However, serological 
phenotyping of D has limitations. For instance, the blood of serologically negative donors 
with weak D antigen expression may be immunogenic and induce the formation of 
immunogenic alloantibodies in the recipient (Flegel and Wagner, 2002; Noizat-Pirenne et al., 
2007). This implies that some of the 8.4% of the Omani populations might have been 
mistyped as D negative and require RHD molecular typing to retype the D status and avoid 
alloimmunization if transfused to D negative recipients.  
In view of these limitations and given the growth/validation/establishment of PCR-
based RHD genotyping in clinical practice, the second aim of this study was to develop a 
real-time PCR based assay for the determination of the molecular background of D negative 
population in Oman. Most of the studies used conventional PCR or TaqMan real-time PCR 
for the determination of the molecular background of D negative. For instance, Singleton and 
colleagues used conventional PCR to detect RHDѰ pseudogene and RHD-CE-Ds screening 
different RHD exons (Singleton et al., 2000). Likewise, Wanger and colleagues also used 
conventional PCR to screen RHD exons and introns of more than 8000 whites with antigen D 
negative and identified many RHD alleles such as Hybrid RHD-CE(3-7)-Ds,  RHD-CE(2-9)-
D and DEL phenotypes RHD (K409K), RHD (M295I) and RHD(IVS3+1G>A) (Wagner, 
Frohmajer and Flegel, 2001). Studies also used modified PCR based on real-time PCR with 
allele specific TaqMan probes or with SYBR Green DNA intercalating dyes for RHD 
genotyping of serological D negative samples (Moezzi et al., 2016; Kim et al., 2020). For 
instance, Khosroshahi and colleagues used melting curve analysis real-time PCR technique 
with SYBR Green to screen 200 D negative Iranian blood donors for RHD exons 5, 7 and 10 
and identified weak D type 11 and RHD-CE(2-9)-D2 alleles in two samples (Khosroshahi et 




in serological D negative phenotype. Mousa and colleagues used TaqMan chemistry to detect 
RHD gene in Tunisian population and were able to detect RHDѰ pseudogene, RHD-CE(3-8)-
D, RHD-CE-Ds, RHD-CE(4-7)-D, weak D type 11,  Weak D type 4·0, Weak D type 29 and 
RHD-CE(5-7)-D (DBT-1) (Moussa et al., 2012).   The study was based on RHD exon 10 
detection in the samples initially and further screening for the presence of other RHD exons 1 
through 5 and 7 through 9.  Another study conducted by Gunel and colleagues for the 
detection of RHD gene in amniotic fluid proven TaqMan chemistry to be more sensitive, 
accurate, and specific for RHD gene than SYBR Green I method (Gunel et al., 2011). Though 
nonspecific reaction products are more likely to develop with SYBR Green protocols, leading 
to increased background and false positives, however, it is less expensive and more 
convenient than probe-based methods. A survey of RHD alleles was lacking in Omani 
population. We aimed to unveil the molecular background of RHD gene by melting curve 
analysis for different RHD exons using SYBR Green and real-time PCR using TaqMan 
chemistry. Such knowledge could improve the efficiency which with blood transfusions are 
delivered to patients with RHD molecular variant 
Objectives: 
1. Perform serological Rh phenotyping for C, E, c and e on D negative donors using 
antibodies in commercially available kits.  
2. Confirm the D status by the indirect anti-human test (IAT). This method enables weak D 
cohorts to be excluded as weak D are D positive    
3. Evaluate anti-D reagent by molecular studies using real-time PCR approaches 
4. Study the molecular background of the serological D negative cohort by designing and 




5. Analyse samples by melting curve analysis for the presence of RHD exons  
6. Analyse samples for the presence of specific RHD exons with a view to developing a 
singleplex and multiplex assays for exon-specific real-time PCR detection    
7.  To compare the molecular background determined based on objectives 4 and 5 above 
with data from a commercial PCR test ( (BAGene test, partial D-TYPE and RH-TYPE).  
8. To sequence RHD exons to reconfirm the presence of few RHD alleles and determine the 






2 CHAPTER TWO 
2.1  Materials 
The samples for the study were collected in BD Vacutainer K2 EDTA (BD Franklin 
Lakes NJ USA). Rhesus Blood grouping and phenotyping was done by tube 
haemagglutination test using commercially available Anti-D IgM/IgG blend (Atlas Medical, 
UK), Anti-C, Anti-c, Anti-E & Anti-e reagents (BioRad Cressier FR, Switzerland). Direct 
(DCT) and indirect (IDT) Coombs tube test for D weak detection was done using clear Anti-
Human Globulin (Atlas Medical Cambridge, UK). Control ID DiaCell I & II from BioRad, 
and coombs control cells (Lorne Laboratories Danehill, UK) were used as procedure and 
washing efficiency controls for IDT and DCT test respectively in D weak detection test. The 
Rh phenotyping, both DAT and IDT tube method was reconfirmed by ID card gel method 
using ID-Card ‘’Coombs Anti-IgG’’, ID-Card ‘’RhD + Phenotype’’ (Human), ID-CellStab, 
Anti-D IgG/IgM blend (Atlas Medical, UK), ID-Diluent 1, ID-Diluent 2, ID-Centrifuge 24, 
ID-Incubator from Bio-Rad (Cressier FR, Switzerland). 
For molecular study of RHD exons, DNA sample was prepared using Whatman™ 
FTA™ Elute Card (GE healthcare Buckinghamshire, UK Limited). DNA extraction was 
done using 3 mm Uni-Core (GE healthcare Buckinghamshire, UK Limited) for obtaining 
punch of sample from FTA card and QIAamp® DNA Investigator Kit (Qiagen Manchester, 
UK) for extraction procedure. DNA concentrations of the extracted samples were recorded 
using Thermo Scientific™ NanoDrop 1000. Presence of RHD exons 1 through 7, 9 and 10 
and human growth hormone factor (HGHF) were tested using forward and reverse primers 
(IDT Leuven, Belgium) (Table 2.1). For TaqMan assay specific primers and probes for exons 
5, 7 and 10 and intron 4 were used (Applied Biosystems®, UK) (table2.1). Quantitative PCR 




QuantiNova™ SYBR Green PCR (Qiagen Manchester, UK), qPCRBIO SyGreen (London, 
UK) and PowerUp™SYBR™Green (Thermo Scientific Vilnius, Lithuania). Quantitative 
PCR specific DNA products were tested with gel electrophoresis and products were 
visualised using BioRad ChemiDoc™ MP, Imaging analyser.  
PCR-SSP was done using BAGene kits RH-TYPE, partial D-TYPE and Weak D-
TYPE from (BAGene,BAG Health Care, Lich,Germany). Samples were prepared using 
Happy Taq polymerase 5 units/µl and 10x PCR buffer both provided by (BAGene,BAG 
Health Care, Lich,Germany). The samples were run using BIO-RAD C1000 Touch Thermal 
Cycler. The products were tested with gel electrophoresis and products were visualised using 
BioRad ChemiDoc™ MP, Imaging analyser. 
For QuantStudio™ 3D Digital PCR System, same primers (IDT  Leuven, Belgium) 
and probes used for real-time PCR (Applied Biosystems®, UK).  In SYBR Green assay, 
SYBR Green I Nucleic Acid Gel Stain, 10,000X concentrate in DMSO and QuantStudio™ 
3D Digital PCR Master Mix both from Applied Biosystems®, UK were used. For TaqMan 
assay the same Master Mix was used.  Sample loading materials, QuantStudio™ 3D Digital 
PCR Chip, QuantStudio™ 3D Digital PCR Chip Adapters, QuantStudio™ 3D Digital PCR 
Thermal Pads and QuantStudio™ 3D Digital PCR Tilt Base were from Applied Biosystems®, 





2.2.1 Ethical approval 
Arabic written consent was obtained from each donor (Appendix 2). The study was 
approved by Research and Ethical Review & Approve Committee (RERAC) of Ministry of 
Health Oman (MOH/DGPS/CSR/PROPOSAL_APPROVED /25/2016) and Liverpool John 
Moores University Research and Ethical Committee (no. 16/PBS/003).  
 
2.2.2 Blood samples collection  
Ethylenediaminetetraacetic (EDTA) is widely used as an anticoagulant blood samples 
for blood groups serology and genotyping as EDTA has DNase inhibition activity and thus 
protects cell free DNA from degradation (Barra et al., 2015; Basu et al., 2018; Ouchari et al., 
2018). Total of 3 ml blood samples was collected from 203 D negative Omani donors 
between September 2016 and April 2017 using vacutainer K2EDTA tubes (BD Franklin 
Lakes NJ USA). The blood donors were from central and regional blood banks in Oman. The 
specified volume was collected as a part of regular whole blood donations process (450 ml) 
in the blood bank. The tubes mixed immediately for 5 minutes on a tube roller. Samples were 
either tested immediately or else stored at 4°C for up to 5 days.   
2.2.3 Dry blood sample preparation  
Dry blood sample preparation using Whatman™ FTA™ Elute Card (GE healthcare 
Buckinghamshire, UK) was initiated prior to Rh blood group serological tests. The FTA elute 
cards are designed for DNA preservation, transport and shipment at room temperature and 
purification for molecular analysis. The patented chemicals on FTA cards causes cells lysis, 
proteins denaturation and protect DNA against degradation by nuclease, oxidative, ultraviolet 




genes observed no correlation between robustness of PCR and collection time for different 
samples stored on the FTA cards for up to 1 year (Mas et al., 2007; Peluso et al., 2015) 
Each card was used for one biological sample and labelled anonymously with 
appropriate sample identification. A total of 40 µl Vacutainer K2EDTA (BD Franklin Lakes 
NJ, USA) venous blood was transferred in all four wells using sterile aerosol resistant tips 
and the card was placed to dry at 80oC oven for 30 minutes. The samples were stored at room 
temperature until used.  
2.2.4 Immunohaematological tube test for RhD & RhCE phenotyping 
The ABO forward and reverse and RHD grouping was done by central and regional 
blood banks as part of donor sample processing. Therefore, results of ABO and RHD 
grouping were provided by blood banks. Both tube and ID-card RhD + phenotype gel 
methods were used to reconfirm D negative initially done by blood banks and further 
phenotyping for RhC, c, E and e antigens were done.  
BioRad protocol for tube test using specifc monoclonal IgM antibodies, Anti-c (cell 
line: MS-33), Anti-e (cell line: MS-16, MS-21, MS-63), Anti-C (cell line: MS-24) and Anti-E 
(cell line: MS-260) (BioRad Cressier FR, Switzerland) and Atlas medical (Cambridge, UK) 
anti-D IgM/IgG blend were used. Specific Rh antisera if reacted with its corresponding 
antigen causes agglutination which indicates the presence of Rh antigen (Figure 2.1). 
Absence of the Rh antigen is indicated by no agglutination (Figure 2.1B). Tube method for 
Rh phenotyping is still a cost-effective method in transfusion medicine and many transfusion 
centres in different countries use this method (Siransy Bogui et al., 2014; Gundrajukuppam et 
al., 2016).   
Typically, 3–5% RBCs suspension was prepared according to the manufacturer’s 
instructions. For each sample, five tubes were allocated. One drop of the respective antibody 




mixed and incubated for 5 minutes at room temperature, centrifuged at 1000 g for 20 seconds 
and observed for agglutination macroscopically. Known positive and negative controls were 
included in accordance with the relevant guidelines of quality assurance. Agglutination 









Figure 2.1 Rh IgM monoclonal antibody agglutination reaction pattern.  
RBCs with correspondence Rh antigen will react with Rh specific monoclonal IgM antibody 
and cause agglutination (A), whereas no reaction occur in the absence of correspondence 




Figure 2.2 Agglutination grading pattern in tube method. 
A +4 grading reaction is given for one solid clump. A clear background with few large clumps is 
graded. A cloudy background with multiple small clumps is graded as +2. A +1 is graded for very 
cloudy background with very small clumps. A negative reaction shows no clumps with very cloudy 





2.2.5 Indirect anti human globulin test (IAT) 
Serological IAT tube method for the detection of weak D has been in practice in 
transfusion medicine by both developed and developing countries (Ouchari et al., 2015; 
Ogasawara et al., 2016; Khosroshahi et al., 2019). An indirect anti human globulin test (IAT) 
was performed on all negative reactions with anti-D to observe weak D. RBCs with 
corresponding antigen (D antigen) are sensitized with IgG antibody (anti-D) when incubated 
at 37oC do not undergo agglutination. Antihuman globulin (AHG) reagent forms a bridge 
between the Fc portion of IgG antibodies that coat RBCs and cause visible agglutination 
indicating positive result (Weak D) (Figure 2.3). Direct anti-human globulin test (DAT) was 
performed as a control to rule out any false positive reaction.   
Negative anti-D reactions were incubated at 37oC for 45 minutes and then washed 3 
times with isotonic saline. The saline was decanted completely at third wash, one drop of 
AHG reagent (Atlas Medical Cambridge, UK) was added and centrifuged at 1000 r.p.m for 
one minute to observe any agglutination. As washing efficiency control, all samples that 
showed no agglutination were tested with one drop coombs control cells (Lorne Laboratories 
Danehill, UK) and centrifuged at 1000 r.p.m for one minute to observe agglutination. 
Procedure control was run using anti-D IgG antibodies with control DiaCell I, II and III 









Figure 2.3 Principle of weak D detection by IAT method.  
Anti-D IgG antibodies coat the RBCs that have corresponding D antigen. IgG is too small to 
bring RBCs together and cause agglutination. AHG form as a bridge and bind to IgG 









2.2.6 Immunohaematological ID card method for RhD & RhCE phenotyping 
The gel card technique has been shown to be more sensitive than tube method in 
different transfusion tests (Novaretti et al., 2003; Novaretti et al., 2004; Finck et al., 2013). 
Recent studies also used this technique to report Rh prevalence and frequencies among 
different ethnic groups (Neeraj et al., 2015; Zahid et al., 2016; Swelem et al., 2018). Each 
column contains dextran acrylamide gel matrix, which acts as sieve and suspended in buffer 
solution. The gel is premixed with Rh antibodies (each column with specific Rh antibody as 
shown in Figure 2.4). Reaction between correspondence Rh antigen and specific Rh antibody 
on the column causes agglutination, which indicates the presence of Rh antigen. Large 
agglutinates remain on the top of gel interference, whereas smaller agglutinates pass partway 
through the gel, depending on the size. Un-agglutinated RBCs pass to the bass of the column 
to form a button (Figure 2.5).  
For Rh phenotyping, 5% RBCs suspension was prepared in ID-Diluent 1 (BioRad 
Cressier FR, Switzerland) according to the manufacturer’s instructions. ID-Diluent 1 (0.5 ml) 
was dispensed in a tube and mixed with 50 µl of EDTA whole blood sample. The mixture 
was incubated for 10 minutes at room temperature and used within 15 minutes. RBCs 
suspension (12 µl) was added to all microtubes on ID-Card Rh+ phenotype (BioRad Cressier 
FR, Switzerland). The ID-Card was centrifuged for 10 minutes in the ID-Centrifuge. The 














Figure 2.4 BioRad ID-Card gel.  
Each column has specific Rh antibody on the top of the matrix. Rh specific antibodies on the 
top of the matrix react with Rh corresponding antigen on RBCs and cause agglutination (+) 
that remain on the top of the gel interference matrix (c and e). Un-agglutinated (-) RBCs pass 










Figure 2.5 ID-card gel technique principle for Rh phenotyping.  
Rh specific antibodies react with Rh corresponding antigen and cause agglutination (+) that 
remain on the top of the gel interference matrix. Un-agglutinated (-) RBCs pass through the 







Figure 2.6 Agglutination grading pattern in ID-Card gel.  
A 4+ grading is given to solid band of red cells at top of the gel. A 3+ grading is designated 
when most of red cell band at the top but started to disperse into the gel media. A designation 
of 2+ is given when agglutinated cells disperse along into the gel media and 1+ designated 
for most of the cells at the lower half of the gel.  A reaction is called weak when two layers, 
agglutinate cells at the top of the gel matrix with un-agglutinated cells at the bottom as a 
button. A negative reaction is given when all cells pass through the matrix and form a button 
at the bottom of the microtube. Adapted from (Nicol, 1998) 
 
The ‘No-wash’ ID-System (gel column) for the IAT incorporates the AHG within the 
gel matrix. Sensitised cells react with the AHG on centrifugation, leaving the liquid reactants, 
including any unbound globulins in the reaction chamber. Cells free from IgG are centrifuged 
to the bottom of the microtube. No control of negative results was necessary as no washing is 
required in this technique.  
For IAT weak D testing method, suspension of 0.8% RBCs with BioRad ID-Diluent 2 
was prepared and 50 µl of the suspension was added in BioRad ID-Card Coombs rabbit Anti-
IgG microtube. A total of 50 µl Atlas Medical anti-D IgG/IgM blend (UK) was added to the 
microtube, incubated for 15 minutes at 37oC and the results were recorded after 10 minutes 
centrifugation using ID-centrifuge. To avoid any false positive, DAT control on the sample 
was performed by adding 50 µl of 0.8% RBCs suspension to the BioRad ID-Card Coombs 
rabbit Anti-IgG microtube, centrifuging the card in ID-centrifuge for 10 minutes and 




2.2.7 Primer selection, design and bioinformatics 
RHD specific primers (IDT Leuven, Belgium) were adapted from different studies 
(Table 2.1 and Table 2.2). The RHD coding sequence were the target for the primer design at 
first instance to amplify the whole RHD exons or to identify the presence of the exons.  
Normal RHD & RHCE gene nucleotides sequence were selected from DNA reference 
number NCBI (NC_000001.11) and Ensembl (ENSG00000187010) websites and the coding 
sequence of 1254 nucleotides long was identified as follows starting from exon 1 through 

























Primers for RHD exon 2 and forward primer for RHD exon 10 was designed in house. 
For primers design, specific nucleotides area on RHD gene (May include 5' UTR, part of 
intron or 3' UTR) was selected and processed in NCBI primer blast online software 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) to get the primer pair. The region of each 




sequence above. Multiple Sequence Alignment using Clustal Omega online software 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) was used for alignment of primers with RHD and 
RHCE specific regions. Selection priority was given to those primers that showed 100% 
specificity for RHD region and differ at least at 3' region with selected homologues RHCE 
region. NCBI Primer BLAST was used to identify specificity of the designed primers. The 
amplicon sequence was identified using UCSC genome browser – InSilico-PCR software 





Figure 2.7 NCBI Primer blast and UCSC genome browser result for RHD exon 2.  
NCBI Primer BLAST showed the primer pair is specific for RHD gene. UCSC genome 
browser showed the nucleotides sequence covered by primer pair. Yellow highlight indicates 
forward primer, whereas blue highlight indicates reverse primer. Capital letters indicates 















specificity Position* Sequence (5′ to 3′) Reference 
1 re01 F D Promoter -
149 to -
132 
atagagaggccagcacaa (Singleton et 
al., 2000) 
RHIN1R R D + CE Intron 1 
84 to 64 
tctgtgcccctggagaaccac 
2 ME2F F D Exon 2 




ME2R R D Intron 2 
39 to 28 
ctctatgacccagaagtgat 
3 ga31 F D Exon 3 







rb21 R D + CE Intron 3 
28 to 11 
aggtccctcctccagcac 
4 ga41 F D Exon 4 







ga42 R D Exon 4 
625 to 602 
CAGACAAACTGGGT
ATCGTTGCTG 
F: Forward primer                        R: Reverse primer 

















Position Sequence (5′ to 3′) Reference 





Wijk et al., 
1998) 
Rex5AD2 R D Intron 5/exon 
5 3 to 787 
cacCTTGCTGATCTT
ACC 
















Wijk et al., 
1998) 




9 re83 F D + CE Intron 8 -54 








10 MDF10  F D + CE Intron 9 -77 
to -54 





rr4 R D 3′ UTR 1,541 
to 1,522 
agcttactggatgaccacca 
*The positions of the synthetic oligonucleotides are indicated relative to their distances from the 
first nucleotide position of the start codon ATG 
F: Forward primer                        R: Reverse primer  







Table 2.2. Primers used for identifying the presence of RHD intron 4 and exons 5, 7 and 10 
using TaqMan chemistry 
Exon/Intron Primer 
name 
Position Sequence (5′ to 3′) Reference 
Intron 4 RHDIn4F Intron 4 113 to 134 gcccttccatcatgattcattt (Dovc-
Drnovsek et 
al., 2013) 
RHDIn4R Intron 4 244 to 223 acaaggaaacaaaggccaagag 
RHDIn4M Intron 4 172 to 188 FAM-aagcacttcacagagca-
MGB 
 
Exon 5 RHD ex5F Exon 5 636 to 654 CGCCCTCTTCTTGTGGA
TG 
(Legler et al., 
2007) 
RHD ex5R Exon 5 717 to 697 GAACACGGCATTCTTCC
TTTC 

























RHDex10R 3'UTR 1372 to 
1355 
cctgcgcgaacattgga 








2.2.8 DNA extraction  
Different biological samples stored on FTA cards such as blood (Wong, Lim and Tan-
Siew, 2012; Lipic, Giordullo and Fredericks, 2018) and urine (Srisiri et al., 2017) have been 
used in clinical research studies for DNA amplification and found to be efficient. Most 
studies using blood on FTA card, targeted blood parasites and viruses (Nzelu et al., 2016; Qin 
et al., 2016). Yet, RHD genotyping on blood samples extracted from FTA card have not been 
studied hence; this is the first report to our knowledge.    
DNA was extracted from FTA card using QIAamp® DNA Investigator reagent 
(Qiagen Manchester, UK) which is silica-based membrane extraction method using a spin 
column. The method is based on cell lysis with lysis buffer to disrupt the cell membrane and 
protinase K to digest proteins such as nuclease. The lysate combined with alcohol and DNA 
binds to the silica based membrane. Multiple buffer washing and centrifugation steps ensure 
removal of proteins and positively charged ions, including magnesium. Pure concentrated 
DNA is eluted from the membrane by ATE (Tris-EDTA) elution buffer (Figure 2.8).  
A 3 mm punch from dry blood on FTA card was placed in 1.5 ml microcentrifuge 
tube. Sample pre-treated with 280 µl of buffer ATL and 20 µl of protinase K. Following 
vortexing, samples were incubated at 56oC for an hour with 10 seconds vortexing every 10 
minutes. Following brief centrifugation, 300 µl of buffer AL was added, vortexed for 10 
seconds and incubated at 70oC for 10 minutes with 10 seconds vortexing every 3 minutes. 
After brief centrifugation, 150 µl of 100% ethanol was added, mixed by vortexing for 15 
seconds and centrifuged briefly. The lysate was transferred to QIAamp MinElute column , 
centrifuged at 8000 r.p.m for 1 minute and collection tube containing flow-through was 
discarded. Similar centrifuging and discarding process were repeated in each of the following 
steps after adding 500 µl AW1 buffer, 700 µl AW2 and 700 µl of 100% ethanol. To dry the 




MinElute column were placed in a 1.5 microcentrifuge tube and incubated at room 
temperature for 10 minutes. ATE elution buffer 50 µl was applied at the centre of the 
membrane and incubated at room temperature for 5 minutes followed by centrifuging at 
14000 r.p.m for 1 minute.  
Stangegaard and colleagues were able to extract DNA from dry blood spot on FTA 
card for up to six additional DNA extractions using the same initial sample (Stangegaard et 
al., 2013). We adopted the same idea to test representative samples (n = 5) for multiple 
extraction for up to four times using the same initial sample. QIAamp® DNA Investigator kit 















Figure 2.8 Principle of DNA extractions from FTA card using Qiagen investigator kit.  
The sample exposed to lysis buffer and proteinase K which causes lysis of the cellular and 
organelle membrane releasing their contents e.g DNA, magnesium, lipid, proteins..etc (A). 
Addition of alcohol leads to binding of DNA to the silica based membrane (B). Multiple 
buffer washing ensures removal of proteins and other cellular components but not DNA 
which remain bound on the silica membrane (C). DNA is eluted by ATE buffer as it dissolves 






2.2.9 DNA purity and estimation of DNA concentration and yield  
FTA cards are a convenient solution for collecting low volume blood samples such as 
those from neonates and for long term storage at room temperatures for archival purposes and 
extended periods. Stangegaard and colleagues studied DNA purity and yield from dry blood 
spot on FTA for forensic genetic analysis and proved to be possible to extract DNA from 
these cards in sufficient amount and quality to obtain complete short tandem repeat (STR) 
using different automated extraction protocols such as QIAcube, QIAsymphony SP and 
PrepFiler Express kit. The study had also proved that following initial sample pretreatment 
and DNA extraction, the processed FTA card pieces were useful to up to six additional DNA 
extractions (Stangegaard et al., 2013). As stated in section 2.2.8 on DNA extraction, for RHD 
genotyping DNA was extracted from dry blood spot on FTA cards using QIAamp® DNA 
Investigator kit.  
The most common technique to determine DNA yield and purity is measurement of 
absorbance. DNA concentration can be estimated using spectrophotometer under ultraviolet 
(UV) light at 260 nm due to purine and pyrimidine bases that strongly absorb UV light. 
However, DNA is not the only molecule that can absorb UV light at 260 nm. Since RNA also 
has a great absorbance at 260 nm, and the aromatic amino acids present in protein absorb at 
280 nm, both contaminants, if present in the DNA solution, will contribute to the total 
measurement at 260 nm. Additionally, the presence of guanidine will lead to higher 260 nm 
absorbance. This means that if the A260 number is used for calculation of yield, the DNA 
quantity may be overestimated.  
To evaluate DNA purity, absorbance from 230 nm to 320nm to detect other possible 
contaminants is required. The most common purity calculation is the ratio of the absorbance 
at 260 nm divided by the reading at 280 nm. Good-quality DNA will have an A260/A280 




lower ratios indicate more contaminants are present. The ratio can be calculated after 
correcting for turbidity (absorbance at 340 nm). 
Strong absorbance around 230 nm can indicate that organic compounds or chaotropic 
salts are present in the purified DNA. A ratio of 260 nm to 230 nm can help evaluate the level 
of salt carryover in the purified DNA. The lower the ratio, the greater the amount of salt is 
present, for example. As a guideline, the A260/A230 is best if greater than 1.5. A reading at 
340 nm will indicate if there is turbidity in the solution, another indication of possible 
contamination. Therefore, taking a spectrum of readings from 230 nm to 340 nm is most 
informative. 
Thermo Scientific™ NanoDrop 1000 was used to estimate DNA concentration and 
purity. Nucleic acid application was selected and the device optical surfaces were cleaned 
using DNA free water. The appropriate constant (dsDNA – DNA 50) for the sample was 
selected and blank measurement was performed using Qiagen ATE buffer from which the 
extracted DNA was eluted. Both optical surfaces were cleaned with a clean, dry, lint-free lab 
wipe. To determine DNA concentration, 1 µl of extracted DNA was dispensed onto the lower 
optical pedestal and the lever arm was closed. The nucleic acid concentration and purity 
ratios (260/280 and 260/230) were calculated automatically by the software and presented as 
data and spectral output. DNA yield was calculated by multiplying total sample volume by 
DNA concentration.  
2.2.10 Molecular analysis of RHD gene by real-time PCR 
During DNA amplification in real-time PCR, light passes through monochromator 
that transmits a mechanically selectable narrow band of wavelengths of light chosen from a 
wider range of wavelengths that is dependent upon fluorophore used. Upon excitation at the 




DNA emits fluorescence that can be captured as data in photodetector every cycle and 
translated as real-time PCR graph (Arya et al., 2005; Valasek and Repa, 2005).  
For SYBR Green chemistry, this DNA binding dye binds only to major groove double 
stranded DNA (dsDNA) but not single stranded (Rapley, 2010). SYBR Green does not emit 
fluorescence when it is in free form but fluorescence signal is emitted as it binds to dsDNA 
(Mirmajlessi and Loit, 2016) .  During amplification detection in real-time, SYBR Green 
emits green light at 520 +/- 10 nm that can be detected by excitation at 470 +/- 10 nm. 
For TaqMan chemistry, qPCR technique uses a probe as a fluorophore. Each TaqMan 
probe has a fluorophore molecule such as 6-carboxyfluorescein (6-FAM) or 2′-chloro-
7′phenyl-1,4-dichloro-6-carboxy-fluorescein (VIC) and a quencher such as 
tetramethylrhodamine (TAMRA), QSY and Minor Groove Binding (MGB) but unable to 
florescent at this stage. As the DNA polymerase extend DNA from primer template it cleaves 
the probe bound to DNA template releasing the fluorophore that emits light at specific 
wavelength to be detected.  Different fluorophores used in TaqMan probes have different 
maximum emission and excitation wavelength. Table 2.2 shows fluorophores used in real 
time PCR for current study. With a choice of many excitation sources and detection filters 
combined (up to 6 in Rotor-Gene® Q) with a short, fixed optical in thermocyclers, it is 









Table 2.2 Absorbance, excitation and emission of different fluorescence dye used in real-









6-FAM 495 470 520 
VIC 538 470 558 
SYBR 495 470 630 
 
Real-time PCR can also be used as qualitative indicator for desired DNA amplicon 
which is known as dissociation curve or melting curve analysis. Fluorescence intensity 
remains high in low temperature and as the temperature is increased, the dsDNA starts to 
dissociate decreasing the intensity (Figure 2.9A). The melting point temperature is calculated 
from the intensity change in a given interval from fluorescence derivative (df) in relation to 
temperature derivative (dt) (Figure 2.9B).   
The real-time PCR was used to investigate the presence and mutation in RHD gene 
exons 1 through 10 using RHD specific and sequence-specific primers (SSP). The D positive 
sample was used as a control for the amplification of exons and melting curve analysis of 










Figure 2.9 Dissociation and melting curve analysis in real-time PCR.  
The fluorescence intensity remains high in dsDNA. As the temperature increases, dsDNA 
starts to dissociate decreasing the intensity until no more dsDNA at zero intensity represented 
as dissociation curve (A). The fluorescence intensity changes in a given interval for 
fluorescence derivative (df) in relation to temperature derivative. This change is calculated 










2.2.11 Screening for RHD deletion  
All DNA samples were screened for the presence of RHD exon 10 to detect the 
deletion or presence of RHD gene by using a real-time PCR SYBR Green and TaqMan 
chemistry. For SYBR Green chemistry, MDF10 and rr4 and primers for RHD exon 10 were 
used, with HGHF and HGHR human growth hormone primers (IDT Leuven, Belgium) as 
positive controls. PCR was performed in a total reaction volume of 10 μL. All RHD exons 
amplifications were programmed on a thermal cycler (Rotor-Gene Q; Qiagen) unless stated 
otherwise and the samples ran in duplicates. The cycling conditions used were as follows: 
Hold at 95°C for 3 minutes and then 40 cycles of : 5 seconds at 95°C and 10 seconds at 60°C. 
All PCR amplifications were carried out in duplicate in 72 well reaction rotor. Melting curve 
analysis in all reactions was performed between 60 and 95°C with a temperature increment of 
0.5°C/s unless stated otherwise. The melting curves were sketched using the instrument’s 
data analysis software (Rotor-Gene Q Pure Detection, version 2.3.1; Qiagen) and evaluated 
visually. The PCR products size were visualised by electrophoresis on a 2% agarose gel and 
then sent to eurofins or GENEWIZ for Sanger sequencing. 
For TaqMan chemistry, real-time PCR was performed from FTA extracted DNA with 
concentration between 20 and 30 ng, 400 nM of each primer and QuantiNova Probe Mater 
Mix (Qiagen, UK) in a total reaction volume of 10 μL. The cycling conditions used were as 
follows: denaturation at 95°C for 3 min and then 40 cycles of 5 seconds at 95°C and 15 






2.2.12 Further molecular characterisation of RHD exons  
All samples positive for RHD exon 10 were further investigated for the presence of 
RHD exons 1 through 7 and 9 by real-time simplex PCR with SYBR Green chemistry. 
Amplification reactions were set up in a total volume of 10 μL using the QuantiNova SYBR 
Green PCR Master Mix (Qiagen). The RHD primers and their concentrations stated in Table 
2.3. An amount between 20 and 30 ng of the extracted blood DNA was used for 
amplification.  
RHD intron 4, exons 5 and 7 were also investigated by a real-time simplex PCR with 
TaqMan chemistry. RHD specific intron4/exon5/exon7 simplex PCR (10 µl reactions) 
consisted of QuantiNova Probe Master Mix (Qiagen), primers and probes previously 
described by Leglar et al. (2007) and Drnovšek et al. (2013) and 2 µl of template. Primer 
pairs and their concentration stated in Table 2.4. After initial incubation at 95°C for 3 min, 40 
cycles of two-step cycling, denaturation at 95℃ for 5 seconds and annealing and extension at 
60℃ for 15 seconds was performed. All reaction were acquired on green channel except exon 












Table 2.3 Primers and their concentrations and cycling condition used to amplify RHD 







real-time PCR Cycling condition** 
 
    Denaturation Annealing Extensiond 
1 re01 and 
RHIN1R 
500  95oC (5 s)a 60oC (15 s) 
2 ME2F and 
ME2R 
100  95oC (5 s)a 60oC (15 s) 
3 ga31 and 
rb21 
200  95oC (15 s)b 70oC (20 s) 72oC (30 s) 
95oC (15 s)c 60oC (20 s) 72oC (30 s) 
4 ga41 and 
ga42 
200  95oC (15 s)b 70oC (20 s) 72oC (30 s) 
95oC (15 s)c 60oC (20 s) 72oC (30 s) 
5 R648 and 
Rex5AD2 
400  95oC (5 s)a 60oC (15 s) 
6 ga62 and 
ga61 
100  95oC (15 s)b 70oC (20 s) 72oC (30 s) 
95oC (15 s)c 60oC (20 s) 72oC (30 s) 
7 R973 and 
R1068 
400  95oC (5 s)a 60oC (15 s) 
8       
9 re83 and 
re94 
400  95oC (15 s)b 70oC (20 s) 72oC (30 s) 
  95oC (15 s)c 60oC (20 s) 72oC (30 s) 
a 40 cycles    b Touch-down 10 cycles with 1℃ decrease in annealing temperature in each 
cycle    C 30 cycles       d Acquired on green channel    s: seconds  
*Prior to the cycling, there was a hold step at 95oC for 3 min     








Table 2.4 Primers for RHD TaqMan real-time PCR used for further molecular 
characterization of RHD gene in Omani population 
Primer / Probe Label RHD region Primer / Probe 
concentration (nM) 
RHDIn4F None Intron 4 800 
RHDIn4F None Intron 4 800 
RHDIn4M FAM-MGBd Intron 4 300 
RHD ex5F None Exon 5 200 
RHD ex5R None Exon 5 200 
RHD ex5Q VIC-QSYe Exon 5 50 
RHD 940S None Exon 7 500 
RHD 1064R None Exon 7 500 
RHD968T FAM-TAMRAd Exon 7 250 
RHDex10F None Exon 10 800 
RHDex10R Note Exon 10 800 
RHDex10M FAM-MGBd Exon 10 300 










2.2.13 Agarose gel electrophoresis  
Agarose gel electrophoresis was performed to check that real-time PCR product gave 
the desired size of RHD specific exon amplicon and to relate that with melting temperature 
(Tm) curve. Agarose gel 2–2.5% (w/v) from (Sigma-Aldrich, USA) was prepared as follows: 
for each 100 ml, 2 to 2.5 g of agarose was added to 100 ml 1xTBE buffer (Lonza, Belgium) 
and microwaved at medium heat for 3-4 minutes until the agarose dissolved. The solution 
was cooled down till 60°C, poured into UV-transparent gel tray with inserted comb and 
allowed to solidify for 30 minutes. The gel was then placed into the tank filled with 1xTBE 
buffer. FastRuler™ Low Range DNA Ladder (ThermoFisher, UK) was loaded in the first 
lane as a marker (50-1500 bp). The marker or sample was loaded by adding 4 µl of the DNA 
and 1 µl of Novel Juice DNA stain (Sigma-Aldrich, USA). The electrophoresis was run at 
80V for 45 minutes. The gel was viewed with BioRad ChemiDoc™ MP, Imaging analyser 
under ultra violet light (ethidium bromide channel).   
2.2.14 RHD exons sequencing  
As this is the first RHD molecular study on Omani population, PCR amplicons for 
exons 1 through 10 were sequenced to find out possible novel mutation(s) in RHD gene 
coding sequence. It also confirmed the specificity of the selected primers to the RHD gene 
specific exon and not RHCE gene exons. Non-purified PCR products were sent to Eurofins 
and GENEWIZ for Sanger sequencing using primers stated in Table 2.1. Both forward and 
reverse primers (5 µM) and DNA templates (20 µl) were submitted in a separate 1.5 mL 
locked Eppendorf tubes. DNA sequencing data were analysed using Chromas (version 2.6) 
software (Technelysium Ply Ltd). NCBI blast was used to perform sequence alignment 




2.10. Mutation within the coding sequence was reconfirmed with both primers (forward and 
reverse). Sequencing result of each primer then aligned using online Clustal Omega software 
to reconfirm the mutation location as shown in Figure 2.11.  
 
Figure 2.10 NCBI BLAST method used to compare Sanger sequencing results with 
reference gene.   
DNA sequence result was entered in the box (highlighted blue) and the database was selected 
as Human RefSeqGene sequences (RefSeq_Gene) highlighted red. The results of the 








Figure 2.11 RHD exon DNA sequence alignment of forward and reverse primers 
Type of nucleic acid is selected (Red highlight), any sequence to be analysed was labelled 
with symbol > and name (Blue highlight) and sequence was added in the box (Blue 








2.2.15 Molecular analysis of RHD gene commercial BAGene SSP kit 
The BAGene kits are used to determine blood group specificities of donors, recipients 
and pregnant women on a molecular genetic basis. A study conducted by Bakanary and 
colleagues using BAGene RH-TYPE kit revealed the importance of genotyping in transfusion 
management of chronically transfused patients as the classical hemagglutination assays may 
be inaccurate (Bakanay et al., 2013). We used Rh-TYPE and partial D-TYPE type kits 
(BAGene,BAG Health Care, Lich,Germany) to determine different RHD alleles in D negative 
Omani population and reconfirm the presence of RHD exons detected by real-time PCR 
stated in section 2.2.12. The kit also reconfirms the serological RhCE phenotyping by 
molecular method to detect C,c, E and e alleles.  Extracted DNA from dried blood on FTA 
card was used as a template.  
The test procedure is performed by using the Sequence Specific Primers (SSP)-PCR 
(Figure 2.12). This method is based on the fact that primer extension, and hence successful 
PCR, relies on an exact match at the 3'-end of both primers. As a result, the amplification is 
obtained only if the primers entirely match the target sequence. The kits consist of PCR plates 
with chambers with pre-aliquoted and dried reaction mixes containing allele-specific primers, 
internal control primers and deoxyribonucleotide triphosphates (dNTPs). The master mix for 
RH-TYPE and partial D-TYPE was prepared according to manufacturer instructions (Table 
2.5) with 10x PCR buffer (included in the kit), DNA template concentration between 20 and 
30 ng, Happy Taq Polymerase (BAGene,BAG Health Care, Lich,Germany) and ddH2O.  
BioRad C1000 Touch™ thermal cycler was used for the assay with the following 
cycling condition: denaturation at 96°C for 5 min; 5 cycles of denaturation at 96°C for 10 
seconds and annealing and extension at 70°C for 60 seconds; 10 cycles of denaturation at 
96°C for 10 seconds, annealing for 50 seconds at 65°C and extension for 45 seconds at 72°C; 




extension at 72°C for 45 seconds and final extension at 72°C for 5 minutes. The product of 
the amplification is visualized by 2.5% (w/v) agarose gel electrophoresis as describe in 
section 2.2.13. 
 
A       B 
 
Figure 2.12 Principle of the BAGene commercial diagnostic assay for RH-TYPE and 
partial D-TYPE.  
A perfect match with Sequence specific primers leads to primer extension and thus 












Table 2.5 Master Mix preparation to run BAGene RH-TYPE and partial D-TYPE in-
vitro test 
BAGene 
 SSP Kit 
Number 












RH-TYPE 13 123.6 15.6 15.6 1.3 156 
Partial D-
TYPE 
15 142.6 18 18 1.4 180 
*For one sample  
 
2.2.16 Molecular analysis of RHD gene by QuantStudio™ 3D digital PCR  
Digital PCR builds on the same principle of the qPCR enabling an absolute value with 
much higher precision compared to standard PCR. It starts with the partition of reaction mix 
into thousands of independent PCR replicates. Some partitions will include the PCR template 
and others do not. Partitions that include DNA template will amplify the DNA at detectible 
level that can be directly proportional to the total number of molecules enabling an absolute 
count to be established (Hudecova, 2015). The reactions are run on integrated fluidic circuits 
(chips). These chips have integrated chambers and valves for partitioning samples and 
reaction reagents. Following identification of positive and negative wells a Poisson model is 
used to calculate the probability of a given reaction receiving 0, 1, 2 or more copies. This 
correction factor enables all molecules to be counted yielding to an absolute value.  
 
 
2.2.16.1 RHD exons 5, 7 and 10 detection using SYBR Green I dye  
TaqMan® assays are recommended by Applied Biosystems® as a proven and validated 




based detection is widely used for target quantification in traditional real-time PCR, they 
have developed a protocol for using SYBR Green I dye for target quantification on the 
QuantStudio™ 3D system. This protocol is meant as a starting point for optimization with 
primer sets that were previously validated for SYBR Green dye based detection.  
SYBR Green I Nucleic Acid Gel Stain, 10,000X concentrate in DMSO (Applied 
Biosystems®, UK) was diluted with 100% DMSO (Applied Biosystems®, UK) to make 
1000X stock solution aliquots. For digital PCR work, stock solution was further diluted to 
20X with TE buffer, pH 8.0 (Qiagen, UK).  Previously validated real-time PCR forward and 
reverse primers for RHD exons 5 (R648 and Rex5AD2), RHD exon 7 (R973 and R1068) and 
RHD exon 10 (MDF10 and rr4) were used with same concentration as indicated in table 2.1.  
Amplification reactions were set up in a total volume of 14.5 μL using the QuantStudio™ 3D 
Digital PCR Master Mix (Applied Biosystems®, UK) as the setup shown in Table 2.6. The 
reaction mix (14.5 μL) was loaded onto the QuantStudio™ 3D Digital PCR chip using the 
chip loader, and ran using the standard thermal cycling conditions recommended by the 
manufacturer (Table 2.7). For the optimization of annealing temperature, temperature 










Table 2.6 Master mix preparation for QuantStudio™ 3D Digital PCR using SYBR 
Green I dye 
Material Volume per chip (µl) Final concentration 
QuantStudio™ 3D Digital PCR 
Master Mix 
7.25 1X 
20X SYBR Green I dye in TE 
buffer, pH 8 
1.45 2X 
Forward and reverse primer Variable Variable* 
DNA template  Variable 20-30 ng 
ddH2O Bring volume up to 
14.5 
 















Table 2.7 Thermal cycler condition used to amplify RHD exons 5, 7 and 10 for 
QuantStudio™ 3D Digital PCR using SYBR Green I dye 
                         PCR protocol Cover 
Temperature 
 Stage 1 Stage 2 Stage 3 
Temperature 96ºC 60ºC* 98ºC 60ºC* 10ºC  
70ºC Time 10 min 2 min 30 sec 2 min ∞ 
Cycles 1x (Hold) 39x 1x (Hold) 
*This temperature was adjusted to 56ºC and 58ºC for optimization process.  
 
We analysed the fluorescent data from the cdPCR with QuantStudio® 3D 
AnalysisSuiteTM online software. A known D positive buccal extracted DNA was used as 
positive control. The threshold was set manually based on NTC and applied to all samples in 
each batch. Based on this, positive and negative droplets were determined. DNA 
concentration (copies/µl) was then determined by the QuantStudio® 3D AnalysisSuiteTM 




2.2.17 Comparison between 3 different SYBR Green master mixes for 
the detection of RHD exon 10 using direct dry blood on FTA card  
Several attempts on direct amplification of DNA from biological samples has been 
going on. Mercier and colleagues successfully amplified HLA DQ A gene using whole blood 
sample without the need of extraction process  (Mercier et al., 1990).  Kline and colleagues 
evaluated the performance of a short tandem repeat multiplex using dried whole blood stains 
preserved on FTA card without extraction and found these cards are useful media for DNA 
study (Kline et al., 2002). However, there are no studies tested direct PCR using FTA card on 
RHD blood group genotyping.   
A total of 40 µl K2EDTA blood sample per well was applied on Whatman FTA card 
(GE Healthcare) and dried at 80oC for 30 minutes. The samples were stored at room 
temperature until used. For sample preparation; 3 mm disc was punched out of sample in 
FTA card and placed in 1.5 microcentrifuge tube. Quick washing and lysis process were 
followed as described previously.  The samples were washed with 20 µl of ddH2O at 50
oC for 
3 minutes. Tris-EDTA buffer pH 8.0 (Qiagen, UK) was added after water removal and the 
samples were incubated for 5 minutes at 98oC in a heating block. Lysate was transferred to 
0.5 ml tube to be used in PCR.   
A total of 14 samples previously known for being positive for RHD exon 10 were 
tested. Real-time PCR was performed in a total volume of 20 µl consisting of either 1x 
Qiagen (QuantiNova SYBR®Green Master Mix), PCRBIOSYSTEMS (qPCRBIO SyGreen 
Mix) or Applied Biosystems (PowerUp™ SYBR™ Green Master Mix), 400nM of each 
primer MDF10 and rr4 (Table 2.1) and 4 µl of lysate (DNA template). The reaction was 
carried out in Rotor-Gene Q thermocycler (Qiagen). Thermocycler was run for 40 cycles 




5 sec, annealing and extension at 60oC for 20 sec.  For direct real-time PCR, a total volume of 
20 µl (4 µl of DNA) in 40 cycles using thermal cycler Rotor-Gene Q (Qiagen, UK) was used. 
Melting curve analysis was performed between 65 and 95oC with a temperature increment of 
0.5oC/second. Curves were sketched using Rotor-Gene Q data analysis software. Melting 
curve peak as RHD exon 10 amplicon was confirmed with a 381 bp band in 2% gel 
electrophoresis. The sensitivity of each master mix to detect RHD exon 10 by direct method 
without DNA extraction was calculated. Real-time PCR result for RHD exon 10 from 
extracted DNA used as a gold standard method for this comparison.   
2.2.18 Statistical and data analysis  
Convenience sampling method were used for collecting D negative donors’ samples. 
For serological methods, data were statistically described in terms of frequencies (number of 
cases) and percentages when appropriate. The results were expressed as percentages by 
dividing total positive cases for the particular positive antigen by total number of samples (n 
= 203) and multiplied by 100. Data were managed and analysed using GraphPad Prism 8 
(USA). Confidence level chosen was 95% and confidence interval (C.I) was calculated using 
https://www.surveysystem.com website. The C.I value was calculated based on unpublished 
data of D negative (8.4%) which estimates about 209000 out of 2.5 million of Omani 
population with D negative. The sample size of 203 with estimated D negative Omani 
population gave 6.87 C.I level with 95% confidence level. The calculated frequency range of 
95% C.I is based on frequency percentage ± 6.87. Rh haplotype frequency was estimated 
using Hardy-Weinberg equation. The following equation was used (r is r haplotype, p is r´ 
haplotype and q is r´´ haplotype, square is diplotype): 




In order to find out the haplotype frequency, dce (r) phenotype was calculated (total 
dce phenotype divided by total samples). This was considered diplotype frequency (r2 in the 
equation). Square root of the r2 was considered the dce haplotype frequency (r). Likewise, 
other haplotypes frequency were calculated and the values were added in the equation as to 
reconfirm total of all values were equal to 1 (please see Appendix 3 for the detailed 
calculation). All other statistical analysis (mean, standard deviation, standard error, t-test, chi-
square test and p value) were performed using GraphPad Prism 8 application unless stated 
otherwise. The distribution of antigens/phenotypes between this study and studies of other 
regional populations was compared using the chi‐square test. A p < 0.05 was considered 
statistically significant. Male to female ratio was calculated by dividing number of males by 
number of females. To find out Rh phenotype’s distribution difference between D negative 
Omani male and female, frequency and p value was calculated. Frequency was calculated by 
dividing specific phenotype by n = 203 and multiplied by 100. Statistical p value using 
frequency value of different Rh phenotypes was calculated. As we used two categorical 
variables (gender and Rh phenotype), chi-square test for 2x5 contingency table was used to 
find out p value.  
To compare Omani population with other populations for a specific Rh major antigen 
(C, c, E or e) and Rh haplotype, frequency of Rh major antigen/Rh haplotype of each 
population was recorded from the literature. Statistical P value using these frequencies was 
calculated to find out significant difference between the populations compared to Omanis. As 
we used two categorical variables (population and Rh major antigen/Rh haplotype), chi-
square test for 2x2 contingency table was used to find out P value.  
For DNA multiple extraction (up to 4 extractions) from initial sample (n = 5 




between each extraction round. Mean standard deviation and standard error was calculated 
and two standard error bar charts were plotted.  As the comparison has one categorical 
variable (extraction round) and one numerical variable (DNA concentration or DNA purity), 
we implemented t-test to compare these variables to get the P value. P value < 0.05 was 
considered significant.   
For molecular genotyping, all RHD exon 10 positive was calculated by number  and 
the percentage calculated by dividing total positive cases for RHD exon 10 by total number of 
samples and multiplied by 100. The result of ASP-PCR for the detection of RHDѰ 
pseudogene, RHD-CE-Ds hybrid gene, and RHD deletion in serological D negative blood 
samples allowed us to calculate experimental allele frequencies for each molecular 
background.  Assuming consistency with Hardy-Weinberg equilibrium, genotype and allele 
frequencies of inactive RHD genes and RHD deletion was calculated using Bernstein formula 
(Touinssi et al., 2009) - detailed calculations can be seen in Appendix .  
The sensitivity assessment for the evaluation of different SYBR Green master mixes 
ability to detect RHD exon 10 from direct dry blood sample on FTA card without DNA 
extraction method was calculated as follows:  
 
In cdPCR using SYBR Green, RHD exon 10 DNA concentration (copies/µl) and 
sample volumes with different dilutions correlation was calculated using statistical Anova 
test and significance was accepted at p < 0.05. Using TaqMan chemistry, DNA concentration 
(copies/µl) and sample volumes was calculated using Anova test and significance was 
accepted at p < 0.05. All statistical analysis was performed using GraphPad Prism 8 (USA).  
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3 CHAPTER THREE: Serological RhCE phenotyping & 
molecular background of D negative Omani population 
3.1 Introduction:  
The D antigen of the Rh blood group system is the most important protein due to its 
involvement in HDFN and in HTR. According to recent data, transfusion with a unit or more 
D positive blood unit leads to the production of anti-D in 20-30% of D negative individuals 
(Frohn et al., 2003; Yazer and Triulzi, 2007; Gonzalez-Porras et al., 2008). Therefore, to 
prevent anti-D alloimmunization, exposure of D negative individuals to D positive RBCs 
should be avoided by appropriate transfusion strategies, and routine administration of anti-D 
immunoglobulin to D negative women during the third quarter of pregnancy and after 
delivery of a D positive infant.  
Studies shown that detection of weak D, DEL phenotype or partial D may be missed 
by standard serologic methods including IAT and may cause anti-D immunization when 
transfused to D negative recipients. Garratty calculated that at least 120 weak D or Del 
donors, typed D negative serologically, are transfused to D negative recipients annually in 
Southern California (Engelfriet and Reesink, 2006). In another study by Flegel and 
colleagues on 46133 serologically D negative donors, the RHD genotyping showed that 96 
samples had RHD gene, half of which harboured Del phenotype (Flegel, von Zabern and 
Wagner, 2009). Moussa and colleagues study realized that a partial D sample type DBT was 
mistyped as D negative by serological tests (Moussa et al., 2012).  
The D negative phenotype is characterized by a high molecular diversity which 
explains the discrepancies found between serologic and molecular methods. RHD genotyping 
is very efficient for managing donors and patients carrying any of the various molecular types 
of weak D, DEL phenotype and partial D. in addition, it overcomes the limitations of 
serological methods that are unable to differentiate between RHD variants and mistyped D 
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status. Moreover, it also unveils the type of molecular RHD genotyping of D negative 
(silent/inactive or full deletion). Unpublished data of frequency of D negative phenotype was 
estimated at 8.4% in Oman. 
Oman has a high prevalence of hereditary blood disorders such as SCD and 
thalassemia (Al-Riyami et al., 2001). Alkindi and colleagues investigated the rates of 
alloimmunization in Omani SCD and thalassemia patients and found that the rate of 
alloimmunization in SCD was 31.6%, whereas in patients with thalassaemia it was 20%. 
Antibodies to E, e, C, c, D, K, S, Fyª, Kpª, Jkª and Cw were observed; 85% of the patients 
were also immunised with Rh and Kell antigens (Alkindi et al., 2017). Another study 
conducted by Al-Dughaishi and colleagues on D negative Omani pregnant women revealed 
that, the prevalence of D negative was 7.3%. and the rate of D negative alloimmunization was 
10%, and anti-D was the most common antibody detected (Al-Dughaishi et al., 2016). 
Therefore, a comprehensive RHD alleles study would be very useful to unveil D status and 
reduce the risk of anti-D alloimmunization in D negative recipients. RHD allele study was 
lacking in Omani population, hence this propelled us to conduct such study.  
Daar and colleagues demonstrated multicentric origin of sickle mutation in Oman 
with haplotypes originated by gene flow from sub-Sahara west Africa, East Africa (Zanzibar) 
and Arab-India haplotype (Iran, Iraq, Pakistan and India) (Daar et al., 2000). Based on this, 
likewise we hypothesized molecular background of RHD negative in Oman would be 
multicentric origin either inactive/silent due to RHDѰ pseudogene and RHD-CE-DS as seen 
in African (Moussa et al., 2012) and full deletion as seen in Iran (Khosroshahi et al., 2019). 
The aim of the current study was to detail RHD molecular background on apparently D 
negative individuals in Omani donors. The first step in the study was to reconfirm D status of 
205 D negative samples and phenotype them for C,c,E and e antigens by two different 
methods (tube and gel card). The second step was to test all these samples for weak D by two 
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different serological methods (tube and gel card). Samples positive for weak D testing (n = 2) 
were excluded from the study. The last step of the study consisted of using real-time PCR to 
confirm the D status of the samples (n = 203) that were typed as D negative after being 
confirmed by AHG testing.  
3.2 Serological determination of ABO/RhCE phenotypes on D negative 
Omani donors 
RhD and RhCE phenotyping by direct gel card serological test was done on 205 D 
negative Omani blood donors. All D negative samples with direct method were further tested 
for positivity by IAT weak D gel card test which excluded two samples as being weak D. 
ABO phenotyping were done by each regional blood bank as routine donor testing. ABO 
group distribution and frequencies for 203 samples (excluding n = 2, positive for weak D) 
were as follows: O (n = 115, 56.7%) > A (n = 49, 24.1%) > B (n = 30, 14.8%) > AB (n = 9, 
4.4%) (Figure 3.1).  
All direct serological tests (n = 203, excluding weak D) showed the following Rh 
phenotypes and probable genotypes: C-c+E-e+ (rr,  n = 158, 77.8%), C+c+E-e+ (r'r, n = 38, 
18.7%), C-c+E+e+ (r˝r , n = 5, 2.5%), C+c-E-e+  (r'r',  n = 1, 0.5%), C-c+E+e- (r˝r˝, n = 1, 
0.5%) (Table 3.1). Both weak D samples showed C-c+E-e+ phenotype and R0r probable 
genotype (excluded from the study). The frequency of Rh phenotype and probable genotypes 
for males and females was also compared. Distribution of RhCE phenotypes is similar in both 
the genders, whereas the distribution of probable genotypes showed rr > r'r > r''r > r'r' > 
r''r'' for male and rr > r'r > r'r' > r''r'' = r''r for female (Table 3.2). The frequency of C, c, E 
and e were 20%, 99%, 3% and 99% respectively (Figure 3.2).  Haplotype frequencies were: 
(dce, 0.89), (dCe, 0.1) and (dcE, 0.01) (Figure 3.3).  Representative images are presented in 
in Figure 3. 4 (A-F), showing RhD  and RhCE phenotyping by gel technique. 
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Figure 3.1 ABO distribution among D negative Omani donors.  
ABO phenotyping on 203 blood samples obtained during routine blood donation in Oman. 
Testing was performed by the respective blood banks using BioRad DiaClon ABO/Rh ID-
Card technique. The most frequent ABO group was O followed by A, B and AB.  
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Table 3.1 Rh phenotypes and probable genotype frequencies in D negative Omani 
donors (n = 203) 
                                                          Probable genotype 







D-C-E-c+e+ rr rr dce/dce 158 77.8 70.9 – 84.7 
D-C+E-c+e+ r'r r'r dCe/dce 38 18.7 11.8 – 25.6 
D-C-E+c+e+ r''r r''r dcE/dce 5 2.5 < 9.4 
D-C-E+c+e- r''r'' r''r'' dcE/dcE 1 0.5 < 7.4 
D-C+E-c-e+ r'r' r'r' dCe/dCe 1 0.5 < 7.4  
Total  n = 203 100  
*The specific Rh phenotype frequency percentage was calculated by dividing Rh phenotype by 
203 and multiply by 100.  
**Confidence interval. C.I was calculated using https://www.surveysystem.com website. The C.I 
value was calculated based on unpublished data of D negative (8.4%) which estimates about 
209000 out of 2.5 million Omani population with D negative. The sample size of 203 with an 
estimated D negative Omani population gave 6.87 C.I level with a 95% confidence level. The 
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Table 3.2 Rh phenotype distribution between D negative Omani male and female blood 
donors (n = 203)  
                     Phenotype*  




























p-value** p = 0.3772  203 
*Frequency was calculated by dividing specific phenotype by n = 203 and multiplied by 100 
**p value was calculated using Prism GraphPad software (USA). A chi-square test for 2x5 
contingency table was used.  
There is no statistical difference between Omani male and female donors with regard to Rh 
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Figure 3.2 Rh phenotype frequencies in D negative Omani blood donors.  
Rh phenotyping was performed on 203 blood donors using Bio-Rad RhD + Phenotype ID-











Figure 3.3 Rh haplotype frequencies in D negative Omani blood donors.  
The haplotype frequencies were determined in 203 blood samples obtained during routine 
blood donation to Omani blood banks using Hardy-Weinberg equation. The haplotypes order 
was dce > dCe > dcE.  
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Figure 3.4 Rh phenotyping by BioRad gel card technique. 
Representative samples (n = 6) shows Rh phenotyping. Agglutination indicates presence of 
the Rh antigen on RBCs and thus phenotyping & probable genotype. Agglutination with only 
c and e suggests D-C-E-c+e+ phenotype with rr probable genotype (A & B). A probable 
genotype r'r and D-C+E-c+e+ phenotype is recorded for samples giving agglutination with C, 
c & e (C), whereas a probable genotype r'r' and D-C+E-c-e+ phenotype is recorded for any 
agglutination with C & e only (D). Agglutination with c, E and e suggests D-C-E+c+e+ 
phenotype with r''r probable genotype (E), whereas agglutination with only c and E suggests 
D-C-E+c+e- phenotype with r''r'' probable genotype (F). (0): no agglutination (–) negative; 
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3.3  Serological determination of weak D on D negative Omani donors 
Weak D testing was performed on 205 samples by IAT to determine any D positive 
sample not detected by direct serological method. The tube technique was negative for all. In 
comparison, gel card method gave negative IAT for all samples (Figure 3.5) except sample 
001 and sample 209 (excluded in the study), which suggests C-c+D+E-e+ phenotype and R0r 
probable genotype (Figure 3.6). DAT was used as a control to rule out any false positive 
weak D.  
Figure 3.5 IAT testing for weak D.  
Representative samples (n = 12) shows weak D test with DAT control results. Weak D 
testing performed using Bio-Rad anti-IgG (rabbit) ID-card. Representative samples showed 
no agglutination, which indicates negative weak D test and thus may confirm serological D 
negative (A-D). DAT test was performed for each sample as a control to rule out false 
positive results. (0: No agglutination – negative). Total of 203 out of 205 samples showed no 
agglutination.  




Figure 3.6 Rh phenotype and serological determination of weak D by IAT for samples 
001 & 209.  
Rh phenotyping was performed using BioRad RhD + Phenotype ID card, whereas ICT weak 
D testing done using BioRad coombs anti-IgG ID card. Both samples showed 4+ 
agglutination with c & e only, which suggested D-C-E-c+e+ phenotype and rr probable 
genotype initially (A & B).  However, weak D testing by ICT gel card technique showed +1 
agglutination for both samples, which determined weak D presence and thus D positive with 
DAT control negative result to rule out any false positive weak D (C & D).This suggests re-






C.                                                                     D. 
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3.4 Serological Rh phenotype of D negative Omanis compared to other 
populations 
The D negative ratio for Omani male to female was 7.1:1. This ratio showed no 
significance compared to 4.2:1 ratio observed in Gana [p = 0.172] (Opoku-Okrah C, Amidu 
N and Amoah-Sakyi S, 2008). However, it showed significant difference (p < 0.001) from 
observed ratio 1.27:1 in a study conducted by Muhammed et al, 2016 in Pakistan 
(Muhammad et al., 2016). 
As stated in section 3.2, current study showed no significant difference between D 
negative male and female Omani blood donors with regard to Rh phenotyping (p = 0.224218) 
[Table 3.2]. The commonest phenotype and probable genotype noticed was C-c+E-e+ (rr). 
This finding is similar  to the result observed in two Arabian countries, Tunisian population 
(Moussa et al., 2012; Sassi et al., 2014) and Saudi Arabia (Al-Shiakh. et al., 1997).  
As seen in Figure 3.2, among D negative blood donors the most common antigen 
found to be e followed by c, C and E. This is similar to that in other Arab countries UAE, 
Saudi Arabia, Morocco and India (Al-Shiakh. et al., 1997; Taha, 2012; Makroo et al., 2014; 
Zahid et al., 2016). Predominantly, there are no significant differences between these 
frequencies compared to the most other Arab countries, Iran and India; nonetheless, 
significant differences have been observed in C and E antigens (Al-Shiakh. et al., 1997; 
Moussa et al., 2012; Makroo et al., 2014). Rate of C positive in the total populations was 
19.7% and showed significant difference compared to 9.52% in Saudi Arabia, 33.5% in India 
and 6.7% in Tunisia (p < 0.001) whereas the rate of E positive was 3% which determined 
significant difference in comparison to India (p < 0.001). Antigen c positivity found to be 
98.5% compared to 93.6% in UAE with significant difference [p < 0.05] (Taha, 2012). 
Frequencies of major Rh antigens in D negative Omani population compared to other 
populations are provided in (Table 3.3).  
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Total n = 205 n = 651 n = 3773 n = 62 n = 131 n = 51 n = 448 
* p < 0.05            **p < 0.01          ***p < 0.001     
p value calculated using GraphPad prism 8 (USA). 2 x 2 contingency table.  
p value compares Omanis with other populations for a specific indicated Rh antigen. Rh 
frequency for the c and e antigens show no statistical difference compared to the listed countries 
with exception of UAE and Tunisia for c antigen. Saudi Arabia, India and Tunisia show statistical 
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As stated in section 3.2, the most common haplotype observed in current study was r 
followed by r' and r˝.  Rh haplotypes frequency order observed in current study was similar 
in other D negative populations. In our study r haplotype frequency was 0.887 which is 
almost proportionate with frequency in UAE, Morocco and Iran, whereas it showed 
significant difference with frequency in Saudi Arabia and India (p < 0.05) (Table 3.4) 
 






















(Keramati et al., 
2011) 
r 0.887 0.944 0.809 0.88 0.916 0.918 
r’ 0.1 0.046 0.178 0.071 0.08 0.072 
r” 0.013 0.006 0.004 0.049 0.004 0.01 
ry 0 0 0.011 0 0 0 
* p < 0.05      
 p value calculated using GraphPad prism 8 (USA) 9 – 2 x 4 contingency table  
p value compares Omanis with other populations for Rh haplotypes. Rh haplotypes frequency for the c 
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3.5 DNA extraction for molecular study  
DNA was extracted using QIAamp® DNA Investigator protocol on 3 mm discs taken 
from the centre of FTA cards spotted with 40 μl of whole human blood. We observed an 
average of 18 ng/µl with a minimum of 2 ng/µl of genomic DNA recovery (n = 203).  
Representative samples (n = 5) were tested for subsequent extraction for 4 times to 
determine the possibility of obtaining DNA from 3 mm FTA card disc. We observed an 
average of 14 ng/µl of genomic DNA recovery from extraction one, which increased to 36 
ng/µl after extraction two and reduced to 29 ng/µl after extraction three. All representative 
samples gave no DNA yield with extraction 4, which suggests repeated extraction of piece of 
FTA cards indicated that the DNA bound to the FTA membrane was not fully eluted in the 
first extraction but cannot be reused after three extractions (Figure 3.7). Combining the DNA 
extracts ( Figure 3.8) obtained from the three rounds of extractions increase the yield. The 
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Figure 3.7 Bar plot of mean DNA concentration from repeated DNA extraction on FTA 
card. 
Qiagen Investigator Kit protocol was used for the extraction process. The bar graph shows 
mean DNA concentration (standard error bar) of representative samples (n = 5) for multiple 
extraction for up to four times using the same initial sample. The mean values are 14, 36 and 
29 from extraction 1, 2 and 3 respectively and no yield was observed from extraction 4. 
Highest yield can be obtained from second extraction, whereas no yield could be obtained 
after three extractions. Asterisk (*) indicates significant difference (p < 0.05) between groups 
compared to extract 1 using t-test.  
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 Figure 3.8 Bar plot of mean DNA purity from repeated DNA extraction on FTA card.  
The mean, standard deviation, standard error and bar graph calculated and plotted using 
GraphPad Prism 8. Statistical t-test and p value calculated using GraphPad Prism 8. The bar 
graph shows mean DNA purity (standard error bar) of representative samples (n = 5) for 
multiple extraction for up to four times using the same initial sample. The mean DNA purity 
values are 2.72, 1.88 and 2.4 from extraction 1, 2 and 3 respectively and no yield was 
observed from extraction 4. Asterisk (*) indicates significant difference (p < 0.05) between 
other extraction groups compared to extract 1 using t-test. A significant difference was found 
between extract 1 and 2, where extract 2 gives the best DNA purity compared to extract 1 as 
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3.6 RHD exon 10 analysis  
All 203 samples were tested for the presence of RHD gene by SYBR Green qPCR 
technique to amplify RHD exon 10 initially. Among the studied samples, 179 (88.18%) 
showed no amplification of the RHD exon 10, suggesting a RHD deletion (del) molecular 
background, in accordance with the serological results. This categorized serological D status 
as true D negative. The remaining 24 (11.82%) samples showed a positive amplification for 
RHD exon 10, indicating a RHD genetic polymorphism (Table 3.5). Total of 50% of the 24 
samples that indicated polymorphism had C or E antigen as per serological results. 
The amplification presence was indicated by Ct and confirmed by melting curve 
which showed 2 peaks; the first between 78.75°C and 79.00°C and the second between 
81.25°C and 81.50°C (Figure 3.9). Negative samples showed no Ct value and no melting 
curve peak (Figure 3.9). Samples amplification data from the Rotor-Gene Q was reconfirmed 
by 2% agarose gel electrophoresis which showed a single expected product size of 392 bp 
(Figure 3.9). For RHD exon 10 positive samples, a further reconfirmation of the product and 
exon presence was done by Sanger sequencing where the BLAST showed 100% similarity 
with normal RHD gene (Figure 3.10) suggesting the primers had amplified the desired gene 
region.  
The sequencing result of the 24 samples showed no single nucleotide mutation (SNP), 
deletion or insertion, which suggested a normal coding sequence for exon 10 in Omani 
population (Figure 3.10). All RHD exon 10 positive samples with SYBR Green chemistry 
were retested with TaqMan chemistry along with 30 representative RHD exon 10 negative 
samples and found to be consistent with SYBR Green results. 
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Table 3.5 Rh phenotype distribution according to the existence of RHD exon 10 
Molecular 
background  
Rh Phenotype of serological D negative samples (n = 203) 
 ddccee  
n = 158 
(77.8 %) 
ddCcee  
n = 37 
(18.2 %) 
ddCCee 
n = 2 
(1 %) 
ddccEe 
n = 5 
(2.5 %) 
ddccEE 
n = 1 
(0.5 %) 
 
RHD deletion* n 

























*RHD gene deletion was considered based on the absence of RHD exon 10 
** RHD gene polymorphism was considered based on the presence of RHD exon 10 
The table shows Rh phenotype distribution according to the molecular background in D 
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Figure 3.9 Melting curve peak versus gel electrophoresis for RHD exon 10 amplicon.  
Shows results for representative samples (n = 9).  All samples were run in duplicates with a 
positive control and non-template control (NTC). Two peaks were observed in all 9 samples, 
first peak (78.75°C-79.00°C) and second peak (81.25°C-81.50°C), indicating RHD exon 10 
amplification with possible second amplicon (contamination), whereas no peak was observed 
in the no template control NTC (A). DNA ladder marked as (C). RHD positive control 
showed specific PCR product for the RHD exon 10 (lane marked Rh+, 393 bp). A negative 
NTC showed no product (lane marked NTC). All representative RHD exon 10 positive 
samples showed 393 bp product (lanes 50, 75 and 82) compared to peaks presence in melting 
view. Negative samples (lanes 17, 46, 51, 53 and 78) showed no RHD exon 10, no peak in 
melting curve and thus a negative genotyping result (B).  correlation between two peaks in 
melting curve (A) and one band in gel view (B) rule out contamination.  





Figure 3.10 Representative nucleotides BLAST result of RHD exon 10 amplicon.  
The BLAST was performed using NCBI BLAST online software. Query is the sample 
nucleotides sequence determined from Sanger sequencing. Subject is the nucleotide sequence 
in RefSeqGene that matches the most with query sequence. The BLAST showed 100% 
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3.7 Molecular analysis of serological D negative samples and positive 
RHD exon 10  
3.7.1 Correlation between melting curve analysis and gel electrophoresis 
of RHD exons 1 through 9  
In order to determine the molecular background of the 24 RHD exon 10 positive 
samples, further molecular investigation was done by testing RHD exons 1 through 9. 
QuantiNova SYBR Green PCR master mix was used with specific primers listed in Table 2.1 
as per the method described in section 2.2.12. The melting curve temperature was determined 
of each RHD exon and further correlated and reconfirmed by agarose gel electrophoresis as 
shown in Table 3.6.  We observed all RHD exons melting curve temperature were close to 
each other (between 81.25 and 87.50oC) except RHD exon 9 (75.25-75.75oC) which suggests 
melting curve analysis of SYBR Green chemistry is not a good tool to discriminate between 
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Table 3.6 RHD exons 1 through 9 melting curve temperature and product size in 
agarose gel electrophoresis 
 
RHD exon 







Peak 1 Peak 2 (if any) 
1 84.25-84.50* 86.25-86.50* 381   Figure 3.11 
2 87.10-87.50*  190  Figure 3.12 
3 82.25-82.75*  154  Figure 3.13 
4 82.75  123  Figure 3.14 
5 82.25  157 Figure 3.15 
6 87.25  133 Figure 3.16 
7 81.25-81.75*  96 Figure 3.17 
9 75.25-75.75*  119 Figure 3.18 
Asterisk (*) indicates the melting temperature range from minimum to maximum for the 
respective RHD exon amplicon  
The table shows RHD exons 1 through 7 and exon 9 melting curve temperature (n = 24) 
determined for SYBR Green chemistry compared to product size in agarose gel 
electrophoresis. RHD exon 9 shows a unique melting temperature curve compared to RHD 
exons 1 through 7 which determined overlapping curves.   
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 Figure 3.11 Melting curve temperature analysis versus gel electrophoresis for RHD 
exon 1.  
Shows results for representative samples (n = 5).  All samples were run in duplicates with a 
positive control and non-template control (NTC). In (A) y axis is the intensity change in a 
given interval from fluorescence derivative (df) in relation to temperature derivative (dt) df/dt 
and x axis is the temperature in oC. Two peaks were observed in 4 samples, first peak 
(83.50°C-84.0°C) and second peak (84.25°C-84.50°C), indicating RHD exon 1 amplification 
with possible second amplicon (contamination), whereas no peak was observed in the no 
template control NTC and sample 124 (A). DNA ladder marked as (M). RhD positive control 
showed specific PCR product for the RHD exon 1 (lane marked Rh+, 381 bp). A negative 
NTC showed no product (lane marked NTC). All representative RHD exon 1 positive 
samples 88, 92, 93 and 95 showed 381 bp product compared to peaks presence in melting 
analysis. Negative sample 124 (lanes 124) showed no RHD exon 1, no peak in melting curve 
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and thus a negative genotyping result (B).  correlation between two peaks in melting curve 
(A) and one band in gel view (B) rule out contamination.  
 
Figure 3.12 Melting curve temperature analysis versus gel electrophoresis for RHD exon 
2.  
Shows results for representative samples (n = 6).  The melting curve analysis showed one 
peak for all representative positive samples (Rh+, 151, 154, 156, 205 and 213), between 
87.10°C and 87.50°C. Sample S95 showed primer dimer (PD) peak at 76.0°C (A). Rh 
positive control showed one band of 190 bp and NTC showed no band.  All representative 
positive samples, showed band of 190 bp band (samples 151, 154, 156, 205 and 213) that 
reflects the melting curve between 87.10 and 87.50, whereas negative sample 95 showed no 
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band at 190 bp but a band under 50 bp that suggests primer dimer (B). DNA ladder marked as 
(M). 
 
Figure 3.13 Melting curve temperature analysis versus gel electrophoresis for RHD exon 
3.  
Shows results for representative samples (n = 9). Rh positive control showed two peaks at 
82.75℃ and primer dimer at 76.0℃ and NTC showed a peak at 76.75℃ indicating primer 
dimer (A).  All representative positive samples (S154, S156, S160, S206, S211 and S234) 
showed two peaks, peak one between 82.25°C and 82.75°C and peak two as primer dimer 
whereas, negative samples (S153) showed primer dimer (PD) peak at 76.75°C (A). Rh 
positive control showed two bands; first as desired 190 bp and second < 50 bp (PD) and NTC 
showed one band as well (PD) (B).  All representative positive samples, showed two bands of 
190 bp band PD (samples 234, 160, 194, 156, 211, 154 and 206), whereas negative sample 
(153) showed one PD band (B). DNA ladder marked as (M). Product size 190 bp showed as a 
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peak between 82.25°C and 82.75°C in melting curve graph, whereas, PD under 50 bp is a 
primer dimer indicated as a peak between 76.0°C and 76.75°C. 
Figure 3.14 Melting curve temperature analysis versus gel electrophoresis for RHD exon 
4.  
Shows results for representative samples (n = 15). Rh positive control showed one peak at 
82.75℃ whereas NTC showed no peak (A).  All representative positive samples (S154, S156, 
S194, S205 and S213) showed melting curve peak at 82.75℃, whereas negative samples 
showed no peak (S28, S75, S88, S95, S126, S160, S209 and S219) (A). Rh positive control 
showed one band of 123 bp and NTC showed no band (B).  All representative positive 
samples, showed a band of 123 bp (samples 154, 156, 194, 205 and 213) (B) that reflect the 
only peak at 82.75℃ in melting curve analysis, whereas negative samples 28, 75, 88, 95, 126, 
160, 209 and 219 showed no band. DNA ladder marked as (M) 
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Figure 3.15 Melting curve temperature analysis for RHD exon 5.  
Shows results for representative samples (n = 8). Rh positive control showed one peak at 
82.25℃ whereas NTC showed no peak (A).  All representative positive samples showed 
melting curve temperature at 82.25℃ (S11, S88 and S209), whereas negative samples 
showed no peak (S82, S95, S153 and S206) (A). Rh positive control showed one band of 157 
bp and NTC showed no band (B).  All representative positive samples, showed a band of 157 
bp samples S11, S88, and S209) that reflect the only peak at 82.25℃ in melting curve graph, 
whereas negative samples S82, S95, S153 and S206) showed no band (B). DNA ladder 
marked as (C) 
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Figure 3.16 Melting curve temperature analysis for RHD exon 6. 
Shows results for representative samples (n = 8). Rh positive control showed one peak at 
87.25℃ whereas NTC showed a peak at 76.25℃ (A).  The melting curve analysis also 
showed one peak at 87.25℃ for all representative positive samples (S153, S205, S211 and 
S213) suggesting existence of RHD exon 6, whereas negative samples showed a peak at 
76.25℃ (S10, S45 and S80) that suggests primer dimmer (A). In gel view, Rh positive 
control showed a band of 133 bp, whereas NTC showed one band <50 bp (primer dimer - 
PD) (B).  All representative positive samples, showed single 133 bp band (samples S153, 
S205, S211 and S213), whereas negative samples S10, S45 and S80 showed one PD band 
(B). DNA ladder marked as (C). Product size 133 bp showed as a peak of 87.25°C in melting 
curve graph, whereas, PD under 50 bp is a primer dimer indicated as a peak between 
76.25°C. 
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Figure 3.17 Melting curve temperature analysis versus gel electrophoresis for RHD exon 
7 using SYBR Green chemistry.  
Shows results for representative samples (n = 10). Rh positive control showed one peak at 
81.25℃ whereas NTC showed no peak (A).  The melting curve analysis also showed one 
peak between 81.25℃ and 81.75℃ for all representative positive samples (samples S11, S28, 
S75, S82 and S92) which suggests amplification of RHD exon 7, whereas negative samples 
showed no peak (samples S106, S4, S111 and S200) which suggests absence of RHD exon 7 
(A). Rh positive control showed one band of 96 bp and NTC showed no band (B).  All 
representative positive samples, showed a band of 96 bp (samples S11, S, 28, S75, S82, and 
S292) that reflect the only peak between 81.25℃ and 81.75℃ in melting curve graph 
confirming the presence of RHD exon 7 specific amplicon, whereas negative samples S106, 
S4, S111 and S200 showed no band (B). DNA ladder marked as (M).  
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Figure 3.18 Melting curve temperature analysis versus gel electrophoresis for RHD exon 
9.  
Shows results for representative samples (n = 9). Rh positive control showed one peak at 
75.75℃ whereas NTC showed no peak (A).  The melting curve analysis also showed one 
peak between 75.25℃ and 75.75℃ for all representative positive samples (S11, S154, S176, 
S75 and S28) suggesting existence of RHD exon 9, whereas negative samples showed no 
peak (S4, S106, and S126) suggesting RHD exon 9 absence (A). Rh positive control showed 
one band of 119 bp and NTC showed no band (B).  All representative positive samples, 
showed a band of 119 bp (samples S28, S176, S154, S75 and S11) that reflect the only peak 
between 75.25℃ and 75.75℃ in melting curve graph confirming the presence of RHD exon 
9 specific amplicon, whereas negative samples S106, S4, and S126 showed no band (B). 
DNA ladder marked as (M).  
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3.7.2 RHD exons and possible allele determination 
Based on singleplex real-time PCR and primers used in Table 2.1, melting curve 
analysis with gel electrophoresis for RHD exons 1 through 7 and RHD exon 9 showed three 
patterns (Table 3.7). Two samples showed DFR partial type of D. Six samples were positive 
for RHD exons 1, 2, 3, 6, 7 and 9 and negative for exons 4 and 5 suggesting the presence of 
RHD-CE (4-5)-D hybrid gene. One sample amplified all RHD exons except exons 3 through 
5 suggesting RHD-CE(3-5)-D hybrid gene. Nine samples amplified all RHD exons except 
exon 5 suggesting homozygous RHDѰ gene or DVa or heterozygous RHDѰ / DVa presence. 
One sample showed RHD-CE(3-6)-D and one sample showed amplification of all RHD exons 
suggesting weak D. All the 8 samples that showed hybrid gene expressed C antigen. Three 
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Table 3.7  Molecular background pf D negative Omani cohort by singleplex real-time 
PCR results with different exon specific primers (sample wise).  
 






















ddCcee 11 + + + 0 0 + + + NT + DFR 
ddCcee 28 + + + 0 0 0 + + NT + RHD-CE(4-5)-D 
ddCcee 75 + + + 0 0 0 + + NT + RHD-CE(4-5)-D 
ddCcee 82 + + + + + +a + + NT + Weak D  
ddccee 88 + + + 0 + + + + NT + DFR 
ddccee 92 + + + + + 0 + + NT + RHDѰ 
ddccee 93 + + + + + 0 + + NT + RHDѰ 
ddCcee 95 + 0 + 0 0 0 + + NT + ? 
ddccee 106 + + + 0 0 0 ? 0 NT 0 ? 
ddccee 126 + + + 0 0 0 + + NT 0 ? 
ddCcee 151 + + + 0 0 0 + + NT 0 RHD-CE(4-5)-D 
ddCcee 153 + + 0 0 0 0 + + NT + RHD-CE(3-5)-D 
ddccee 154 + + + + + 0 + + NT + RHDѰ/DVa 
ddccee 156 + + + + + 0 + + NT + RHDѰ/DVa 
ddccee 160 + + + 0 0 + + + NT + DFR 
ddCcee 176 + + + + + 0 + + NT + RHDѰ/DVa 
ddccee 194 + + + + + 0 + + NT + RHDѰ/DVa 
ddccee 205 + + + + + 0 + + NT + RHDѰ/DVa 
ddccee 206 + + + + + 0 + + NT + RHDѰ/DVa 
ddCcee 211 + + + 0 0 0 + + NT + RHD-CE(4-5)-D 
ddccee 213 + + + + + 0 + + NT + RHDѰ/DVa 
ddCcee 219 + + + 0 0 0 + + NT + RHD-CE(4-5)-D 
ddCcee 230 + + + 0 0 0 0 + NT + DVI.2 
ddccEe 234 + 0 + + + 0 + + NT + RHDѰ/DIIIb 
+: Positive        0: Negative               NT: Not tested              Ex: RHD exon       Int: RHD Intron 
? : Inconclusive     a: No amplification with primers R648 and Rex5AD2 for SYBR Green, but 
amplified with TaqMan primers RHDex5F and RHDex5R 
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Table 3.8 Molecular background of D negative Omani cohort by singleplex real-time 
































ddCcee 1 + + + 0 0 + + + NT + DFR 
ddccee 2 + + + 0 0 + + + NT +  
ddCcee 5 + + + 0 0 0 + + NT + RHD-CE(4-5)-D 
ddccee 8 + + + + + 0 + + NT + RHDѰ 
ddCcee 1 + + + + + 0 + + NT + 
ddCcee 1 + + + + + + + + NT + Weak D 
ddCcee 1 + 0 + 0 0 0 + + NT + ? 
ddCcee 1 + + 0 0 0 0 + + NT + RHD-CE(3-5)-D 
ddccee 1 + + + 0 0 0 ? 0 NT 0 ? 
ddccee 1 + + + 0 0 0 + + NT 0 ? 
ddCcee 1 + + + 0 0 0 + + NT + DV1.2 
ddccEe 1 + 0 + + + 0 + + NT + RHDѰ/DIIIb 
Total  24            
+: Positive        0: Negative               NT: Not tested              Ex: RHD exon       Int: RHD Intron 
? : Inconclusive  
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3.7.3 Determination of mutation in RHD coding sequence  
All the 24 samples listed in Table 3.7 were sequenced for RHD exons 1 through 7 and 
RHD exon 9 to identify any mutations within the coding sequence of RHD gene using the 
primers stated in the Table 2.1. In addition, sequencing also confirmed the amplification of 
the target RHD exon and eliminated the possibility of RHCE gene interference and false 
positive results. None of the positive samples for RHD exon 1, exon 2, exon 5, exon 7 and 
exon 10 showed any SNP, whereas exons 3, 4, 6 and 9 showed mutation in coding sequence 
with few at intronic region. RHD exon 4 also showed (IVS3-19 dupl 37) typical for the 
presence of RHDѰ pseudogene in 10 samples.  
For RHD exon 3, out of 24 positive samples, two samples (75 and 211) showed 
combined mutations c.455A>C (rs_17418085) and IVS3+9 T>C (rs_113795383) in the 
coding sequence and intronic region respectively using forward primer (Figure 3.19). 
However, reverse primer could not reconfirm c.455A>C mutation as it showed a normal A 
nucleotide in the same position. This would suggest heterozygous mutation but allelic 
dropout due to either degraded DNA or less DNA quantity in the sample. Reverse primer 
could not even reconfirm IVS3+9 T>C mutation as the region where it is located was very 
near to the reverse primer and Sanger sequencing result could not cover that specific area 
(Figure 3.20).  
Intron 3/Exon 4 specific primers for RHDѰ showed 10 samples (Samples 92, 93, 154, 
156, 176, 194, 205, 206, 213 and 234) having 37 bp insertion with c.609 G>A mutation. This 
suggests and confirms the presence of African RHD genotype responsible for D negative 
phenotype (Figure 3.21).  
For exon 6, out of 24 positive samples, a total of 11 samples showed a novel 
heterozygous mutation (c.928 A>G) using forward primer (Figure 3.22). NCBI BLAST 
confirmed the mutation at RHD gene region (Figure 3.23). Reverse primer could not 
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reconfirm this mutation as the SNP location was within the reverse primer sequence and 
Sanger sequencing result using this reverse primer could not cover that specific area for 
sequencing (Figure 3.24).  
For exon 9, out of 24 positive samples, two samples (S82 and S230) showed 
rs_28669938 heterozygous mutation (IVS8-31 T>C) in intron 8 region using reverse primer 
(Figure 3.25 A and B). NCBI BLAST for the sequenced DNA demonstrated replacement of 
nucleotide T with C in these samples compared to wild type RHD gene (Figure 3.25 C). 
Forward primer could not reconfirm mutation IVS8-31 T>C as the good sequencing data 
analysis started at base 26 using this primer and IVS8-31 T>C SNP is at base 22 which 
hindered the sequencing result.  
Based on singleplex real-time PCR results stated in sections 3.6 and  3.7.2 and sanger 
sequencing results in this section, molecular background of serological D negative was 
divided into four general categories. These are; absence of hybrid and pseudogene (del/del), 
presence of pseudogene and absence of hybrid (RHDѰ/RHDѰ or RHDѰ/del), presence of 
hybrid and absence of pseudogene (RHD-CE-D/RHD-CE-D or RHD-CE-D/del) and presence 
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Figure 3.19 Validation of RHD exon 3 SNPs using DNA sequencing  
Representative Sanger sequencing images for PCR products obtained from two samples (S75 
and S211)  showing (A) the c.455 A>C SNP and (B) the IVS3+9 T>C SNPs in RHD 
exon/intron 3. NCBI blast was used to perform sequence alignment between each primer pair 
sequencing result and human reference gene as seen in (C). The reference human genome 
(GRCh38) for RHD exon 3 showing the c.455 A>C SNP (highlighted in pink) and IVS3+9 
T>C SNP (highlighted in yellow).  
 
 




Figure 3.20 Combined SNP (c.455 A>C) and (IVS3+9 T>C) in RHD exon  
Representative Sanger sequencing images for PCR products obtained from two samples (S75 
and S211) showing homozygous mutation c.455 A>C highlighted in pink (A) with forward 
primer, whereas reverse primer showed wild type A nucleotide highlighted in yellow (B). 
Clustal Omega was used to perform sequence alignment between each primer pair 
sequencing result as seen in (C). Alignment of the sequencing for both primers showed 
reverse primer could not confirm forward primer result highlighted in green and could not 
cover the intronic region where second mutation IVS3+9 T>C is located and highlighted in 










Figure 3.21 RHDѰ allele in Omani population 
Representative image for RHDѰ allele found in Omani population. RHD exon 4 sequencing 
showed c.609G>A mutation (A). NCBI blast was used to perform sequence alignment 
between each primer pair sequencing result and human reference gene as seen in (B). The 
reference human genome (GRCh38) for RHD intron 3/exon 4 showing the 37 bp insertion 











Figure 3.22 A novel heterozygous SNP (c.928 A>G) in RHD exon 6 in Omani population 
Representative images for a novel heterozygous (c.928 A>G) and normal samples. Forward 
primer target sequence showed two peaks (for nucleotides A and G) that indicated a novel 
heterozygous (c.928 A>G) mutation (n = 11) circled red (A and B), whereas normal samples 
(n = 13) did show only one normal nucleotide A peak (C and D).  
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Figure 3.23 NCBI BLAST for the novel heterozygous mutation (c.928 A>G).  
NCBI blast was used to perform sequence alignment between each primer pair sequencing 
result and human reference gene. The reference human genome (GRCh38) for RHD exon 6 
showing (c.928A>G) highlighted in yellow.  
 
 
Figure 3.24 Forward and reverse primers sequence alignment for RHD exon 6.  
CLUSTAL O was used to perform sequence alignment between forward and reverse primer. 
Alignment of the sequencing for both primer sequences showed reverse primer could not 
confirm forward primer that showed novel mutation (c.928A>G) highlighted in yellow.  
 
 




Figure 3.25 Validation of RHD intron8/exon 9 SNPs using DNA sequencing  
The figure shows SNP (IVS8-31 T>C) found on RHD intron 8/exon 9 for samples S82 (A) 
and S230 (B). Sanger sequencing result showed heterozygous mutations, C circled red for 
sample 82 (A) and sample 230 (B). NCBI blast was used to perform sequence alignment 
between each primer pair sequencing result and human reference gene as seen in C. The 
reference human genome (GRCh38) for RHD intron 8/exon 9 showing IVS8-31 T>C 
(highlighted in yellow) (C). 
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Table 3.9 Presence of the RHD deletion (del), RHD pseudogene (RHDѰ), and RHD-CE-
D hybrid gene in the serological D negative Omani cohort 




ddCcee 11 No amplification of RHD exon 4 with 
c.928A>G heterozygous SNP in exon 6 
  
RHD-CE(4)-D/RHD-CE(4)-D  
ddCcee 28 No amplification of RHD exon 4 and 5 
with c.928A>G heterozygous SNP in 
exon 6 
RHD-CE(4-5)-D/del or  RHD-
CE(4-5)-D/ RHD-CE(4-5)-D 
ddCcee 75 No amplification of RHD exon 4 and 5 
Heterozygous SNP c.455A>C and 
IVS3+9 T>C in exon 3 & intron 3 
respectively. Heterozygous SNP 
c.928A>G in exon 6 
 
RHD-CE(4-5)-D/del or  RHD-
CE(4-5)-D/ RHD-CE(4-5)-D 




ddccee 88 No amplification of RHD exon 4 RHD-CE(4)-D/del or RHD-
CE(4)-D/ RHD-CE(4)-D 
 
ddccee 92 No amplification of RHD exon 5* with 
37 bp insertion in RHD Intron3/exon4 
and c.609 G>A mutation in exon 4. In 
addition, c.928A>G heterozygous SNP 
in exon 6 
 
RHDѰ/del or RHDѰ/ RHDѰ 
ddccee 93 No amplification of RHD exon 5* with 
37 bp insertion in RHD Intron3/exon4 
and c.609 G>A mutation in exon 4 
 
RHDѰ/del or RHDѰ/ RHDѰ 
ddCcee 95 No amplification of RHD exons 2, 4 and 
5 
Inconclusive RHD-CE-D /del or 
RHD-CE-D /RHD-CE-D  
 
ddccee 106 No amplification of RHD exons 4 




ddccee 126 No amplification of RHD exons 4, 5 and 
9 with c.928A>G heterozygous SNP in 
exon 6 
 
Inconclusive RHD-CE-D /del or 
RHD-CE-D /RHD-CE-D  
 
ddCcee 151 No amplification of RHD exons 4, 5 and 
9 
Inconclusive RHD-CE-D /del or 
RHD-CE-D /RHD-CE-D  
 
 









ddCcee 153 No amplification of RHD exons 3 
through 5 
RHD-CE(3-5_-D /del or RHD-
CE(3-5)-D /RHD-CE(3-5)-D  
 
ddccee 154 No amplification of RHD exon 5* with 
37 bp insertion in RHD Intron3/exon4 
and c.609 G>A mutation in exon 4 
 
RHDѰ/del or RHDѰ/ RHDѰ 
ddccee 156 No amplification of RHD exon 5* with 
37 bp insertion in RHD Intron3/exon4 
and c.609 G>A mutation in exon 4. In 
addition, c.928A>G heterozygous SNP 
in exon 6 
 
RHDѰ/del or RHDѰ/ RHDѰ 
ddccee 160 No amplification of RHD exons 4 with 




ddCcee 176 No amplification of RHD exon 5* with 
37 bp insertion in RHD Intron3/exon4 
and c.609 G>A mutation in exon 4 
 
RHDѰ/del or RHDѰ/ RHDѰ 
ddccee 194 No amplification of RHD exon 5* with 
37 bp insertion in RHD Intron3/exon4 
and c.609 G>A mutation in exon 4 
 
RHDѰ/del or RHDѰ/ RHDѰ 
ddccee 205 No amplification of RHD exon 5* with 
37 bp insertion in RHD Intron3/exon4 
and c.609 G>A mutation in exon 4. In 
addition, c.928A>G heterozygous SNP 
in exon 6 
 
RHDѰ/del or RHDѰ/ RHDѰ 
ddccee 206 No amplification of RHD exon 5* with 
37 bp insertion in RHD Intron3/exon4 
and c.609 G>A mutation in exon 4 
 
RHDѰ/del or RHDѰ/ RHDѰ 
ddCcee 211 No amplification of RHD exon 4 and 5  
Heterozygous SNP c.455A>C and 
IVS3+9 T>C in exon 3 & intron 3 
respectively. Heterozygous SNP 
c.928A>G in exon 6 
 
RHD-CE(4-5)-D/del or  RHD-
CE(4-5)-D/ RHD-CE(4-5)-D 
ddccee 213 No amplification of RHD exon 5* with 
37 bp insertion in RHD Intron3/exon4 
and c.609 G>A mutation in exon 4. In 
addition, c.928A>G heterozygous SNP 
in exon 6 
RHDѰ/del or RHDѰ/ RHDѰ 
 




3.7.4 Further determination of RHD allele by BAGene kits for Rh  
The RhCE serological phenotyping and RHD molecular background results indicated 
in Table 3.7 was further reconfirmed by SSP-PCR BAGene partial D-TYPE and BAGene 
RH-TYPE. Testing samples with BAGene kits further explored the type of RHD alleles 
involved in Omani population.  
Singleplex real-time PCR results in Table 3.7 were used to support few inconclusive 
results.  The molecular background of serological D negative samples that possess RHD exon 
10 (n = 24) were re-evaluated D classified as true serological D negative or false serological 
D negative.  The true serological D negative indicated two patterns that are; presence of 37 
bp insertion in exon 4 that is unique for RHDѰ (n = 8, representative Figure 3.26) and 
presence of RHDѰ in cis to partial D without RHCE hybrid (n = 2, Figure 3.27 & Figure 
3.28).  D positive (serological false D negative, n = 9) indicated patterns that are; RHD-CE-
Ds/RHD-CE(4)-D (n = 1, Figure 3.29), RHD-CE(5)-D in cis to weak D DAR2.00 (n = 1, 
Figure 3.30), partial D without RHCE hybrid (DIIIb) in cis to weak D type 45 (n = 1, Figure 




ddCcee 219 No amplification of RHD exon 4 and 5   RHD-CE(4-5)-D/del or  RHD-
CE(4-5)-D/ RHD-CE(4-5)-D 
 
ddCcee 230 No amplification of RHD exon 4 through 
6. Heterozygous (IVS8-31 T>C) in 
intron 8 region 
 
RHD-CE(4-6)-D/del or  RHD-
CE(4-6)-D/ RHD-CE(4-6)-D 
ddccEe 234 No amplification of RHD exon 2 and 5*. 
with 37 bp insertion in RHD 
Intron3/exon4 and c.609 G>A mutation 
in exon 4. In addition, c.928A>G 
heterozygous SNP in exon 6    
Hemizygous RHD-CE(2)-D and  
RHDѰ/del 
Detection of Exons 4 and 5 was carried out according to (Singleton et al., 2000) and (Maaskant-van 
Wijk et al., 1998) respectively. RHD exon 4 and 5 positivity and negativity distinguish RHD from 
RHD pseudogene (RHDѰ).  
 * No amplification of RHD exon 5: The forward primer 3’ specific for wild type c.654 in exon 5 and 
do not amplify mutation G>C (M218I) associated with RHDѰ 
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3.31), RHD-CE(4)-D in cis to weak D DAR2.00 (n = 1, Figure 3.32), weak D type 4.2 in cis to 
weak D type 41 (n = 1, Figure 3.33), RHD-CE(4)-D in cis to RHD-CE(8-9)-D (n = 1, Figure 
3.34), RHD-CE(4)-D in cis to weak D type 4.2 (n = 2, Figure 3.35), DVI.2 (RHD-CE(4-6)-D 
in cis or trans to DEL(IVS8-31T>C) (n = 1, Figure 3.36). Total of 5 samples were 
unclassified as no bands were detected with multiple RHD exons. Table 3.10 summarizes the 
findings of SSP-PCR BAGene partial D-TYPE. Therefore, total of 189 samples were 
classified as serological true D negative, whereas 9 samples were reclassified as D positive 
and 5 samples were unclassified. Genotype and allele frequencies of inactive RHD genes and 
RHD deletion from 189 D negative individuals is summarized in Table 3.11. Figure 3.39 
summarizes the serological and molecular methods used in order to reclassify the D status.     
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Table 3.10 BAGene partial D assay to determine RHD allele in serological D negative an RHD exon 10 positive Omani population 
BAGene tube Mix 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Possible RHD allele
a
  
Phenotype  Sample D1 D2 D3 D4 D5 D6 D7 D7/8 D9 D10 D2 D6 D7 D7 D8   
ddCcee 11 + + + 0 + + + + + + 0 0 0 0 0 RHD-CE-Ds/DFR-1 
ddCcee 28  + +   + 0  +   +  + 0   0  +  0  0  0  0 0   Unclassified  
ddCcee 75 +   +  0 0   +  +  + +  0   +  0  0  0 0  0   Unclassified 
ddCcee 82 + + + + 0  + + 0  + + 0  0   0  0  0 DBS-0 in cis to DAR2.00 
ddccee 88 + + + 0  + + + 0  + + 0  0   0 0  0 DFR-1 in cis to DAR2.00 
ddccee 92 + + + 0  + + + +  + +  0  0  0  0  0 RHDѰ/del or RHDѰ/ RHDѰ 
ddccee 93 + + + 0  0  + + 0  + +  0  0 0   0 + RHDѰ in cis to  DAU-5 and DAR2.00 
ddCcee 95 +  0 + + + + + + 0  + 0   0  0  0 0  DIIIb in cis to weak D type 45 
ddccee 106 +   +  +  0  0 0   +  0  0  + 0   0  0 0  0   Unclassified 
ddccee 126 + + + + + + + 0   0 + 0   0  0  0 0  Weak D type 4.2 in cis to weak D 41 
ddCcee 151 + + + 0  + + + 0   0 w+  0  0 0   0  0 DFR in cis to RHD-CE(8-9)-D  
ddCcee 153 + + + 0   0 + + 0   0 +  0  0 0   0  0  Unclassified 
ddccee 154 + + +  0 + + + + + +  0  0  0 0   0 RHDѰ/del or RHDѰ/ RHDѰ 
ddccee 156 + + +  0 + + + + + +  0  0  0 0   0 RHDѰ/del or RHDѰ/ RHDѰ 
ddccee 160  +  + +   0  +  + +   0 w+   + 0   0  0  0  0 DFR in cis to weak D 4.2  
ddCcee 176 + + + 0  + + + NR  + +  0  0  0 0   0 RHDѰ/del or RHDѰ/ RHDѰ 
ddccee 194 +  + + 0  + +  + + + +  0  0  0 0   0 RHDѰ/del or RHDѰ/ RHDѰ 




CHAPTER THREE: Serological RhCE phenotyping & molecular background of D negative Omani population 
138 
 
Table 3.10 BAGene partial D assay to determine RHD allele in serological D negative an RHD exon 10 positive Omani population (Cont…) 
ddccee 206 +   +  + 0   + +   +  +  +  +  0  0  0 0   0 RHDѰ/del or RHDѰ/ RHDѰ 
ddccee 211 + + +  0 + + + 0  + +  0  0  0 0   0 DFR in cis to weak D 4.2  
ddccee 213 + + +  0 + + + + + +  0  0  0 0   0 RHDѰ/del or RHDѰ/ RHDѰ 
ddCCee 219 + + +  0 0  ? +  0 ?  +  0  0  0 0   0  Unclassified 
ddCcee 
230 + + +  0  0 0 + + + +  0  0  0 0   0 
DVI.2 in cis or trans to DEL(IVS8-
31T>C) 
ddccEe 234 +  0 +  0 + + + + + +  0  0  0 0   0 RHD*DIIIb in cis to RHDѰ  
                  
a Reported in correlation with real-time singleplex PCR and RH-TYPE BAGene.  
NR: Not reliable as it showed negative for both target product and control  
?: inconclusive  














 Table 3.11 Genotype and allele frequencies of inactive RHD genes and RHD deletion from 188 D negative individuals* 
Genotype    Allele 






Absence of hybrid (RHD-CE-DS)** and 
pseudogene (del/del) 
179 94.701 RHD deletion (del) 0.9732 
Presence of pseudogene and absence of 
(RHD-CE-DS) hybrid (RHDѰ / RHDѰ or 
RHDѰ /del) 
10 5.291 Pseudogene (RHDѰ) 0.0268 
Total  189 100  1 
*Assuming consistency with Hardy-Weinberg equilibrium, the Bernstein’s formula was applied to define allele frequencies of 
RHD gene deletion, hybrid RHD-CE-Ds gene, and RHDѰ pseudogene. Because only two genotypes were observed the deviation 
value (D) was 0 (Appendix 3). 
**(RHD-CE-DS) genotype and allele frequency was not calculated as it was observed only in one sample that was in trans to 
partial D hybrid allele and the sample was reclassified as D positive.  
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Figure 3.26 Representative image for a possible hemizygous or homozygous RHDѰ 
allele detected in Omanis  
The gel images are for sample 156 as to represent all other samples that showed similar 
pattern.  Partial D-TYPE gel analysis shows lanes 1-10 for RHD exons 1-10 respectively 
(A). The gel (A) showed amplification of RHD exon 1 (134 bp), 2 (146 bp), 3 (118 bp), 5 
(132 bp), 6 (132 bp), 7 (120 bp), exon 8 (673 bp), exon 9 (184 bp) and exon 10 (132 bp). 
This suggests either RHD exon 4 deletion/hybrid or existence of RHDѰ. RH-TYPE gel 
view (B) showed bands 224 bp and 123 bp amplification for exons 4 and 7 respectively 
(lane 1), 154 bp specific for RHDѰ (lane 2), 220 bp for negative K409K DEL RHD (lane 
4), 145 bp for Rhc gene (lane 11) and 155 bp for Rhe gene (lane 13) for which it suggests 
Rhccee with presence of RHDѰ. The gel did not show any band in lane 3 for RHDѰ 
negative which suggests the absence of normal RHD exon 4 and therefore RHDѰ/ del or 
RHDѰ/ RHDѰ allele. The gel did not show any band for DEL RHD (K909), DEL RHD 
(M295I), DEL RHD (IVS3+1G>A) and Cdes in lanes 5, 6, 7 and 8 respectively suggesting 
absence of these alleles. Human growth hormone control amplicon of 434 bp was detected 
in all lanes. Lane M denotes 100 bp DNA ladder 
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Figure 3.27 Inconclusive but possible DAU5 allele detection on sample 93.  
Partial D-TYPE gel analysis shows lanes 1-10 for RHD exons 1-10 respectively (A). This 
shows amplification of exon 1 (134 bp), 2 (146 bp), 3 (118 bp), 6 (132 bp), 7 (120 bp), 
exon 9 (184 bp) and exon 10 (132 bp). A missing band of RHD exon 4 in lane 4 (135 bp) 
suggests either DFR or RHDѰ existence. A missing band of 132 bp (lane 5) and 673 bp 
(lane 8) for RHD exons 5 and 8 respectively suggests DAR2.00 (weak D type 4). No bands 
seen in lane 11 through 14 for unique partial D except lane 15 which showed 140 bp 
specific for DAU-5. This could exclude the existence of DAR2.00 supporting DAU-5. RH-
TYPE gel view (B) showed 123 bp amplification for exons 7 (lane 1), 145 bp for Rhc gene 
(lane 13) and 155 bp for Rhe gene (lane 15) for which it suggests Rhccee. Lane 2 is not 
reliable, as the control did not appear thus RHDѰ is not excluded. The gel did not detect 
RHDѰ negative which suggests no wild type RHD exon 4, DEL RHD (K909) negative, 
DEL RHD (K909), DEL RHD (M295I), DEL RHD (IVS3+1G>A) and Cdes in lanes 3 
through 8 respectively. Both gel views have Human Growth Hormone control of 434 bp in 
all lanes. Human growth hormone control amplicon of 434 bp was detected in all lanes. 
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Figure 3.28 Possible Hemizygous RHDѰ and RHD*DIIIb (Sample 234). 
Partial D-TYPE gel view shows lanes 1-10 for RHD exons 1-10 respectively (A). This 
shows amplification of exon 1 (134 bp), exon 3 (118 bp), exon 5 (132 bp), exon 6 (132 bp), 
exon 7 (120 bp), exon 8 (673 bp), exon 9 with (184 bp) and exon 10 (132 bp) for lanes 1, 
3, 5, 6, 7, 8, 9 and 10 respectively. Missing band of 146 bp in lane 2 for exon 2 suggests 
partial D type DIIIb and a missing band of 135 bp for exon 4 (lane 4) may suggest DFR or 
RHDѰ. RH-TYPE gel view (B) showed 123 bp and 224 bp amplification for exons 7 and 
intron4/exon4 respectively (lane 1) which suggests the presence of RHD exon 4 and 
excludes partial D DFR involvement. No control band appeared in lane 3, therefore this 
lane result for RHDѰ is not reliable and therefore, presence of RHDѰ allele is not 
excluded. Missing band of 140 bp for the wild type RHD exon 4 suggests possible 
hemizygous RHDѰ. The gel also showed 220 bp for DEL RHD (K909) negative (lane 4) 
which suggests the presence of wild type RHD allele in intron9/exon9 boundary and 
excludes K409K DEL phenotype. A 145 bp, 157 bp and 155 bp for Rhc, RhE and Rhe 
respectively (lanes 10, 11 and 12 respectively) which suggests RhccEe. The gel did not 
detect RHDѰ negative, DEL RHD (K909) negative, DEL RHD (K909), DEL RHD 
(M295I) and Cdes in lanes 3 through 8 respectively. Lane M denotes 100 bp DNA ladder. 
Both gel views have human growth hormone control of 434 bp in all lanes 
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Figure 3.29 RHD (C)ces/DFR-1 allele detection on sample 11.   
BAGene partial D-TYPE gel analysis shows lanes 1-10 for RHD exons 1-10 respectively 
(A). The gel view shows amplification of RHD exon 1 (134 bp), 2 (146 bp), 3 (118 bp), 6 
(132 bp), 7 (120 bp), Intron 7/Exon 8 (673 bp), exon 9 (184 bp) and exon 10 (132 bp). The 
absence of RHD exon 4 suggests hybrid RHCE(4) or RHDѰ presence.  BAGene RH-TYPE 
gel view (B) showed 123 bp amplification for exon 7 (lane 1), 220 bp for negative K409K 
DEL RHD (lane 4), 215 bp for Cdes (lane 8), 145 bp for Rhc allele (lane 10) and 155 bp 
for Rhe allele (lane 12) and no RhC allele band (lane 9) which conflicts with serological 
phenotyping shown in Figure 3.4C . Lane 8 suggests existence of hybrid RHD-CE-Ds. The 
gel did not detect RHDѰ, RHD exon 4, DEL RHD (K909), DEL RHD (M295I), DEL RHD 
(IVS3+1G>A) in lanes 2, 3, 5, 6 and 7 respectively which confirms existence of RHCE(4) 
hybrid and no RHDѰ. Both partial D-Type and RH-Type gel views confirmed RHD exon 4 
deletion in lane 4 and lane 3 respectively suggesting hybrid RHD-CE(4)-D called DFR 
existence. Therefore, the D status can be reclassified as D positive. Lane M denotes 100 bp 
DNA ladder. Both gel views have human growth hormone control of 434 bp in all lanes 
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Figure 3.30 DBS-0 in cis to DAR2.00 allele on sample 82. 
BAGene partial D-TYPE gel analysis shows lanes 1-10 for RHD exons 1-10 respectively 
(A). This shows amplification of exon 1 (134 bp), 2 (146 bp), 3 (118 bp), 4 (135 bp), 6 
(132 bp), 7 (120 bp), exon 9 (184 bp) and exon 10 (132 bp). No amplification bands of 
exon 5 (132 bp) and intron 7/exon 8 (637 bp) in lanes 5 and 8 respectively suggests 
DAR2.00. BAGene RH-TYPE gel view (B) showed bands 224 bp and 123 bp 
amplification for exons 4 and 7 respectively (lane 1), 140 bp band for RHDѰ negative 
(lane 3) which suggests the presence of normal RHD exon 4, 220 bp for negative K409K 
DEL RHD (lane 4), 162 bp for RhC gene (lane 10), 145 bp for Rhc gene (lane 11), 157 bp 
for RhE gene (lane 12) and 155 bp for Rhe gene (lane 13) for which it suggests RhCcEe. 
The gel did not detect RHDѰ, DEL RHD (K909), DEL RHD (M295I), DEL RHD 
(IVS3+1G>A) and Cdes alleles in lanes 2, 5, 6, 7 and 8 respectively. Therefore, the D 
status can be reclassified as D positive. Both gel views have human growth hormone 
control of 434 bp in all lanes. Lane M is FastRuler™ LowRange DNA ladder.  
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Figure 3.31 Inconclusive but possible DIIIb hybrid allele (sample 95).  
Partial D-TYPE gel analysis shows lanes 1-10 for RHD exons 1-10 respectively (A). This 
shows amplification of exon 1 (134 bp), exon 3 (118 bp), exon 4 (135), exon 5 (132 bp), 
exon 6 (132 bp), exon 7 (120 bp), exon 8 (673 bp), and exon 10 (132 bp). Missing band 
(146 bp) for RHD exon 2 (lane 2) suggests partial D type DIII. This accompanied with 
missing band in lane 9 for RHD exon 9 which may suggest weak D type 41 or 45 
involvement as well. RH-TYPE gel view (B) showed 123 bp amplification for RHD exons 
7 (lane 1), 262 bp for RhC allele (lane 12), 145 bp for Rhc allele (lane 13) and 155 bp for 
Rhe allele (lane 15) for which it suggests RhCcee. Lane 2 is not reliable, as the control did 
not appear for RHDѰ detection. The gel did not detect RHDѰ negative, DEL RHD (K909) 
negative, DEL RHD (K909), DEL RHD (M295I), DEL RHD (IVS3+1G>A) and Cdes in 
lanes 3 through 8 respectively. The result for RH-TYPE is inconclusive. Both gel views 
have human growth hormone control of 434 bp in all lanes. Lane M is FastRuler™ 
LowRange DNA ladder.  
  




Figure 3.32 A possible DFR partial D in cis to DAR2.00 seen in sample 88  
 BAGene partial D-TYPE gel analysis shows lanes 1-10 for RHD exons 1-10 respectively 
(A). This shows amplification of RHD exon 1 (134 bp), 2 (146 bp), 3 (118 bp), 5 (132 bp), 
6 (132 bp), 7 (120 bp), exon 9 (184 bp) and exon 10 (132 bp). No amplification of exon 4 
and 8 suggests hybrid RHD-CE(4)-D in cis to  DAR 2.00. BAGene RH-TYPE gel view (B) 
showed bands 224 bp and 123 bp amplification for exons 4 and 7 respectively (lane 1) 
which suggests the existence of RHD exon 4.  The gel view also showed 220 bp for 
negative K409K DEL RHD (lane 4), 145 bp for Rhc allele (lane 11) and 155 bp for Rhe 
allele (lane 13) for which it suggests Rhccee. The gel did not detect RHDѰ negative 140 
bp band (lane 3) for RHD exon 4 which conflicts with results of lane 1 that detects 224 bp 
band for exon 4 and may suggest existence of hybrid RHCE(4). The gel did not detect 
RHDѰ, DEL RHD (K909), DEL RHD (M295I), DEL RHD (IVS3+1G>A) and Cdes alleles 
in lanes 2, 5, 6, 7 and 8 respectively. Both gel views have Human Growth Hormone control 
of 434 bp in all lanes. Lane M denotes 100 bp DNA ladder. Both gel views have human 
growth hormone control of 434 bp in all lanes. Lane M is FastRuler™ LowRange DNA 
ladder.  
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Figure 3.33 Possible weak D 4.2 in cis to weak D type 41 (sample 126). 
Partial D-TYPE gel analysis shows lanes 1-10 for RHD exons 1-10 respectively (A). This 
shows amplification of exon 1 (134 bp), exon 2 (146 bp), exon 3 (118 bp), exon 4 (135), 
exon 5 (132 bp), exon 6 (132 bp), exon 7 (120 bp) and exon 10 (132 bp). Missing bands 
673 bp (lane 8) and 184 bp  (lane 9) of exon 8 and 9 respectively suggests either RHD-
CE(8-9)-D or weak D type 41 in cis with weak D 4.2. RH-TYPE gel view (B) showed 123 
bp amplification for RHD exons 7 (lane 1), and 155 bp for Rhe gene (lane 15). Rhc gene 
band of 145 bp (lane 13) was expected to be seen in correlation with serological c 
phenotype for Rhccee genotype. Possibility of  RHD-CE(8-9)-D is excluded as this allele is 
seen in Cde haplotype. Lane 2 is not reliable, as the control did not appear for RHDѰ 
detection. The gel did not detect RHDѰ negative, DEL RHD (K909) negative, DEL RHD 
(K909), DEL RHD (M295I), DEL RHD (IVS3+1G>A) and Cdes in lanes 3 through 8 
respectively. The result for RH-TYPE is inconclusive and the Rh genotype could not be 
confirmed and compared with serological phenotype. Both gel views have human growth 
hormone control of 434 bp in all lanes. Lane M is FastRuler™ LowRange DNA ladder.  
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Figure 3.34 A possible hemizygous DFR in cis to RHD-CE(8-9)-D (Sample 151). 
Partial D-TYPE gel analysis shows lanes 1-10 for RHD exons 1-10 respectively (A). This 
shows amplification of exon 1 (134 bp), exon 2 (146 bp),  exon 3 (118 bp), exon 5 (132 
bp), exon 6 (132 bp), exon 7 (120 bp) and exon 10 (132 bp). Missing band of 135 bp (lane 
4) for exon 4 suggests either DFR or RHDѰ existence. Missing bands of 673 bp and 184 
bp of exons 8 and 9 respectively suggests RHD-CE(8-9)-D. RH-TYPE gel view (B) has 
missing band of exon 4 (224 bp) and showed 123 bp amplification for exons 7 (lane 1) 
which suggested exon 4 deletion and replacement with RHCE exon 4. A band of 162 bp 
for RhC allele (lane 12), 145 bp for Rhc allele (lane 13) and 155 bp for Rhe allele (lane 15) 
also seen which suggests RhCcee genotype. Lane 2 is not reliable, as the control did not 
appear for RHDѰ detection but since there is RHD exon 4 deletion it predicted to be not 
present. The gel did not detect RHDѰ negative due to RHD exon 4 deletion. Missing bands 
for DEL RHD (K909) negative, DEL RHD (K909), DEL RHD (M295I), DEL RHD 
(IVS3+1G>A) and Cdes alleles in lanes 3 through 8 respectively. Lane M denotes 100 bp 
DNA ladder. Both gel views have human growth hormone control of 434 bp in all lanes. 
 
 
CHAPTER THREE: Serological RhCE phenotyping & molecular background of D negative Omani population 
149 
 
Figure 3.35 A possible hemizygous RHD*DFR1 and weak D 4.2 (Sample 160). 
Partial D-TYPE gel analysis shows lanes 1-10 for RHD exons 1-10 respectively (A). Lane 
M is FastRuler™ LowRange DNA Ladder in (A). This shows amplification of exon 1 (134 
bp), exon 2 (146 bp), exon 3 (118 bp), exon 5 (132 bp), exon 6 (132 bp), exon 7 (120 bp), 
exon 9 with weak band (184 bp) and exon 10 (132 bp). Missing band of 135 bp (lane 4) for 
exon 4 suggests DFR or RHDѰ. Missing band of 673 bp for exons 8 (lane 8) may suggest 
weak D 4.2 allele presence. RH-TYPE gel view (B) showed 123 bp amplification for exons 
7 (lane 1), multiple bands in lane 7 (contamination indicator) and 145 bp for Rhc allele 
(lane 10) and 155 bp for Rhe allele (lane 12). Lane 2 is not reliable, as the control did not 
appear for RHDѰ detection but since there is missing RHD exon 4 it predicted to be not 
present. The gel did not detect RHDѰ negative due to missing RHD exon 4. The gel did 
not detect negative allele for DEL RHD (K409K), DEL RHD (K409K), DEL RHD (M295I) 
and Cdes in lanes 3 through 8 respectively. Lane M denotes 100 bp DNA ladder in (B). 
Both gel views have human growth hormone control of 434 bp in all lanes. 
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Figure 3.36 A possible partial D type DVI.2 (Sample 230) 
Partial D-TYPE gel analysis shows lanes 1-10 for RHD exons 1-10 respectively (A). This 
shows amplification of exon 1 (134 bp), exon 2 (146 bp), exon 3 (118 bp), exon 7 (120 bp), 
exon 8 (673 bp), exon 9 (184 bp) and exon 10 (132 bp). Deletion of exons 4-6 (laned 4-6) 
suggests DVI.2. RH-TYPE gel view (B) showed 123 bp amplification for exons 7 (lane 1), 
220 bp for DEL RHD (K909) negative (lane 4), 940 bp for H and U box (lanes 10 and 11 
respectively), 162 bp for RhC allele (lane 12), 145 bp for Rhc allele (lane 13) and 155 bp 
for Rhe allele (lane 15). Lanes 2 and 3 did not appear for RHDѰ positive and negative due 
missing exon 4. No bands seen in DEL RHD (K909), DEL RHD (M295I), DEL RHD 
(IVS3+1G>A), Cdes and DAR1 in lanes 5 through 9 respectively, which suggests missing 
of these alleles. Lane M denotes 100 bp DNA ladder. Both gel views have human growth 
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3.7.5 Sensitivity evaluation of different SYBR Green master mix for the 
direct real-time PCR from Blood preserved on FTA card 
We also evaluated sensitivity of three different SYBR Green master mix suppliers, 
Qiagen (QuantiNova SYBR®Green Master Mix), PCRBIOSYSTEMS (qPCRBIO SyGreen 
Mix) and Applied Biosystems (PowerUp™ SYBR™ Green Master Mix) were evaluated 
for the direct detection of RHD exon 10 from dry blood on FTA card without extraction of 
DNA. The previously identified RHD exon 10 positive samples (n = 14) were used in this 
analysis. We found that qPCRBIO SyGreen Mix performed the best with sensitivity of 
71% (n = 10) followed by PowerUp™ SYBR™ Green Master Mix with 43% (n = 6) and 
QuantiNova SYBR®Green Master Mix with only 29% (n = 4) ( Figure 3.37). We also 
observed dissociation curve appearance for different supplier’s master mix and observed 
that qPCRBIO SyGreen mix gives a single melt point peak compared to other two with 
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 Figure 3.37 Sensitivity of three different SYBR Green master mixes.   
This is a representative image that compares three different SYBR Green master mixes for 
the direct detection of RHD exon 10 from dry blood spot on FTA card without DNA 
extraction (n = 7 in this representative image, originally 14 samples used). M lane is 100 
bp DNA ladder. Rh+ and Rh- are positive and negative controls respectively. All the 
samples (93, 95, 106, 126, 151, 205 and Rh+) were tested previously from extracted DNA 
and should have given 393 bp product for RHD exon 10.  All suppliers master mixes were 
able to give 393 bp product but with different sensitivity. qPCRBIO SyGreen gave the best 
sensitivity (71%), followed by PowerUp™ SYBR™ Green (43%) and QuantiNova 
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Figure 3.38 Melting curve peak appearance using three different master SYBR Green 
master mixes 
Representative images showing melting curve peaks for RHD exon 10 amplicon using 
qPCRBIO SyGreen, PowerUp™ SYBR™ Green and QuantiNova SYBR Green master 
mixes.  Master mix qPCRBIO SyGreen gave a single peak compared to PowerUp™ 
SYBR™ Green and QuantiNova SYBR Green master mixes that gave anomalous peaks 
(pointed with arrows).  
 




Figure 3.39 Flowchart for the serological and molecular confirmatory D tests 
performed for samples in current study. 
 
A total of 205 D negative samples were collected and D status was further reconfirmed by 
IAT method using anti-D IgM/IgG blend (Atlas,UK) which excluded (n = 2) from the 
study as both samples were reclassified to D positive.  The remaining 203 samples were 
tested for the existence of RHD exon 10 using ASP real-time PCR which divided the 
samples into two categories; RHD complete deletion (n = 179) and RHD variant (n = 24). 
RHD variant samples (n = 24) were further explored by ASP-Singleplex real-time PCR and 
BAgene ASP-PCR for RH-Type and partial D-Type which reclassified (n = 10) as D 
positive. Total of (n = 9) were classified to be true D negative due to inactive RHDѰ 
existence and (n = 5) remained unclassified.    
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3.8 Discussion:  
This study was done on serological D negative Omani population to explore the Rh 
common antigens (C, c, E and e) by molecular phenotyping. There is evidence that some 
RBC units with weak D or DEL phenotype may escape detection by standard serologic 
methods including the IAT method (Sassi et al., 2014). The D negative phenotype is 
characterized by a high molecular diversity which explains the discrepancies found 
between serologic and molecular methods. Therefore, we also studied the molecular 
background of the serological D negative phenotype to further explore the actual D status. 
To the best of our knowledge, there are no published data on Rh common blood group 
antigens and haplotypes frequencies for D negative Omani individuals. Seven Omani 
regional transfusion centres associated with the CBB in capital were involved in the 
collection of samples.  
The D− C− c+ E− e+ phenotype was the most frequent phenotype observed in the 
D negative samples. These results were in accordance with the previous study in other 
Arab populations (Moussa et al., 2012; Khosroshahi et al., 2019) and in Caucasians 
population (Avent et al., 1997c). The negativity of IAT test for samples that has been 
reclassified later as D positive by molecular method may be explained by the low 
sensitivity of the Anti-D IgM/IgG blend (Atlas Medical, UK) used. The negativity could 
also exist due to more than one D variants allele in cis to each other (hemizygous) or in 
trans so both haplotypes will show qualitative or/and quantitative effect on D antigen.   
Melting curve analysis of RHD exons 1 through 7 and RHD exons 9-10 showed Tm 
that are too close to each other’s (Table 3.6) to be separated by real-time PCR SYBR 
Green chemistry. This makes it difficult to make a multiplex assay for RHD exons 
detection in order to be analysed by Tm. A future study with high resolution melt (HRM) 
could be an option to explore further this melting curve analysis by SYBR Green I (Farrar, 
2015) or Eva Green chemistry (Jiang, 2019).  
CHAPTER THREE: Serological RhCE phenotyping & molecular background of D negative Omani population 
156 
 
Total of 11.82% of D negative samples from Omanis expressed RHD variant allele. 
The molecular results showed that D negative results are highly associated with complete 
deletion of RHD gene with frequency of 0.878 (Table 3.5). This frequency is lower than 
those reported in Caucasian population (Singleton et al., 2000; Touinssi et al., 2009) and 
Iran  (Khosroshahi et al., 2019) but higher than those reported in East Asian (Luettringhaus 
et al., 2006; Ji et al., 2017). In contrast, there was a high African contribution associated to 
the presence of RHDѰ pseudogene either alone, identified in eight samples or in 
combination identified in two samples, whereas RHD-CE-D variants (C)ces was identified 
in combination in one sample. RHD gene deletion (18%), RHD-CE-D (15%) and RHDѰ 
(66%) are the main causes of the D negative phenotype among black Africans (Singleton et 
al., 2000). The identified African contribution frequency of 0.06 in Omani population was 
higher than those reported in North African Tunisian population (Moussa et al., 2012; 
Sassi et al., 2014), but lower than those reported in West African Mali population (Wagner 
et al., 2003).  
In line with the RHD genotyping results that showed African origin alleles, we 
observed one sample (Sample 11) with hybrid RHD-CE-D (C)ces, but with complete RHD 
exons 6 and 7 (Figure 3.29, partial D gel view), specific amplicon of IVS2 (Figure 3.29, 
RH-TYPE gel view lane no.8) for the detection Cdes and no C allele detection (Figure 
3.29), RH-TYPE gel view lane no.9).  Existence of RHD exons 6 and 7 is unlikely to be 
found in hemizygous and homozygous types 1 and 2 of RHD hybrid gene (C)ces (Wagner, 
Frohmajer and Flegel, 2001; Fasano et al., 2010). The presence of another partial hybrid 
RHD-CE(4)-D allele haplotype is a possible  reason to combine with that and mask 
missing of RHD exons 6 and 7 accompanied with (C)ces. BAGene partial D type detected 
deletion of RHD exon 4 which suggests partial D DFR-1 is combined with (C)ces to give 
possible Cdes/cDe (Figure 3.40).  Other types of DFR are excluded as they are reported 
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with C allele existence (http://www.rhesusbase.info/), which is not possible in this case to 
be as trans haplotype. This is due to c allele existence (confirmed by serological and 
molecular methods).  Therefore, this sample can be reclassified as D positive. Individual 
with this diplotype may be at risk of producing anti-C if transfused with C positive unit, as 
(C)ces haplotype has alerted C and not compensated with another C in trans (Fasano et al., 
2010).  The Ccdes allele of the RHD gene is typically linked to the ce allele of the RHCE 
gene. Because there is no Ce allele, the kits are not supposed to detect any C allele signal, 
and that explains no reaction in mix 9 (Figure 3.29, RH-TYPE gel view, lane 9) with 
positive weak C in serological test. Due to the presence of another haplotype with ce allele, 
serological phenotyping of c and e remained strong and not weak as seen partial in (C)ces.  
The presence of C antigen with weak e antigen on BioRad gel card (Figure 3.4C) 
supported by the absence of C allele in BAGene kit suggests the presence of VS antigen 
with partial C but not V antigen. This also suggests presence of an additional substitution 
Gly336Cys, in addition to Leu245Val. V and VS antigens should be tested for this sample 
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 Figure 3.40 Possible RH genotype of DFR/Cdes on sample 11.   
The 10 exons of the RHD (black box) & RHCE (white box) genes are symbolized by 
squares and numbered 1 to 10. Sample 11 genotype possibly composed of the variant DFR 
(Dce) haplotype (top panel) and (C)ces (dces) haplotype (bottom panel). In DFR, RHD 
exon 4 is replaced by hybrid RHCE exon 4. In (C)ces, the variant amino acid substitutions 
are shown by positions and amino acids involved, relative to the common RH alleles. The 
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We also observed a case (Sample 82) of possible novel DBS-0 like allele in cis to 
DAR weak D 4.2 (Figure 3.41).  BAGene partial D has detected no amplification with mix 
5 and 8 (Figure 3.30, lane 5 and 8, partial D-Type gel view). DBS appears as a CDe 
haplotype (RhesusBase website) with hybrid RHcE [226P] (5:667-5:712) (Avent et al., 
1996a).  The hybrid gene has RHD exons 1-4, part of RHCE exon (5:667-5:712) and RHD 
exons 6 through 10.  Both BAGene partial D-Type SSP and SYBR Green I singelplex real-
time PCR failed to amplify exon 5 as the allele specific primers used target location 697 bp 
(G nucleotide) on RHD exon 5 underlined which is replaced by RHCE (C nucleotide) with 
hybrid RHCE involvement and thus explains negative result.  Taq Man real-time PCR 
primers (RHDex5F and RHDex5R) amplified RHD exon 5 as they target different location 
on RHD exon 5 that did not overlap with specific RHCE nucleotides in RHCE hybrid.  
Serological result was found to be ddCcee phenotype, however a discrepancy was found 
compared to molecular genotyping by BAGene RH-TYPE that showed amplification of C, 
c, E and e RH alleles (Figure 3.30, RH-TYPE gel view Lanes 10 through 13) suggesting 
RHCcEe instead. Many studies compared between genotyping and serological phenotyping 
of RHCE blood group to explain discrepancies seen between both.  
As stated in section 1.5 , RHCE gene encodes for C/c and E/e antigens. RhC/c rises 
from single base substitution(C307T) CCT (RhC) for serine or TCT (Rhc) for proline in 
exon 2 at nucleotide (nt) 307.  There are other polymorphisms in exon 1 but not shown to 
be involved in RhC/c serology. The RHC allele has identical sequence to the RHD allele in 
exon 2 and thus the use of ASP directed toward the nt307 polymorphism cannot 
discriminate between RHC and RHD alleles. A combination of two ASPs can be used; one 
that targets nt307 for RHc allele and other that targets nt48 (C48G) in exon 1 specific for 
RHC allele in the presence of both RHD and RHc alleles. Hyland and colleagues found 
100% of individuals with C allele have expected nt48 cytosine, so did 5.2% of individuals 
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with c allele (Hyland et al., 1994). In another study on black Africans, 74% of Rhcc 
individuals had the nt48 cytosine (Avent et al., 1997a).  Therefore, possibility of false 
positive for the detection of RHC allele is high among African ancestry using these 
primers.  
Poulter and colleagues described RHC specific insertion in intron 2 of RHCE gene 
and designed PCR-RFLP test that detects this allele (Poulter, Kemp and Carritt, 1996). 
Avent described and defined RHC allele specific intron 2 sequence to be insert of 109 bp 
and developed ASP for the typing of Rh C/c (Avent, 1998).  This unique 109 bp insertion 
has been correlated with RhC serology in two different studies that evaluated more than 
600 individuals and found to be in complete concordance (Avent et al., 1997a; Flegel et al., 
1998).   
Zhou and colleagues studied the comparison between genotyping and serological 
phenotyping in RhCE blood group and found the results of E/e and c alleles genotyping 
were correct with PCR-SSP and accordant with that of phenotyping. However, using the 
C48G polymorphism in exon 1 of RHCE to genotype C allele would result in false positive 
resulting from c allele mutation at this locus, and using the 109 bp insertion to genotype C 
allele gene would result in false negative because of the absence of the 109 bp (Zhou et al., 
2008). Existence of hybrid RHCE (5:667-5:712) that carries p.A226P specific for E 
phenotype explains the amplification observed in (Figure 3.30, RH-TYPE gel view, lane 
12) for E allele.  
Avent and colleagues found that mRNA transcript by RT-PCR and amplification of 
genomic DNA has failed to identify any RHCE gene or transcript that encodes RhE in 
DBS (Avent et al., 1996a). However, they found partial E in serological test, where in this 
case it came to be negative.  BAGene partial D-Type also showed possible intron 7/exon 8 
missing or have allelic mutation at primers binding site, suggesting combination of another 
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DAR (weak D 4.2) allele on the same haplotype. Sample 82 would need further 
investigations, which could reveal a new DBS-0 like allele in this sample. Our studied 
sample is reclassified as D positive sample since partial D DBS-0 allele was detected and 
to be removed from the D negative donor pool, but should be studied further in future at 
messenger RNA (mRNA) level. As the sample showed RHD*DAR allele, this suggests 
inheritance with RHCE*ceAR or RHCE*ceEK (Hemker et al., 1999) which requires 
confirmation in future.  
Another thought, DVI type 1 gives an incorrect E genotype signal derived from the 
RHD gene. The RHD-CE-D hybrid of DVI type 1 is always linked to an RHCE with E 
genotype & phenotype. Hence, the sample has no E antigen, therefore cannot have DVI 
type 1. The other 3 DVI type (2 to 4) all come with C antigen & phenotype also not an 
explanation for the sample. The solution of the observed discrepancy will require 
establishing the RHD-RHCE haplotype in sufficient detail in future.  
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Figure 3.41 Possible DBS-0 allele in cis to DAR 2.00 (novel DBS-0 like allele) on 
sample 82. 
The 10 exons of the RHD (pink box) & RHCE (grey box) genes are symbolized by squares 
and numbered 1 to 10. The grey box within RHD box indicates hybrid RHcE involved in 
DBS-0 partial D allele. The black line within RHD exon denotes for missense mutation 
involved in DAR 2.00. Sample 82 genotype possibly composed of the variant DBS-0 in cis 
to DAR 2.00 (DCe) haplotype (top panel) and complete RHD gene deletion (bottom panel). 
A possible novel DBS-0 like allele is composed of hybrid RHcE[226P](5:667-5:712) and 
602C>G, 667T>G and 1025T>C missense mutations in RHD exons 4, 5 and 7 respectively 
(top panel).    
 
 
Sample 88, was observed to have no exon 4 with real-time PCR and BAGene 
partial D-Type PCR-SSP. This is an indication of the existence of DFR partial D type. 
Many partial D DFR types has been categorized with similar molecular background. DFR 
type 1 (ISBT RHD*DFR1) characterized by hybrid RHD-CE(4:505-4:514)-D with multiple 
haplotypes (Rouillac et al., 1995), DFR type 2 (ISBT RHD*DFR2) with hybrid RHD-
CE(4)-D in CDe haplotype, DFR type 3 (ISBT RHD*DFR3) with 539G>C (G180A) and  
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RHD-CE(4:505-4:514)-D with CDe haplotype (von Zabern and Flegel, 2007) and DFR 
type 4 (ISBT RHD*DFR1) with hybrid RHD-CE(4:505-4:514)-D in haplotype CDe. 
According to serological finding, sample 88 phenotype is ddccee (No C antigen), therefore 
DFR type 1 is most probably the phenotype. BAGene partial D-Type PCR-SSP failed to 
show the amplification of exon 4 due to the primer that targets base pair 505, which is 
substituted in this case with RHCE hybrid nucleotides. This was reconfirmed by BAGene 
RH-TYPE as mix 1 showed 224 bp band for the amplification of exon 4/intron4 as it 
targets a different location in exon 4 away from hybrid RHCE (4:505-4:514). In contrast, 
BAGene RH-TYPE failed to amplify exon 4 in mix 3 that target exon 4 at the area where 
RHCE (4:505-4:514) exist which confirms the finding. BAGene partial D-Type PCR-SSP 
failed to show in band with mix 8 which suggests DAR 2.00 allele involvement in the same 
haplotype. Therefore, existence of DFR-1 in cis to DAR 2.00 in one haplotype and 
complete RHD deletion in another haplotype (Figure 3.42) could explain serological D 
negative phenotype. This sample therefore, is most probably Dce/dce genotype and should 
be reclassified as D positive.  Similar to sample 82, this sample also showed RHD*DAR 
allele, which suggests inheritance with RHCE*ceAR or RHCE*ceEK that requires 
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Figure 3.42 Possible DFR-1 in cis to DAR 2.00 in sample 88.  
The 10 exons of the RHD (pink box) & RHCE (grey box) genes are symbolized by squares 
and numbered 1 to 10. The grey box within RHD box indicates hybrid RHCE involved in 
DFR-1 partial D allele. The black line within RHD exon denotes for missense mutation 
involved in DAR 2.00. Sample 88 genotype possibly composed of the variant DFR-1 in cis 
to DAR 2.00 (cDe) haplotype (top panel) and complete RHD gene deletion (bottom panel). 
DFR-1 in cis to DAR weak D 4.2 is composed of hybrid RHCE (4:505-4:514) and 
602C>G, 667T>G and 1025T>C missense mutations in RHD exons 4, 5 and 7 respectively 
(top panel).   The hybrid RHCE (4:505-4:514) is unique to DFR partial D type.  
 
We also observed another African origin hemizygous / homozygous RHDѰ in eight 
samples. This allele causes 37 bp insertion in RHD exon Intron3/exon4.  For real-time 
PCR, primers RHDѰ-F and RHDѰ-R adapted from (Singleton et al., 2000) designed in a 
way to amplify existence of exon 4 in general with or without duplication of 37 bp to give 
a product of 381 bp for a normal type RHD exon 4 (without 37 bp insertion) and 418 bp for 
RHDѰ. Sequence specific Primers (SSP) for exon 5 adapted from (Legler et al., 2007) 
designed in a way so the forward primer 3’ specific for wild type c.654 in exon 5 and do 
not amplify mutation G>C (M218I) associated with RHDѰ. Therefore, amplification of 
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exon 4 and no amplification of exon 5 suggests RHDѰ. Samples that suggested 
hemizygous / homozygous RHDѰ in real-time PCR showed amplification of exons 1 
through 10 except exon 5. This observation was further confirmed by BAGene partial-D 
and BAGene RH-TYPE. BAGene partial D-Type for RHDѰ presence showed deletion of 
exon 4 (Figure 3.28, lane 4) only.  The SSP in mix 4 (lane 4 in partial D-TYPE gel view) 
in the kit targets the area of exon 4 and 37 bp insertion due to RHDѰ interferes with primer 
target region and thus explains the failure to amplify exon 4. BAGene RH-TYPE 
reconfirmed the finding by showing amplification in mix 1 and 2 (Figure 3.28, lane 1 and 
2, RH-TYPE gel view) for exon 4/intron 4 (222 bp) and RHDѰ respectively, whereas mix 
3 (lane 3) did not show any amplification for exon 4 that is specific for normal RHD exon 
4 without 37 bp insertion.  
The Omani population is heterogeneous, with mixed ethnicity tracking their 
ancestral roots to neighboring countries via tribal migrations and trading contacts. The 
main ethnicities are Arab, Baluchi, Sindi and African. Arabs migrated from what was 
known as Arabia since the 9th century BC onward and settled in Oman. Some Omani 
African originated from Africa, due to the historical trade between Oman, Zanzibar and 
Mombasa favoured by the Indian Oceans monsoons. Oman was a Portuguese colony from 
1508 to 1741, and when the Portuguese were forced out, Oman became an empire that 
expanded to Zanzibar. This lasted until 1861, when Zanzibar was separated from Omani 
control. Omani African started coming back to Oman, as a result of that (Suha, 2015; Suha 
et al., 2015). This might explain the existence of African RHD alleles (RHDѰ and RHD- 
CE-Ds) in Omani population.  
As stated in Table 3.7, sample 93 showed amplification of exon 4 and no 
amplification of exon 5 in real-time PCR which suggests existence of RHDѰ gene. In 
contrast, BAGene partial D-Type gel view in Figure 3.27 showed no amplification in mix 
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tubes for RHD exon 4, 5 and 8 (lanes 4, 5 and 8 respectively), which supported the 
possibility of RHDѰ gene existence along with other RHD alleles. It also showed 
amplification of all other exons in addition to mix 15 (lane 15) that which 140 bp band and 
confirmed the existence of 1136C>T (T379M) in exon 8 that is unique for partial D DAU 
allele. No amplification in tubes 5 and 8 (lanes 5 and 8 respectively) suggest existence of 
DAR 2.00 allele, whereas no amplification in tube mix 5 with amplification in mix 15 (lane 
15) suggests DAU.  Allele specific primers used in BAGene partial D-Type for mix 5 
targets RHD exon 5 nucleotide 697 that is substituted in both DAU and DAR2.00 alleles 
and this explains the failure to amplify.  BAGene RH-TYPE showed unreliable results with 
RHD alleles detection (no amplification) but confirmed presence of RHce alleles. Sanger 
sequencing from the real-time PCR product of exon 4 confirmed the existence of 37bp 
insertion with c.609G>A point mutation as previously observed (Singleton et al., 2000). 
The results are consistent with RHDѰ in cis to DAU and DAR2.00 as one haplotype, 
which is in agreement with Rhce phenotype in this sample. Exon 8 deletion was excluded 
in this case, due to detection of RHD allele 1136C>T found in exon 8 (detected by 
BAGene partial-D kit). This sample is possibly RHDѰ Hemizygous and the insertion of 37 
bp makes the gene inactive and therefore phenotype exist as D negative in serology. 
Therefore, sample 93 has inactive RHD gene and can be classified as D negative with 
possible dce/dce genotype (Figure 3.43).  The existence of DAU and DAR may be 
associated with RHCE*ceMO (Westhoff et al., 2013b) and RHCE*ceAR or RHCE*ceEK 
variants respectively.  
Sample 95 phenotypes as RhCcee with no amplification of exon 2, 4 and 5 with 
real-time PCR and no amplification of exon 2 and 9 with BAGene partial D-Type. The 
absence of amplification of exon 9 in BAgene and its existence in real-time PCR excludes 
the possibility of RHD (delEx9) allele presence. According to the BAGene worksheet 
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instructions, present of weak D types 41 and 45 may cause missing reaction with exon 9. In 
real-time PCR, using allele specific reverse primers re94 stated in Table 2.1 targets 
nucleotide 1193 (mutation site for weak D type 41 in exon 9) which amplified the exon 
suggesting no mutation at this site. Therefore, weak D type 45 (1195G>A) is possibly the 
case in this sample but not weak D type 41. However, further confirmation with BAGene 
Weak D-TYPE would unmask the type.  The missing amplification in real-time PCR for 
exon 2 is due to specificity of the 3´ forward primer ME2F and probably forward primer in 
BAGene kit to detect 203 base pair in RHD exon, which is different in RHCE and thus 
suggests hybrid RHCE(2) called DIIIb partial D. Missing reaction in exon 5 probably is 
due to mutation at location c.654, which is allele specific primer target of forward primer 
RHDex5F, whereas BAGene allele specific primer target location of exon 5 is 697 and this 
explains amplification reaction in the mix 5. Therefore, this sample is possibly DIIIb in cis 








Figure 3.43 Possible hemizygous RHDѰ in cis to DAU-5 and DAR2.00 in sample 93. 
  
The 10 exons of the RHD (pink box) & RHCE (grey box) genes are symbolized by squares 
and numbered 1 to 10. The orange box within RHD box 4 indicates 37 bp insertion in RHD 
Intron3/exon4 unique for RHDѰ. The white line within RHD exons denotes for missense 
mutation involved in RHDѰ gene. The black line within RHD exons denotes for missense 
mutation involved in DAR2.00. The blue line with RHD exon 8 denotes for unique 
missense mutation seen in DAU-5.  The green lines within RHD exon 5 denote the mutual 
missense mutation between DAU-5 and DAR2.00. Sample 93 genotype possibly composed 
of the variant RHDѰ in cis to DAU-5 and DAR2.00 (cDe) haplotype (top panel) and 
complete RHD gene deletion (bottom panel). One haplotype is possible RHDѰ in cis to 
DAU-5 and DAR2.00 (Top panel). IVS3-19 dupl 37 and 609G>A was confirmed with 
Sanger sequencing. Exon 5 mutations c.654G>C and 667T>G was assumed to be in as 
exon 5 primers for Taq-Man and SYBR Green chemistry target these alleles respectively 
and showed negative. Exon 5 for c.674C>T was not tested. BAGene confirmed the 
presence of 697G>A and 1136C>T alleles specific for DAU. The other haplotype is 
complete gene deletion (bottom panel). The inactivation of the gene due to IVS3-19dupl 37 
is the cause for D negative phenotype.  
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Sample 126 phenotypes as Rhccee, showed missing reaction with exons 8 and 9 in 
BAGene partial D-Type and missing reaction with exon 9 in real-time PCR. In both 
methods missing reaction suggests RHD(delEx9), RHD*D-CE(8-9)-D or weak D type 41. 
Both RHD(delEx9) and RHD*D-CE(8-9)-D were excluded as they come with CDe and 
Cde respectively and C antigen is negative in this case. Both real-time PCR forward ASP 
used for the detection of exon 9 in this study and BAGene ASP primer in mix 9 target 
c.1193, this could explain failure to amplify exon 9 in both reactions. A missing reaction in 
mix 8 with BAGene partial-D Type suggests existance of DAR1.00 (weak D 4.2) as well. 
Therefore, this is possibly a case of weak D 4.2 in cis to weak D type 41 with probably a 
Dce/dce genotype and can be classified as D positive. Existence of weak D 4.2 may be 
associated with a RHCE*ceAR allele (Prisco Arnoni et al., 2016).  
Sample 151 with RhCcee phenotype showed no amplification of exon 4, 8 and 9 
with BAGene partial D-Type (Figure 3.34, lane 4, 8 and 9 respectively), whereas no 
amplification with exon 4, 5 and 9 with real-time PCR. RH-TYPE gel view showed no 
amplification of exon 4 in lane 1 and 3 which further confirmed the deletion of exon 4 and 
no amplification in lane 4 (K409K negative) which confirms RHD exon 9 deletion / RHCE 
hybrid. The findings are suggestive of DFR as all exon 4 primers in BAgene and real-time 
PCR failed to amplify. Exon 5 deletion in real-time PCR with amplification in BAGene 
suggests mutation existence in exon 5 in addition to DFR, which needs further study. Exon 
9 deletion in both may confirm RHD-CE(8-9)-D allele presence. Presence of C allele is in 
consistent with DFR and RHD-CE(8-9)-D combination in one haplotype. Though both 
alleles are reported to be CDe haplotype, however  RHD-CE(8-9)-D existence may explain 
D negative phenotype in the serology as observed in  previous studies (Wagner, Frohmajer 
and Flegel, 2001). Therefore, this sample may be hemizygous DFR in cis to RHD-CE(8-9)-
D and categorized as D negative due to the presence of hybrid RHCE(8-9).  
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Sample 160 (Figure 3.35) with Rhccee phenotype with weak e (Figure 3.4B) 
showed amplification of exons 1, 2, 3, 5, 6, 7, 9 and 10 with RH partial D-Type. Real-time 
PCR showed no amplification with exon 4 only (Exon 8 not tested). Combining missing 
exon 4 in both methods suggests DFR-1 as no C antigen exists. As exon 8 band (lane 8) 
was also not seen, weak D 4.2 is predicted to be in cis to DFR-1 as one haplotype. BAGene 
RH-TYPE gel view showed no amplification of 224 bp band for exon 4, no amplification 
in lane 2 and 3 all for exon 4 which further confirms deletion of RHD exon 4 and 
possibility of hybrid RHCE(4). Lane 7 has a band of 143 bp which confirms DEL RHD 
(IVS3+1G>A). Exon 9 amplification in real-time PCR suggests no hybrid or deletion of 
exon 9. Sanger sequencing from real-time PCR exon 3 did not show DEL RHD 
(IVS3+1G>A), which suggested a contamination band seen in RH-TYPE gel. Lane 8 did 
not show any band to suggest involvement of (C)ces, due to the presence of weak e in 
serology test. Therefore, this sample can be classified as D positive.  Weak e with weak D 
type 4.2 may be associated with RHCE*ce.01 (Fichou et al., 2015). This needs further 
testing and evaluation at molecular level.  
Sample 230 serological phenotyping appeared to be ddCcee. Both real-time PCR 
and BAGene partial D-Type showed missing exons 4, 5 and 6 (Figure 3.36, lane 3, 5 and 6 
respectively) suggesting partial D type DVI.2. RH-TYPE gel view confirmed deletion of 
exon 4 by missing reaction band of 244 bp in lane 1, missing reaction in lane 2 and 
missing reaction in lane 3 (Figure 3.36). Sanger sequencing of exon 9 from real-time PCR 
product revealed existence of heterozygous DEL(IVS8-31T>C) (Figure 3.25).  The 
presence of heterozygosity suggests RHD gene is not completely deleted on the other 
haplotype. Present of antigen C is consistent with DEL and DVI.2 existence, however, 
molecular basis of zygosity determination would be a good approach to further explore the 
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case. Therefore, this case is classified as D positive with a haplotype DCe and probable 
DCe/dce or DCe/Dce genotype where DVI.2 in cis or trans to DEL(IVS8-31T>C).  
Sample 234 with serological phenotype ddccEe showed missing reaction in mix 2 
and mix 4 (Figure 3.28, lane 2 and 4) with BAGene partial D-Type and missing reaction 
with exon 2 and 5 in real-time PCR. This suggested existence of RHDѰ and DIIIb partial 
D in one haplotype (Figure 3.44). This is consistent with appearance of E in partial D DIIIb 
which was retyped to DIII type 7 (Lomas-Francis et al., 2012). Missing reaction in mix 2 
with BAGene is specific for DIIIb, RH-TYPE gel view showed 2 bands in mix 1 which 
suggests existence of exon 4, but failed to amplify RHDѰ as control did not appear as well 
in mix 2 but also failed to prove non-existence of RHDѰ in mix 3, (Figure 3.28, lane 1, 2 
and 3, RH-TYPE gel view). However, Sanger sequencing of exon 4 amplified by real-time 
PCR showed IVS3-19 dupl 37 and 609G>A hemizygous which confirms the finding. 
Therefore, this is a D negative sample caused by inactive RHDѰ allele with a probable 
DcE/dce genotype.  
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Figure 3.44 Possible RH genotype in sample 234.  
The 10 exons of the RHD (pink box) & RHCE (grey box) genes are symbolized by squares 
and numbered 1 to 10. The green box within RHD box 4 indicates 37 bp insertion in RHD 
Intron3/exon4 unique for RHDѰ. The green line within RHD exons denotes for missense 
mutation involved in RHDѰ gene. The blue line within RHD exons denotes for missense 
mutation involved in DIIIb. The haplotype (cDE) is possibly have DIIIb in cis to RHDѰ 
(Top panel) with complete RHD deletion in other haplotype (bottom panel – cde). IVS3-19 
dupl 37 and 609G>A was confirmed with Sanger sequencing. Exon 5 mutations c.654G>C 
and 667T>G was assumed to be in as exon 5 primers for Taq-Man and SYBR Green 
chemistry respectively target these alleles and showed no amplification. Exon 5 for 
c.674C>T was not tested. BAGene confirmed the presence of DIIIb by missing reaction for 
exon 2. The other haplotype is complete gene deletion. The inactivation of the gene due to   
IVS3-19 dupl 37 is the cause for D negative phenotype and thus cdE haplotype as DIIIb 
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In PCR, failure of amplification of one of two alleles at any single target locus may 
be due to either sequence independent factors or allele-specific sequence variations (Blais 
et al., 2015). Use of extracted DNA from degraded specimen as a template for DNA typing 
results in less efficient PCR amplification. Additionally, using trace amounts of extracted 
DNA for the template poses the risk of allele drop-out. Allelic drop-out can even be 
observed in undegraded DNA sample with enough amount of extracted DNA (Tsukada et 
al., 2008). Therefore, inability of primer pairs used in sequencing of RHD exon 3 to 
reconfirm heterozygosity of c.455A>C mutation (see section 3.7.3) may be due to allelic 
drop-out raised from trace amount of extracted or possibly degraded DNA.  
Overall RHD deletion was the commonest cause for serological D negative in 
Omani population (n = 179, 87.8%), followed by existence of African ancestry RHDѰ (n = 
10, 4.43%) that makes RHD gene inactive. The existence of different D variants such as 
weak D and partial D in cis to each other with RHD deletion in other haplotype and low 
sensitivity of anti-D IgM/IgG blend (Atlas, UK) may explain the failure to detect these 
variants and reclassify them as D positive in serology. PCR are useful for the identification 
of common Rh variants, but are not assertive in excluding the presence of variant alleles, 
even with multiplex reactions (Dezan et al., 2017). Therefore, digital PCR based assay 
could be very effective to unveil the correct molecular background.  
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4 CHAPTER FOUR: RHD genotyping using QuantStudio™ 
3D Digital PCR System 
4.1 Introduction: 
Detection of specific DNA sequence by PCR test is essential in research and 
diagnostic laboratories. The first generation of PCR analyses were based on qualitative 
detection of DNA amplicons that were visualised by agarose gel electrophoresis. The 
advent of second-generation so called real-time PCR was based on quantitation by 
monitoring the progression of amplification after each cycle using fluorescence probes.  
However, in order to estimate unknown concentration in real-time PCR external calibrators 
or normalization to endogenous controls are required. Imperfect amplification efficiencies 
affect cycle threshold (Ct) values which in turn limits the accuracy of this technique for 
absolute quantitation (Hindson et al., 2011). Next to the well-established method real-time 
PCR (qPCR); a new quantification strategy, digital PCR (dPCR), has been developed 
(Bustin et al., 2009; Huggett et al., 2013). This new approach is based on portioning of the 
measured sample into thousands of uniform droplets (separate reactions) which are then 
amplified and analysed individually.  
Several dPCR platforms are available and generally they can be divided in two 
groups: droplet digital PCR (ddPCR) such as Bio-Rad’s QX100/QX200 and chip-based 
digital PCR (cdPCR) such as Thermo Fisher Scientific QuantStudio™ 3D. Currently, 
traditional PCR and quantitative real-time PCR (qPCR) is the popular choice for specific 
nucleic acid detection including RHD genotyping. However, studies on RHD genotyping 
using ddPCR have been in practice as well. Svobodova and colleagues implemented 
ddPCR for fetal RHD genotyping from maternal plasma, compared it with real-time PCR 
and found that the precision of both methods equalized with decreasing concentrations of 
tested DNA samples (Svobodova et al., 2015). Another similar study conducted by 
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Sillence and colleagues demonstrated ddPCR to be greater sensitivity than real-time PCR 
(Sillence et al., 2015). Droplet digital PCR has also been used for the determination of 
RHD zygosity as qPCR and Rhesus box PCR have limitations particularly for black 
African populations as some individuals have differences in the hybrid box (Matheson and 
Denomme, 2002; Grootkerk-Tax et al., 2005). Sillence and colleagues extracted DNA 
from blood samples and found that ddPCR is highly accurate method to rapidly define 
RHD zygosity (Sillence et al., 2017).  
Extracted DNA from blood sample and cell free DNA (cfDNA) has been used for 
RHD genotyping using cdPCR. Yet, determination of RHD genotyping using DNA sample 
extracted from dry blood spot on FTA card has not been studied. In our study, cdPCR was 
implemented for RHD genotyping using DNA sample extracted from dry blood spot on 
FTA card which we believe is the first with this kind of sample. We hypothesized that 
dPCR will rapidly amplify extracted DNA from dry blood spot on FTA card.   The study 
was divided into two parts. In the first part, RHD exons 5, 7 and 10 amplification were 
observed using SYBR Green chemistry. The method was optimized by using temperature 
gradient (56oC, 58oC and 60oC) experiment.  In the second part of our study, RHD exon 5 











4.2 Target quantification of RHD exons 5, 7 and 10 using 
QuantStudio™ 3D Digital PCR System using SYBR Green chemistry 
We evaluated the ability of the QuantStudio™ 3D Digital PCR System to detect 
and quantify RHD exons 5, 7 and 10 concentration extracted from dried blood on FTA card 
using SYBR Green and TaqMan chemistry. The manufacturer’s recommended precision 
range is <10% but our detection precision was >15%, which suggests DNA purity issues 
with FTA extracted DNA or DNA concentration (For exon 10, Table 4.1 and Table 4.2, for 
exon 5, Table 4.3 and Table 4.4, for exon 7, Table 4.5 and Table 4.6). For optimization we 
performed a temperature gradient study on ten D positive samples, with annealing 
temperatures (60oC, 58oC and 56oC) and compared buccal DNA with DNA extracted from 
dry blood spot on FTA card. In these experiments, we focussed on RHD exons 5, 7 and 10 
(because we had TaqMan probes for the detection of these exons) with a total DNA 
volume of 1 µl (Figures 4.1 to 4.9). The optimum annealing temperature and primer pair 
concentration should give the best separation of positive and negative droplets. No good 
separation was observed between amplified (D positive) and non-amplified reaction 
compared to buccal DNA.  The optimum annealing temperature for SYBR Green assay for 
RHD exons 5, 7 and 10 was found to be 56oC as per buccal extracted DNA data.   
Once the optimum annealing temperature had been determined (56oC), further 
study was performed to increase sample volume and thus DNA concentration to detect and 
quantify RHD exon 10. We tested 10 known RHD exon 10 positive samples (DNA 
concentration between 20 and 30 ng/µl) previously tested with real-time PCR. We found 
that even increasing the volume and concentration of DNA did not improve the precision 
(> 15%) and detection of the RHD gene, which suggested inhibitors effect.  
CHAPTER FOUR: RHD genotyping using QuantStudio™ 3D Digital PCR System 
177 
 
To test for inhibitors effect, the same RHD exon 10 positive (n = 10) samples 
diluted 1 in 4 with final sample volumes 1µl, 2.5µl and 5µl to decrease the effect of 
inhibitors if any. We found that even diluting the samples did not improve the precision (> 
15%) and detection of the RHD exon (Figure 4.10), which suggested purity issues with 
FTA extracted samples.  
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Figure 4.1 Data quality for RHD exon 10 with annealing temperature 
60oC as displayed in QuantStudio™ 3D AnalysisSuite™ Cloud 
Software.  
Scattered plot views for NTC (A), RHD exon 10 buccal DNA extracted 
(B) and  RHD exon 10 extracted from dry blood spot on FTA card (C) 
with SYBR Green I read in the FAM™ channel. Yellow dots correspond 
to no amplification whereas blue dot correspond to amplification of target 
exon using FAM channel. As per NTC plot view with non-amplified 
wells, the adjusted FAM threshold is 29107 (A). Only plot view of buccal 
extracted RHD exon 10 (B) show two populations: the larger yellow 
population corresponds to the non-amplified wells with lower 
fluorescence, and the very smaller blue population corresponds to the 
amplified wells with significantly higher fluorescence.   
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Figure 4.2 Data quality for RHD exon 10 with annealing temperature 
58oC as displayed in QuantStudio™ 3D AnalysisSuite™ Cloud 
Software. 
Scattered plot views for NTC (A), RHD exon 10 buccal DNA extracted 
(B) and  RHD exon 10 extracted from dry blood spot on FTA card (C) 
with SYBR Green I read in the FAM™ channel. Yellow dots correspond 
to no amplification whereas blue dot correspond to amplification of target 
exon using FAM channel. As per NTC plot view with non-amplified 
wells, the adjusted FAM threshold is 29200 (A). Only buccal extracted 
RHD exon 10 (B) show good discrimination and very large population of 
amplified specific exon with higher fluorescence compared to FTA 
extracted which showed smaller population of exon amplification (C).   
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Figure 4.3 Data quality for RHD exon 10 with annealing 
temperature 56oC as displayed in QuantStudio™ 3D 
AnalysisSuite™ Cloud Software. 
Scattered plot views for NTC (A), RHD exon 10 buccal DNA 
extracted (B) and  RHD exon 10 extracted from dry blood spot on 
FTA card (C) with SYBR Green I read in the FAM™ channel. 
Yellow dots correspond to no amplification whereas blue dot 
correspond to amplification of target exon using FAM channel. As 
per NTC plot view with non-amplified wells, the adjusted FAM 
threshold is 19500 (A) . Only buccal extracted RHD exon 10 (B) 
show good discrimination and very large population of amplified 
specific exon with higher  fluorescence compared to FTA extracted 
which showed smaller population of exon amplification (C). 
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Table 4.1 SYBR Green I assay summary of results for RHD exon 10 quantification 
extracted from buccal cells, with statistical analysis performed on AnalysisSuite™ 
software. 
Annealing temperature  Copies / µl CIa (copies/µl) Precisionb (%) Chipsc 
56oC 191.97 184.25 -- 200.01 4.9 2 
58oC 2618.1 2529.4 -- 2710 3.5 1 
60oC 1.18 0.699 -- 1.992 68.85 1 
a Lower and upper 95% confidence interval for quantity of sample in copies/μl. 
b Calculated precision (%) for the data group, defined as size of the confidence interval for 
distinguishing between two sample concentrations at a given confidence level. 
c Number of chips containing the data group. Multiple chips can be combined to improve 



















Table 4.2 SYBR Green I assay summary of results for RHD exon 10 quantification 
extracted dried blood on FTA card, with statistical analysis performed on 
AnalysisSuite™ software 
Annealing temperature  Copies / µl CIa (copies/µl) Precisionb (%) Chips 
56oC 1.899 1.283 -- 2.81 48 1 
58oC 0.556 0.265 -- 1.166 110 1 
60oC < 0.5 < 0.5 610 1 
a Lower and upper 95% confidence interval for quantity of sample in copies/μl. 
b Calculated precision (%) for the data group, defined as size of the confidence interval for 
distinguishing between two sample concentrations at a given confidence level. 
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Figure 4.4 Data quality for RHD exon 5 with annealing temperature 60oC 
as displayed in QuantStudio™ 3D AnalysisSuite™ Cloud Software. 
Scattered plot views for NTC (A), RHD exon 5 buccal DNA extracted (B) and  
RHD exon 5 extracted from dry blood spot on FTA card (C) with SYBR 
Green I read in the FAM™ channel. Yellow dots correspond to no 
amplification whereas blue dot correspond to amplification of target exon 
using FAM channel. As per NTC plot view with non-amplified wells, the 
adjusted FAM threshold is 24550 (A) . Only buccal extracted RHD exon 5 (B) 
show good discrimination and very large population of amplified specific 
exon with higher  fluorescence compared to FTA extracted which showed 
smaller population of exon amplification (C). 
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Figure 4.5 Data quality for RHD exon 5 with annealing 
temperature 58oC as displayed in QuantStudio™ 3D 
AnalysisSuite™ Cloud Software. 
Scattered plot views for NTC (A), RHD exon 5 buccal DNA extracted 
(B) and  RHD exon 5 extracted from dry blood spot on FTA card (C) 
with SYBR Green I read in the FAM™ channel. Yellow dots 
correspond to no amplification whereas blue dot correspond to 
amplification of target exon using FAM channel. As per NTC plot view 
with non-amplified wells, the adjusted FAM threshold is 21000 (A) . 
Only buccal extracted RHD exon 5 (B) show good discrimination and 
very large population of amplified specific exon with higher  
fluorescence compared to FTA extracted which showed smaller 
population of exon amplification (C). 
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 Figure 4.6 Data quality for RHD exon 5 with annealing temperature 
56oC as displayed in QuantStudio™ 3D AnalysisSuite™ Cloud 
Software. 
Scattered plot views for NTC (A), RHD exon 5 buccal DNA extracted 
(B) and  RHD exon 5 extracted from dry blood spot on FTA card (C) 
with SYBR Green I read in the FAM™ channel. Yellow dots correspond 
to no amplification whereas blue dot correspond to amplification of 
target exon using FAM channel. As per NTC plot view with non-
amplified wells, the adjusted FAM threshold is 21000 (A) . Only buccal 
extracted RHD exon 5 (B) show good discrimination and very large 
population of amplified specific exon with higher  fluorescence 
compared to FTA extracted which showed smaller population of exon 
amplification (C). 
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Table 4.3 SYBR Green I assay summary of results for RHD exon 5 quantification 
extracted from buccal cells, with statistical analysis performed on AnalysisSuite™ 
software. 
Annealing temperature  Copies / µl CIa (copies/µl) Precisionb (%) Chips 
56oC 49.695 45.705 -- 54.033 8.7 1 
58oC 41.946 38.362 -- 45.866 9.3 1 
60oC 37.79 34.353 -- 41.57 10 1 
a Lower and upper 95% confidence interval for quantity of sample in copies/μl. 
b Calculated precision (%) for the data group, defined as size of the confidence interval for 
distinguishing between two sample concentrations at a given confidence level. 
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Table 4.4 SYBR Green I assay summary of results for RHD exon 5 quantification 
extracted dried blood on FTA card, with statistical analysis performed on 
AnalysisSuite™ software 
Annealing temperature  Copies / µl CIa (copies/µl) Precisionb (%) Chips 
56oC 1.552 0.936 -- 2.575 65.9 1 
58oC 1.115 0.558 -- 2.229 100 1 
60oC 0.564 0.235 -- 1.355 140 1 
a Lower and upper 95% confidence interval for quantity of sample in copies/μl. 
b Calculated precision (%) for the data group, defined as size of the confidence interval for 
distinguishing between two sample concentrations at a given confidence level. 
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Figure 4.7 Data quality for RHD exon 7 with annealing temperature 60oC 
as displayed in QuantStudio™ 3D AnalysisSuite™ Cloud Software. 
Scattered plot views for NTC (A), RHD exon 7 buccal DNA extracted (B) and  
RHD exon 7 extracted from dry blood spot on FTA card (C) with SYBR Green 
I read in the FAM™ channel. Yellow dots correspond to no amplification 
whereas blue dot correspond to amplification of target exon using FAM 
channel. As per NTC plot view with non-amplified wells, the adjusted FAM 
threshold is 21134 and has small population of exon amplification that is 
contaminant (A) . Only buccal extracted RHD exon 7 (B) show good 
discrimination and large population of amplified specific exon with higher  
fluorescence compared to FTA extracted which showed smaller population of 
exon amplification (C). 
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Figure 4.8 Data quality for RHD exon 7 with annealing temperature 
58oC as displayed in QuantStudio™ 3D AnalysisSuite™ Cloud 
Software. 
Scattered plot views for NTC (A), RHD exon 7 buccal DNA extracted (B) 
and  RHD exon 7 extracted from dry blood spot on FTA card (C) with 
SYBR Green I read in the FAM™ channel. Yellow dots correspond to no 
amplification whereas blue dot correspond to amplification of target exon 
using FAM channel. As per NTC plot view with non-amplified wells, the 
adjusted FAM threshold is 25990 and has small population of exon 
amplification that is contaminant (A) . Both buccal extracted RHD exon 7 
(B) and FTA extracted DNA (C) with higher  fluorescence show good 
discrimination but large and low population of amplified exon 
respectively. 
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Figure 4.9 Data quality for RHD exon 7 with annealing temperature 56oC 
as displayed in QuantStudio™ 3D AnalysisSuite™ Cloud Software. 
Scattered plot views for NTC (A), RHD exon 7 buccal DNA extracted (B) 
and  RHD exon 7 extracted from dry blood spot on FTA card (C) with SYBR 
Green I read in the FAM™ channel. Yellow dots correspond to no 
amplification whereas blue dot correspond to amplification of target exon 
using FAM channel. As per NTC plot view with non-amplified wells, the 
adjusted FAM threshold is 25909.9 and has small population of exon 
amplification that is contaminant (A) . Both buccal extracted RHD exon 7 (B) 
and FTA extracted DNA (C) with higher  fluorescence show good 
discrimination and large population of amplified exon. 




Table 4.5 SYBR Green I assay summary of results for RHD exon 7 quantification 
extracted from buccal cells, with statistical analysis performed on AnalysisSuite™ 
software 
Annealing temperature  Copies / µl CIa (copies/µl) Precisionb (%) Chips 
56oC 170.493 165.26 – 175.89 9.2 1 
58oC 14.564 12.536 -- 16.919 16.2 1 
60oC 5.838 4.611 -- 7.391 26.3 1 
a Lower and upper 95% confidence interval for quantity of sample in copies/μl. 
b Calculated precision (%) for the data group, defined as size of the confidence interval for 
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Table 4.6 SYBR Green I assay summary of results for RHD exon 7 quantification 
extracted dried blood on FTA card, with statistical analysis performed on 
AnalysisSuite™ software 
Annealing temperature  Copies / µl CIa (copies/µl) Precisionb (%) Chips 
56oC 4.741 3.593 -- 6.255 31.9 1 
58oC 1.595 1.04 -- 2.446 53.4 1 
60oC 1.552 1.127 -- 2.839 58.7 1 
a Lower and upper 95% confidence interval for quantity of sample in copies/μl. 
b Calculated precision (%) for the data group, defined as size of the confidence interval for 
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Figure 4.10 inhibitor effect study on DNA samples extracted from dry blood spot on 
FTA card  
Analysis of RHD exon 10 DNA copies with different sample volume tested by 
QuantStudio™ 3D Digital PCR System using SYBR Green chemistry. The line inside of 
the box indicates 95% confidence interval range for the mean value of each sample volume 
(n = 10). The undiluted sample bar graph shows decrease in the mean copies of the DNA 
as the DNA concentration and sample volume increase which may suggest inhibitor effect. 
The 1 in 4 diluted samples bar graph show decrease in the mean copies of the DNA as the 
sample volume increase which excluded inhibitor effect as a cause. (*) The mean value of 
DNA copies and different sample volumes (undiluted) versus ¼ dilution showed no 
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4.3 Target quantification of RHD exons 5 using QuantStudio™ 3D 
Digital PCR System with TaqMan chemistry 
We also evaluated the ability of the QuantStudio™ 3D Digital PCR System to 
detect and quantify RHD exons 5 extracted from dried blood spot on FTA card using 
TaqMan chemistry and specific primers and probe with concentration as indicated in Table 
2.3. Annealing temperature 60oC was used as recommended by the manufacturer. We 
found that the detection precision is above the range recommended by the manufacturer (< 
10% precision) which again suggests DNA purity issues with FTA extracted DNA. We 
tested known D positive sample extracted from FTA card (Figure 4.11) versus buccal 
extracted with a 1 µl sample volume. No good separation was observed between amplified 
(D positive) and non-amplified reaction compared to buccal extracted DNA for the same.   
Further study was performed to increase sample volume and thus DNA 
concentration to detect and quantify RHD exon 5. We tested (n = 5) RHD exon 5 positive 
samples (DNA concentration between 20 and 30 ng/µl) previously tested with real-time 
PCR. We found that though increasing the volume and concentration of DNA caused 
increase of mean DNA copies (Figure 4.12), it did not improve the precision (> 15%) and 
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Figure 4.11 Data quality for RHD exon 5 with annealing temperature 
60oC as displayed in QuantStudio™ 3D AnalysisSuite™ Cloud Software.  
Scattered plot views for NTC (A), RHD exon 5 buccal DNA extracted (B) and  
RHD exon 5 extracted from dry blood spot on FTA card (C) with TaqMan 
chemistry read in the VIC™ channel. Yellow dots correspond to no 
amplification whereas red dot correspond to amplification of target exon 
using VIC channel. As per NTC plot view with non-amplified wells, the 
adjusted VIC threshold is 550 (A) . Only buccal extracted RHD exon 5 (B) 
show good discrimination and large population of amplified specific exon 
with higher  fluorescence compared to FTA extracted which showed smaller 
population of exon amplification (C). 
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Figure 4.12 Effect of sample volume on mean DNA copies extracted from from dry 
blood spot on FTA card   
RHD exon 5 DNA copies with different DNA sample volumes (1, 5 and 7 ul) tested by 
QuantStudio™ 3D Digital PCR System using TaqMan chemistry. Y axis represent mean 
DNA copies/µl of RHD exon 5 for different volumes of DNA samples (n = 5). The line 
inside of the box indicates 95% confidence interval range for the mean value of each 
sample volume. The mean DNA copies increases as the sample volume increases. (*) The 
mean value of DNA copies and different sample volumes showed significant difference (p 
< 0.0001). Though there is statistical difference, however the precision is above the 
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Table 4.7 TaqMan assay summary of results for RHD exon 5 with statistical analysis 
performed on AnalysisSuite™ software 
Sample Type / 
Volume (µl) 
Copies / µl CIa (copies/µl) Precisionb (%) Chips 
Buccal / 1 µl 47.778 44.123 -- 51.735 8.3 1 
Dry blood FTA/ 1 µl 2.014 1.338 -- 3.031 50.5 5 
Dry blood FTA/ 5 µl 6.212 4.939 -- 7.814 25.8 5 
Dry blood FTA/ 7 µl 10.094 8.447 -- 12.063 19.51 5 
a Lower and upper 95% confidence interval for quantity of sample in copies/μl. 
b Calculated precision (%) for the data group 
 
4.4 Discussion  
Digital PCR has been proved to be an accurate quantitative PCR method that is 
replacing the conventional real-time PCR. Here, we studied if cdPCR rapidly amplify RHD 
gene exons from DNA extracted from dry blood spot on FTA cards.  Without doubt, the 
most appropriate technique would be the assessment of known D positive sample (buccal 
extracted) and compare it with FTA extracted. A dce (D negative) sample was required to 
be involved in this experiment as well.  As the study ethical approval was to collect dry 
blood on FTA card from Omani population and due to the limitation, time constraints and 
other ethical issues; we were unable to collect a blood sample from a D negative dce 
Caucasian. The most frequent cause for the absence of the antigen D in Caucasians is the 
lack of the whole RHD gene. This can be an excellent candidate sample for a negative 
control in this study as it could have been of an aid to define D specificity of the primers in 
temperature gradient experiment.   
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The recommended, proven and validated chemistry for digital PCR is TaqMan® 
Assays. Since SYBR Green dye based detection is widely used for target quantification in 
traditional real-time PCR, we have tested SYBR Green I dye for RHD exons 5,7 and 10 
target quantification on the QuantStudio™ 3D system. The optimization study with 
temperature gradient worked quite well in determining the best annealing temperature for 
the detection of RHD exons 5, 7 and 10 which came out to be 56oC. This is because the 
buccal extracted D positive sample gave the best precision (<10%) that is recommended by 
the manufacturer with this temperature (Table 4.1, Table 4.3 and Table 4.5). In contrast, 
this precision was above 10% with DNA sample extracted from dry blood spot on FTA 
card (Table 4.2, Table 4.4 and Table 4.6). Digital PCR technology can be used for 
extremely low-target quantitation from variably contaminated samples (Racki et al., 2014), 
therefore DNA concentration and inhibitors as causes for lower quantification accuracy in 
this study were excluded. To support what we stated, we conducted inhibitor effect test by 
diluting the FTA extracted DNA samples 1 in 4 (to dilute the effect of inhibitors if any) 
and compared it with undiluted sample. Our study showed that inhibitors (if any) could not 
affect the quantitation (DNA copies / µl) as no significant difference were observed p = 
0.2, which suggests no inhibitors interference at all or cdPCR result is not affected by 
inhibitors.  
We have also tested TaqMan® Assays for RHD exons 5 target quantification on the 
QuantStudio™ 3D system. As seen with SYBR Green dye–based detection, buccal 
extracted D positive DNA sample gave the best precision (<10%) that is recommended by 
the manufacturer compared to FTA card extracted DNA that showed >10% (Table 4.7). 
This again suggests purity issues with FTA extracted DNA. Though there is significant 
difference (p < 0.0001) between DNA copies/µl and the increasing volume of DNA 
CHAPTER FOUR: RHD genotyping using QuantStudio™ 3D Digital PCR System 
199 
 
(Figure 4.12), however lower quantification accuracy was observed with precision >10% 
which further supports the purity issue.    
These results demonstrate that the QuantStudio™ 3D system may be not 
compatible with SYBR Green dye– based digital PCR and TaqMan® Assay based digital 
PCR for the quantitation of RHD gene extracted from dry blood spot on FTA card.   
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5 CHAPTER FIVE: Discussion 
The limitations of serology can be overcome by molecular typing. In order to 
evaluate the contribution of RH systematic genotyping and its implication in transfusion 
practice, a genotyping of D negative blood donors was studied in Omani population for the 
first time. We aimed to explore the molecular background of serological D negative cohort 
by different methods such as real- time PCR Tm curve analysis, ASP singleplex real-time 
PCR and ASP-PCR using BAGene kits. The outcome showed that the existing IAT method 
with anti-D reagent used to find out D variants such as weak D and partial D demonstrated 
to be quite ineffective for the classification of D status based on serological data in 
transfusion practice in Oman.  
We aimed to develop a multiplex real-time PCR method for the detection of RHD 
exons based on Tm analysis curve study. We studied and recorded Tm curve analysis of 
each RHD gene exon with exception of exon 8 in real-time PCR with SYBR Green 
chemistry. We found Tm study to be ineffective for the study of molecular background of 
serological D negative cohort.  We observed Tm curve analysis of RHD exons to be too 
close to each other’s (Table 3.6). This makes it difficult to develop a multiplex assay for 
RHD exons detection in order to be analysed by Tm.  
Molecular study using ASP singleplex real-time PCR and BAGene ASP-PCR 
reclassified a total of 4.4% (n = 9, out of 203 samples tested) of serological D negative as 
D positive (section 3.7.4 and Table 3.10). From the molecular background details collected 
for Omani cohort, it is clear that Omanis may possess multiple RHD gene alleles that make 
existing ASPs and related techniques quite challenging. For example, molecular study 
using BAGene partial D-Type kit failed to classify about 21% (n = 5, out of 24 samples 
tested) of D variants (section 3.7.4 and Table 3.10). In addition, BAGene kit with support 
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of singleplex real-time PCR determined more than one D variant may exist in a haplotype 
which further makes the available diagnostic kit quite challenging to explore the molecular 
background of serological D negative in Omanis.  
We adopted a strategy described previously to detect deletion or presence of RHD 
gene in serological D negative Omani cohort by screening of RHD exon 10 (Moussa et al., 
2012; Sassi et al., 2014). Based on this we were able to classify 88.18% (n = 179, out of 
203 samples) of the samples as D negative due to complete RHD gene deletion (see section 
3.6). However, the most common D negative haplotype in all populations is caused by the 
deletion of the whole RHD gene with the concomitant presence of the hybrid Rhesus box 
(Flegel, 2011). In the RHD positive haplotype, the RHD gene is flanked by two highly 
homologues DNA segments called Rhesus boxes, that are located 5´upstream Rhesus box 
and 3´downstream Rhesus box of RHD gene.  In D negative (Caucasians), the RHD gene 
composed of 5´ end of the upstream Rhesus box and 3´end of downstream Rhesus box that 
results in hybrid Rhesus box (Prager, 2007). Therefore, serological D negative, RHD exon 
10 negative samples in this study should be tested in future for the presence of only hybrid 
Rhesus box in order to reconfirm the complete RHD gene deletion.  
As discussed in chapter three, 11.82% (n = 24, out of 203 samples) of the cohort 
showed D variants.  These D variants included homozygous or hemizygous RHDѰ, RHD-
CE-Ds in trans to partial, combination of RHD alleles (weak D and partial D) on the same 
chromosome (in cis to each other’s) and combination of RHD alleles on both chromosomes 
(in trans to each other’s). The BAGene RH-Type diagnostic kit failed to determine 
zygosity of few RHD alleles such as RHDѰ/RHD.   The D zygosity test would further 
confirm the existence of RHD gene on one chromosome or both.  The hybrid Rhesus box 
may also be used for D zygosity testing. Our future work with these samples is to use PCR-
SSP that allows the determination of RHD zygosity (homozygosity or hemizygosity of D) 
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by the amplification of the downstream Rhesus box (DD), or by the hybrid Rhesus box 
(dd), or by the downstream and the hybrid Rhesus box (Dd), respectively. For RHD alleles, 
which cannot be determined serologically (D negative), a discrepancy between the 
serological test result and genotyping may occur. The positive detection of the downstream 
Rhesus box shows the presence of an RHD allele (serological D positive), except RHDѰ 
homozygous and hemizygous respectively. The reaction hereby is negative although an 
RHD allele is present. In addition, the result with a genetically modified downstream 
Rhesus box may be also false negative, although the specimen is serologically D positive. 
Thus, with a serologically D positive result and positive PCR for the hybrid Rhesus box, 
the outcome is Dd. It is DD when a negative PCR result for the hybrid Rhesus box occurs. 
Our body work detected partial D alleles that are due to hybrid RHD-CE-D (section 
3.7.4). Due to combination of two RHD alleles (for partial D) on one chromosome, the 
BAGene partial-D diagnostic kit failed to confirm possible existence of hybrid RHCE. 
BAGene RH-Type also detected RHD-CE-Ds African allele in cis to a partial D, in contrast 
to singleplex real-time PCR which did not test for RHD-CE-Ds.  The primers used for 
singlepex real-time PCR detected the alleles that are specific for RHD gene specific allele 
on the exon. However, we did not confirm the existence of the RHCE hybrid on RHD gene 
by using primers that are specific for RHCE gene as well. Therefore, our potential future 
work is to perform RHCE molecular testing for these samples to confirm the existence of 
hybrid RHCE. In addition, characteristic SNPs are also needed for all tested samples to 
determine the novel (if any) RHCE allele linked to the detected RHD allele in Omani 
cohort, thus constituting RH haplotypes. For example, RHD-CE-Ds would need 
demonstration of the RHCE(Leu245Val) and RHD(Asn152Thr) substitutions characteristic 
of Cdes as well as missing RHD exons 3 through 7 that are replaced with RHCE exons 3 
through 7. There are many other RHCE variants that are inherited with altered RHD, 
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includes;  RHCE*ceAR inherited with RHD*DAR (Hemker et al., 1999), RHCE*ceTI is 
frequently in cis to RHD*DIVa-2 (Westhoff et al., 2013a), RHCE*ceMO is often found 
with RHD*DAU0 (Westhoff et al., 2013b) and RHCE*ce48C,733G,1006T is usually 
associated to RHD*DIIIa (Westhoff et al., 2010).  
Anti-D monoclonal antibodies to Rh low frequency antigens to detect specific 
partial D are unavailable.  It has been difficult to define the precise population frequencies 
of the various RH haplotypes because of the inability to differentiate between homo or 
hemizygous individuals and prediction of the Rh genotype based on serological data and 
common haplotype in the population would be incorrect in these cases (Sillence et al., 
2017). Rh genotyping overcomes the limitation associated with serological method as it 
can detect low frequency antigens by wide range of PCR based molecular methods to 
detect predefined nucleotides and DNA region. However, as of the designed methods, 
these cannot detect the novel variants and alleles (Avent et al., 2015).  Sequencing of RHD 
and RHCE coding regions by Sanger method may unveil the search for Rh variants, 
however the results may be difficult to interpret due to deletions, inclusions and hybrid 
alleles (Stabentheiner et al., 2011). Recent advances in NGS technologies offer a more 
comprehensive DNA sequence based approach to determine Rh variants (Fichou et al., 
2014; Fichou et al., 2016).  Due to possible multiple RHD alleles that were predicted on 
one chromosome in a few samples from Omani cohort, Sanger sequencing results that were 
difficult to interpret in some cases, RHD exon 8 that was not studied and unclassified 
molecular background (n = 5), NGS would be one of the best options to unveil possible 
novel RHD alleles in Omani cohort.  
Many studies used NGS different technologies for blood group genotyping. Dezan 
and colleagues and Chou and colleagues used exome sequencing for the identification of 
Rh variants (Chou et al., 2017; Dezan et al., 2017). However, the sequence sharing 
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between wild type RHD and RHCE exons 8 and 10 (Figure 1.4) makes it difficult to 
analyse the data. A long-range PCR (LR-PCR) method was used by Hyland and colleagues 
to amplify RHD exon 2 through 7 (Hyland et al., 2017), which still cannot unveil the 
remaining RHD exons 1, 8, 9 and 10 genotyping. LR-PCR can be used to amplify DNA to 
over 30 kb by the use of modified polymerases such as SequalPrep polymerase (Invitrogen, 
Carlsbad, CA), AccuPrime Taq DNA Polymerase (Invitrogen, Carlsbad, CA), PrimeSTAR 
GXL polymerase (TaKaRa Bio, Shiga, Japan), LA Taq Hot Start Version Polymerase 
(TaKaRa Bio, Osaka, Japan), KAPA long Range HotStart DNA polymerase (KAPA 
Biosystems, Wobum, MA) and QIAGEN LongRange PCR Polymerase (Hilden, Germany) 
(Jia et al., 2014). These polymerases are of high fidelity with enhanced DNA binding that 
results in accurate long fragment DNA amplification.  The blend of Taq DNA polymerase 
is combined with a small amount of proofreading polymerase that repairs DNA 
mismatches incorporated at the 3’ end of the growing strand, allowing Taq polymerase to 
continue to elongate the DNA much further than it would otherwise, resulting in longer 
DNA amplification. These technical advances have brought the speed and simplicity of 
PCR to genomic mapping and sequencing and have facilitated studies in molecular genetic 
including NGS. Tounsi and colleagues were able to establish a reference RHD allele using 
long-range PCR and NGS that amplified the complete RHD gene by sequencing full RHD 
gene including promoter, introns, and all exons (Tounsi, Madgett and Avent, 2018).  
Providing Rh antigen matched RBCs is considered the best prophylaxis to avoid 
alloimmunization caused by Rh antibodies, especially in Beta thalassaemia major and SCD 
cases. However, this can be compromised by existence of RHD & RHCE variants if not 
disclosed at the start of prophylaxis.  As Oman has a high prevalence of hereditary blood 
disorders such as SCD and thalassemia (see section 3.1) and our study detected multiple 
RHD alleles that needs further study (see section 3.7.4), we aim to do a D zygosity test and 
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adopt Tounsi and colleagues RHD alleles reference NGS method as a future follow up 





Overall, the serological limitation of phenotyping RHD in Omani cohort has proved 
to be existing. We used dry blood spot on FTA card as a source for DNA sample for RHD 
genotyping. We observed that RHD exons 4, 5 and probably exon 8 with RHD intron 7 are 
the regions where most of the polymorphism detected in Omani cohort. We demonstrated 
RHD positive haplotype in serological D negative Omanis and found that these positive 
haplotypes are either inactive RHD gene (RHDѰ) giving true serological D negative or 
partial D / weak D alleles giving false serological D negative. We also observed RHD 
negative haplotype with complete RHD gene deletion that gives true serological D 
negative. The study could not unveil molecular background of few samples that are 
predicted to possess RHD haplotype. BAGene kits may not be suitable choice for RHD 
genotype screening in Omani population due to multiple RHD alleles existence. 
Though real-time PCR using SYBR Green and Taq-Man chemistry was successful 
to amplify different RHD exons, however; Melting curve analysis by SYBR Green 
chemistry has not been successful to distinguish different RHD exons and to be 
recommended for multiplexing study. The nature of extracted DNA from dry blood on 
FTA card has also not been successful to be used with most sophisticated PCR technology 
for testing RHD genotyping as dPCR could not robustly amplified RHD exons on DNA 
samples extracted from dry blood spot on FTA card which reflects the poor quality of 
extracted DNA sample.  
Further study may unmask novel RHD alleles that should add a contribution to 
transfusion science and safety practice. RHCE genotyping would be a potential future work 
with these samples in order to link type of RHCE allele(s) involved with detected RHD 
alleles in Omani cohort. D zygosity and next generation sequencing would be the methods 




future work aim will be to adopt established referenced RHD allele genotyping by NGS to 
unveil the complete RHD gene screening test to help clinicians in their current practice to 




Future work  
Our future work on these samples will be focused mainly on three assays: a 
complete RHD allele genotyping by NGS, finding out D zygosity and exploring RHCE 
alleles involved in detected RHD alleles. These will provide more understanding of 
molecular background of D negative phenotype in Omanis. The outcome of these assays 
should suggest a better management of the donors and the patients genotyped with weak D 
or partial D who can receive D positive blood units.  
Though our study of RHD genotyping unveiled RHD alleles involved in serological 
D negative Omani cohort, however it is uncertain of possibility of having two or more 
RHD alleles on the same haplotype (cis). To confirm the existence of multiple RHD alleles, 
a complete RHD genotyping; previously described LR-PCR and NGS technology could be 
adopted as a potential future work (Tounsi, Madgett and Avent, 2018). A fresh EDTA 
sample from the participants who showed serological D negative but RHD positive 
haplotype (n = 24) would be ideal to avoid DNA purity issues as observed in this study 
with extracted DNA from dry blood spot on FTA card. Genomic DNA will be extracted 
using Qiagen investigator kit or any available DNA extraction kit. DNA concentration and 
purity will be determined using Thermo Scientific™ NanoDrop 2000.  Six sets of RHD 
specific primers previously published by Tounsi and colleagues will be used to amplify the 
RHD gene in 6 LR-PCR amplicons. LR-PCR, Library construction and NGS will run as 
described by the authors.  
We predicted complete RHD gene deletion (del/del) based on the absence of RHD 
exon 10, but; we were uncertain if the presence of different weak D/partial D RHD alleles 
are homozygous [RHD allele(s)/RHD allele(s)] or hemizygous [RHD allele(s)/del]. In both 
cases, D zygosity testing will be very helpful to unveil that. As a future work, all samples 




type kit or running sequence specific amplification PCR using previously described 
primers that detect hybrid Rhesus box as a marker for RHD deletion and/or downstream 
Rhesus box as marker for the existence of RHD gene (Wagner and Flegel, 2000).   
Once zygosity and complete RHD genotyping determined, RHCE testing would be 
very useful to determine RHCE alleles that are involved with RHD alleles detected in 
Omani cohort. Sequence specific amplification PCR for the specific detection of the 10 
RHCE exons from genomic DNA will be carried out and sequencing of each product with 
sequencing primers will be performed according to previous description (Wagner, Ladewig 
and Flegel, 2003). In the long term, these efforts may translate into practice in transfusion 
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